def14a
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934 (Amendment No. )
Filed by the Registrant þ
Filed by a Party other than the Registrant o
Check the appropriate box:
o Preliminary Proxy Statement
o Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
þ Definitive Proxy Statement
o Definitive Additional Materials
o Soliciting Material Pursuant to Rule 14a-12
WRIGHT MEDICAL GROUP, INC.
(Name of Registrant as Specified in Its Charter)
Not Applicable
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box):
þ |
|
No fee required. |
|
o |
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
|
(1) |
|
Title of each class of securities to which transaction applies: |
|
|
(2) |
|
Aggregate number of securities to which transaction applies: |
|
|
(3) |
|
Per unit price or other underlying value of transaction computed pursuant to Exchange
Act
Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was
determined): |
|
|
(4) |
|
Proposed maximum aggregate value of transaction: |
|
|
(5) |
|
Total fee paid: |
o |
|
Fee paid previously with preliminary materials: |
|
o |
|
Check box if any part of the fee is offset as provided by Exchange
Act Rule 0-11(a)(2) and identify the filing for which the
offsetting fee was paid previously. Identify the previous filing
by Registration Statement number, or the Form or Schedule and the
date of its filing. |
|
(1) |
|
Amount previously paid: |
|
|
(2) |
|
Form, Schedule or Registration Statement no.: |
|
|
(3) |
|
Filing party: |
|
|
(4) |
|
Date filed: |
|
|
|
|
Wright
Medical Group, Inc. |
5677 Airline Road, Arlington, Tennessee 38002 |
901-867-9971 |
www.wmt.com |
NOTICE OF
2010 ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON MAY 13, 2010
To Our Stockholders:
The 2010 Annual Meeting of Stockholders of Wright Medical Group,
Inc. will be held at the River Inn of Harbor Town, located at 50
Harbor Town Square, Memphis, Tennessee, on May 13, 2010,
beginning at 8:00 a.m. (Central Time). At the meeting,
our stockholders will vote on the following proposals to:
1. Elect directors to serve on our Board of Directors for a
term of one year;
|
|
|
|
2.
|
Approve an amendment to our 2009 Equity Incentive Plan to
increase by 700,000 the number of shares of our common stock
available for awards thereunder;
|
|
|
3.
|
Approve the material terms of our 2010 Executive Performance
Incentive Plan for the purpose of enabling us to fully deduct
for tax purposes compensation paid thereunder; and
|
4. Ratify the selection of KPMG LLP as our independent
auditor for 2010.
Stockholders also will transact any other business that properly
comes before the meeting.
OUR BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE FOR
ALL THE PROPOSALS.
Only stockholders of record at the close of business on
March 22, 2010, are entitled to receive notice of, and to
vote at, the meeting and any postponement or adjournment
thereof. A list of such stockholders will be available for
inspection by any stockholder at the office of our legal
counsel, Baker, Donelson, Bearman, Caldwell &
Berkowitz, PC, 165 Madison Avenue, 22nd Floor, Memphis,
Tennessee, during ordinary business hours beginning
May 1, 2010, as well as at the River Inn of Harbor
Town during the meeting on May 13, 2010.
Important Notice Regarding the Availability of Proxy
Materials for the Annual Meeting of Stockholders To Be Held on
May 13, 2010. The Proxy Statement and 2009 Annual Report
are available at www.wmt.com/proxy.
YOUR VOTE IS IMPORTANT. REGARDLESS OF WHETHER YOU
PLAN TO ATTEND THE MEETING, PLEASE PROMPTLY VOTE BY TELEPHONE OR
COMPLETE, SIGN, DATE, AND RETURN THE ENCLOSED PROXY CARD IN THE
ACCOMPANYING POSTAGE-PAID ENVELOPE. NO ADDITIONAL POSTAGE IS
NECESSARY IF THE PROXY IS MAILED IN THE UNITED STATES OR CANADA.
YOU MAY REVOKE YOUR PROXY AT ANY TIME BEFORE IT IS VOTED AT THE
MEETING.
By Order of our Board of Directors,
Thomas L. McAllister
Secretary
April 15, 2010
TABLE OF
CONTENTS
|
|
|
|
|
|
|
Page
|
|
|
|
|
2
|
|
|
|
|
2
|
|
|
|
|
2
|
|
|
|
|
2
|
|
|
|
|
2
|
|
|
|
|
2
|
|
|
|
|
2
|
|
|
|
|
3
|
|
|
|
|
3
|
|
|
|
|
3
|
|
|
|
|
3
|
|
|
|
|
4
|
|
|
|
|
4
|
|
|
|
|
4
|
|
|
|
|
4
|
|
|
|
|
5
|
|
|
|
|
5
|
|
|
|
|
7
|
|
|
|
|
8
|
|
|
|
|
8
|
|
|
|
|
8
|
|
|
|
|
8
|
|
|
|
|
8
|
|
|
|
|
8
|
|
|
|
|
9
|
|
|
|
|
10
|
|
|
|
|
11
|
|
|
|
|
12
|
|
|
|
|
12
|
|
|
|
|
12
|
|
|
|
|
13
|
|
|
|
|
13
|
|
|
|
|
27
|
|
|
|
|
27
|
|
|
|
|
28
|
|
|
|
|
28
|
|
|
|
|
30
|
|
|
|
|
31
|
|
|
|
|
32
|
|
|
|
|
32
|
|
|
|
|
33
|
|
|
|
|
|
|
|
|
Page
|
|
|
|
|
34
|
|
|
|
|
34
|
|
|
|
|
35
|
|
|
|
|
36
|
|
|
|
|
36
|
|
|
|
|
36
|
|
|
|
|
37
|
|
|
|
|
40
|
|
|
|
|
41
|
|
|
|
|
42
|
|
|
|
|
42
|
|
|
|
|
43
|
|
|
|
|
43
|
|
|
|
|
43
|
|
|
|
|
43
|
|
|
|
|
46
|
|
|
|
|
46
|
|
|
|
|
47
|
|
|
|
|
47
|
|
|
|
|
47
|
|
|
|
|
47
|
|
|
|
|
48
|
|
|
|
|
49
|
|
|
|
|
49
|
|
|
|
|
51
|
|
|
|
|
52
|
|
|
|
|
52
|
|
|
|
|
52
|
|
|
|
|
52
|
|
|
|
|
52
|
|
|
|
|
52
|
|
|
|
|
A-1
|
|
|
|
|
B-1
|
|
ii
|
|
|
|
Wright
Medical Group, Inc. |
5677 Airline Road, Arlington, Tennessee 38002 |
901-867-9971 |
www.wmt.com |
PROXY
STATEMENT
FOR
2010 ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON MAY 13, 2010
This Proxy Statement is being furnished in connection with the
solicitation of proxies by Wright Medical Group, Inc., on behalf
of our Board of Directors, for use at the 2010 Annual Meeting of
Stockholders and any postponement or adjournment thereof. The
meeting will be held at the River Inn of Harbor Town, located at
50 Harbor Town Square, Memphis, Tennessee, on May 13,
2010, beginning at 8:00 a.m. (Central Time).
At the meeting, our stockholders will vote on proposals to
(1) elect directors to serve on our Board of Directors for
a term of one year, (2) approve an amendment to our 2009
Equity Incentive Plan to increase by 700,000 the number of
shares of our common stock available for awards thereunder,
(3) approve the material terms of our 2010 Executive
Performance Incentive Plan, and (4) ratify the selection of
KPMG LLP as our independent auditor for 2010. The proposals are
set forth in the accompanying Notice of 2010 Annual Meeting of
Stockholders and are described in more detail in this Proxy
Statement. Stockholders also will transact any other business,
not known or determined at the time of this proxy solicitation,
that properly comes before the meeting, although our Board of
Directors knows of no such other business to be presented.
When you submit your proxy, by either voting by telephone or
executing and returning the enclosed proxy card, you will
authorize the proxy holders Gary D. Henley, our
President and Chief Executive Officer; Lance A. Berry, our
Senior Vice President and Chief Financial Officer; and Thomas L.
McAllister, our Assistant General Counsel and
Secretary to represent you and vote your shares of
our common stock on these proposals at the meeting in accordance
with your instructions. These persons also will have
discretionary authority to vote your shares on any other
business that properly comes before the meeting. They also may
vote your shares to adjourn the meeting and will be authorized
to vote your shares at any postponement or adjournment of the
meeting.
Our 2009 Annual Report, which includes our audited consolidated
financial statements, accompanies this Proxy Statement. Although
the 2009 Annual Report is being distributed with this Proxy
Statement, it does not constitute a part of the proxy
solicitation materials and is not incorporated herein by
reference.
We will provide, without charge, a copy of our annual report on
Form 10-K
for the year ended December 31, 2009, to our stockholders
upon request. All stockholder requests should be sent to the
Corporate Secretary, Wright Medical Group, Inc., 5677 Airline
Road, Arlington, Tennessee 38002.
This Proxy Statement and the accompanying materials are first
being sent or given to our stockholders on or about
April 15, 2010.
YOUR VOTE IS IMPORTANT. REGARDLESS OF WHETHER YOU PLAN TO
ATTEND THE MEETING, PLEASE PROMPTLY VOTE BY TELEPHONE OR
COMPLETE, SIGN, DATE, AND RETURN THE ENCLOSED PROXY CARD IN THE
ACCOMPANYING POSTAGE-PAID ENVELOPE.
INFORMATION
ABOUT THE MEETING
What is
the purpose of the meeting?
At the meeting, our stockholders will vote on the following
proposals to:
|
|
|
|
1.
|
Elect directors to serve on our Board of Directors for a term of
one year;
|
|
|
2.
|
Approve an amendment to our 2009 Equity Incentive Plan to
increase by 700,000 the number of shares of our common stock
available for awards thereunder;
|
|
|
3.
|
Approve the material terms of our 2010 Executive Performance
Incentive Plan for the purpose of enabling us to fully deduct
for tax purposes compensation paid thereunder; and
|
|
|
4.
|
Ratify the selection of KPMG LLP as our independent auditor for
2010.
|
In addition, our management may report on our performance during
2009 and will respond to appropriate questions from stockholders.
Who is
entitled to vote?
The record date for the meeting is March 22, 2010. Only
stockholders of record at the close of business on
March 22, 2010, are entitled to receive notice of the
meeting and to vote at the meeting the shares of our common
stock that they held on that date. Each outstanding share of
common stock entitles its holder to one vote on each matter
voted on at the meeting. At the close of business on
March 22, 2010, there were 38,804,774 outstanding shares of
common stock.
Am I
entitled to vote if my shares are held in street
name?
If you are the beneficial owner of shares held in street
name by a brokerage firm, bank, or other nominee, such
entity, as the record holder of the shares, is required to vote
the shares in accordance with your instructions. If you do not
give instructions to your nominee, it will nevertheless be
entitled to vote your shares on discretionary items
but will not be permitted to do so on
non-discretionary items. Proposal 1 (election
of directors), Proposal 2 (approval of an amendment to our
2009 Equity Incentive Plan) and Proposal 3 (approval of the
material terms of our 2010 Executive Performance Incentive Plan)
are non-discretionary items for which a nominee will not have
discretion to vote in the absence of voting instructions from
you. However, Proposal 4 (ratification of the selection of
the independent auditor) is an item on which your nominee will
be entitled to vote your shares even in the absence of
instructions from you.
How many
shares must be present to conduct business at the
meeting?
A quorum must be present at the meeting before conducting any
business. The presence at the meeting, in person or by proxy, of
the holders of a majority of the shares of our common stock
outstanding on the record date of March 22, 2010, will
constitute a quorum. Abstentions and broker non-votes will be
included in the number of shares considered present at the
meeting for the purpose of determining whether there is a quorum.
What
happens if a quorum is not present at the meeting?
If a quorum is not present at the scheduled time of the meeting,
the holders of a majority of the shares present in person or
represented by proxy at the meeting may adjourn the meeting to
another place, date, or time until a quorum is present. The
place, date, and time of the adjourned meeting will be announced
when the adjournment is taken, and no other notice will be given
unless the adjournment is for more than thirty days, or if after
the adjournment a new record date is fixed for the adjourned
meeting.
How do I
vote my shares?
If you are a registered stockholder, you may vote by
telephone. If you are a registered stockholder
(i.e., your shares are held in your own name), you
may vote by telephone by following the instructions included on
the proxy card. You do not need to return your proxy card if you
vote by telephone.
2
If your shares are held in street name, you may
be eligible to provide voting instructions to your nominee by
telephone or on the Internet. If you are a
beneficial owner of shares held in street name
(i.e., your shares are held in the name of a brokerage
firm, bank, or other nominee), you may be eligible to provide
voting instructions to your nominee by telephone or on the
Internet. A large number of brokerage firms, banks, and other
nominees participate in a program provided through Broadridge
Investor Communications Solutions (Broadridge) that offers
telephone and Internet voting options. If your shares are held
in street name by a brokerage firm, bank, or other
nominee that participates in the Broadridge program, you may
provide voting instructions to your nominee by telephone or on
the Internet by following the instructions set forth on the
voting instruction form provided to you. You do not need to
return your proxy card if you provide voting instructions to
your nominee by telephone or on the Internet.
You may vote by mail. If you are a registered
stockholder, you may vote by properly completing, signing,
dating, and returning the accompanying proxy card. The enclosed
postage-paid envelope requires no additional postage if it is
mailed in the United States or Canada. If you are a beneficial
owner of shares held in street name, you may provide
voting instructions to the brokerage firm, bank, or other
nominee that holds your shares by properly completing, signing,
dating, and returning the voting instruction form provided to
you by your nominee.
You may vote in person at the meeting. If you
are a registered stockholder and attend the meeting, you may
deliver your completed proxy card in person. In addition, we
will pass out written ballots to registered stockholders who
wish to vote in person at the meeting. If you are a beneficial
owner of shares held in street name and wish to vote
at the meeting, you will need to obtain a proxy form from the
brokerage firm, bank, or other nominee that holds your shares.
Can I
change my vote after I submit my proxy?
Yes, you can revoke your proxy and change your vote at any time
before the polls are closed at the meeting in any of the
following ways: (1) by voting again by telephone, because
only your latest telephone vote will be counted; (2) by
properly completing, signing, dating, and returning another
proxy card with a later date; (3) if you are a registered
stockholder, by voting in person at the meeting; (4) if you
are a registered stockholder, by giving written notice of such
revocation to our Corporate Secretary prior to or at the
meeting; or (5) if you are a beneficial owner of shares
held in street name, by following the instructions
given by the brokerage firm, bank, or other nominee that holds
your shares. Your attendance at the meeting itself will not
revoke your proxy unless you give written notice of revocation
to our Corporate Secretary before the polls are closed.
Who will
count the votes?
American Stock Transfer & Trust Company (AST),
the registrar and transfer agent for our common stock, will
tabulate and certify the stockholder votes submitted by proxy. A
representative of AST will serve as the inspector of election at
the meeting.
How does
our Board of Directors recommend that I vote on the
proposals?
Our Board of Directors recommends that you vote:
|
|
|
|
1.
|
FOR the election of the director nominees to serve on our Board
of Directors for a term of one year;
|
|
|
2.
|
FOR the approval of an amendment to our 2009 Equity Incentive
Plan to increase by 700,000 the number of shares of our common
stock available for awards thereunder;
|
|
|
3.
|
FOR the approval of the material terms of our 2010 Executive
Performance Incentive Plan for the purpose of enabling us to
fully deduct for tax purposes compensation paid
thereunder; and
|
|
|
4.
|
FOR the ratification of the selection of KPMG LLP as our
independent auditor for 2010.
|
What
happens if I do not specify how my shares are to be
voted?
If you submit a proxy but do not indicate any voting
instructions, your shares will be voted FOR each of the
proposals.
3
Will any
other business be conducted at the meeting?
As of the date hereof, our Board of Directors knows of no
business that will be presented at the meeting other than the
proposals described in this Proxy Statement. However, if any
other proposal properly comes before the stockholders for a vote
at the meeting, the proxy holders will vote your shares in
accordance with their best judgment.
How many
votes are required for action to be taken on each
proposal?
Election of Directors. The director nominees
will be elected to serve on our Board of Directors for a term of
one year if they receive a plurality of the votes of the shares
present in person or represented by proxy at the meeting and
entitled to vote on the subject matter. This means that the
director nominees will be elected if they receive more votes
than any other person at the meeting. If you vote to
Withhold Authority with respect to the election of
one or more director nominees, your shares will not be voted
with respect to the person or persons indicated, although they
will be counted for the purpose of determining whether there is
a quorum at the meeting.
Approval of an Amendment to Our 2009 Equity Incentive
Plan. The Amendment to our 2009 Equity Incentive
Plan will be approved if a majority of the shares present in
person or represented by proxy at the meeting and entitled to
vote on the subject matter are voted in favor of the proposal.
Approval of the Material Terms of Our 2010 Executive
Performance Incentive Plan. The material terms of
our 2010 Executive Performance Incentive Plan will be approved
if a majority of the shares present in person or represented by
proxy at the meeting and entitled to vote on the subject matter
are voted in favor of the proposal.
Ratification of Selection of Independent
Auditor. The selection of KPMG LLP as our
independent auditor for 2010 will be ratified if a majority of
the shares present in person or represented by proxy at the
meeting and entitled to vote on the subject matter are voted in
favor of the proposal.
How will
abstentions be treated?
You do not have the option of abstaining from voting on
Proposal 1 (election of directors), but you may abstain
from voting on Proposal 2 (approval of an amendment to our
2009 Equity Incentive Plan), Proposal 3 (approval of the
material terms of our 2010 Executive Performance Incentive
Plan), and Proposal 4 (ratification of the selection of the
independent auditor). With respect to Proposal 1, because
the directors are elected by a plurality vote, an abstention
will have no effect on the outcome of the vote and, therefore,
is not offered as a voting option on the proposal. In the case
of an abstention on Proposal 2, Proposal 3, or
Proposal 4, your shares would be included in the number of
shares considered present at the meeting for the purpose of
determining whether there is a quorum. Because your shares would
be voted but not in favor of Proposal 2, Proposal 3,
or Proposal 4, your abstention would have the same effect
as a negative vote in determining the outcome of the vote on the
proposal.
How will
broker non-votes be treated?
A broker non-vote occurs when a brokerage firm,
bank, or other nominee does not vote shares that it holds in
street name on behalf of a beneficial owner, because
the beneficial owner has not provided voting instructions to the
nominee with respect to a non-discretionary item.
Proposal 1 (election of directors), Proposal 2
(approval of an amendment to our 2009 Equity Incentive Plan) and
Proposal 3 (approval of the material terms of our 2010
Executive Performance Incentive Plan) are non-discretionary
items for which a nominee will not have discretion to vote in
the absence of voting instructions from the beneficial owner.
Proposal 4 (ratification of the selection of the
independent auditor), on the other hand, is a discretionary item
for which a nominee will have discretion to vote even without
voting instructions from the beneficial owner. Accordingly, it
is possible for there to be broker non-votes with respect to
Proposals 1, Proposal 2, and Proposal 3 but there
will not be broker non-votes with regard to Proposal 4.
In the case of a broker non-vote, your shares would be
included in the number of shares considered present at the
meeting for the purpose of determining whether there is a
quorum. A broker non-vote, being shares not entitled to vote,
would not have any effect on the outcome of the vote on
Proposal 1, Proposal 2, and Proposal 3.
4
STOCK
OWNERSHIP
Directors,
Executive Officers, and Other Stockholders
The following table provides information about the beneficial
ownership of our common stock as of February 28, 2010, by
each of our directors, each of our executive officers named in
the Summary Compensation Information table in this
Proxy Statement, all of our directors and executive officers as
a group, and each person known to our management to be the
beneficial owner of more than 5% of the outstanding shares of
common stock.
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage
|
|
|
Number of Shares
|
|
of Shares
|
Name of Beneficial Owner
|
|
Beneficially
Owned(1, 2,
3)
|
|
Outstanding(4)
|
|
Directors and Executive Officers:
|
|
|
|
|
|
|
|
|
Gary D. Henley
|
|
|
436,601
|
|
|
|
1.12
|
%
|
Lance A. Berry
|
|
|
154,762
|
|
|
|
*
|
|
John K.
Bakewell(5)
|
|
|
8,043
|
|
|
|
*
|
|
William L. Griffin, Jr.
|
|
|
62,258
|
|
|
|
*
|
|
Edward A. Steiger
|
|
|
36,863
|
|
|
|
*
|
|
Frank S. Bono
|
|
|
72,679
|
|
|
|
*
|
|
Gary D. Blackford
|
|
|
23,435
|
|
|
|
*
|
|
Carmen L. Diersen
|
|
|
6,790
|
|
|
|
*
|
|
Martin J. Emerson
|
|
|
43,265
|
|
|
|
*
|
|
Lawrence W. Hamilton
|
|
|
25,765
|
|
|
|
*
|
|
John L. Miclot
|
|
|
25,765
|
|
|
|
*
|
|
Amy S. Paul
|
|
|
13,435
|
|
|
|
*
|
|
Robert J. Quillinan
|
|
|
25,765
|
|
|
|
*
|
|
David D. Stevens
|
|
|
60,765
|
|
|
|
*
|
|
All directors and executive officers as a group (15 persons)
|
|
|
1,156,864
|
|
|
|
2.93
|
%
|
Other Stockholders:
|
|
|
|
|
|
|
|
|
FMR LLC(6)
82 Devonshire Street
Boston, MA 02109
|
|
|
3,381,287
|
|
|
|
8.72
|
%
|
T. Rowe Price Associates,
Inc.(7)
100 East Pratt Street
Baltimore, MD 21202
|
|
|
3,055,300
|
|
|
|
7.88
|
%
|
Wellington Management Company,
LLP(8)
75 State Street
Boston, MA 02109
|
|
|
2,646,029
|
|
|
|
6.83
|
%
|
Neuberger Berman Group
LLC(9)
605 Third Avenue
New York, NY 10158
|
|
|
2,410,034
|
|
|
|
6.22
|
%
|
Kornitzer Capital Management,
Inc.(10)
5420 West 61st Place
Shawnee Mission, KS 66205
|
|
|
2,376,480
|
|
|
|
6.13
|
%
|
BlackRock,
Inc.(11)
40 East 52nd Street
New York, NY 10022
|
|
|
2,269,102
|
|
|
|
5.85
|
%
|
Wells Fargo &
Company(12)
420 Montgomery Street
San Francisco, CA 94163
|
|
|
2,261,810
|
|
|
|
5.83
|
%
|
|
|
|
*
|
|
Less than 1% of the outstanding
shares of common stock.
|
5
|
|
|
(1)
|
|
A persons beneficial
ownership of common stock is determined in accordance with the
rules and regulations of the U.S. Securities and Exchange
Commission (SEC). Except as indicated elsewhere in the footnotes
to this table and subject to applicable community property laws,
the persons named in the table have sole voting power and sole
investment power with respect to the shares of common stock that
they beneficially own.
|
|
(2)
|
|
The shares of common stock shown in
the table include the following numbers of shares that the
indicated persons have the right to acquire as of
February 28, 2010, or within sixty days thereafter
(i.e., April 29, 2010), upon the exercise of options
granted by us: Mr. Henley 337,500 shares;
Mr. Berry 115,451 shares;
Mr. Bakewell 0 shares;
Mr. Griffin 25,000 shares;
Mr. Steiger 12,500 shares;
Mr. Bono 41,000 shares;
Mr. Blackford 3,750 shares;
Ms. Diersen 0 shares;
Mr. Emerson 35,000 shares;
Mr. Hamilton 17,500 shares;
Mr. Miclot 17,500 shares;
Ms. Paul 3,750 shares;
Mr. Quillinan 17,500 shares;
Mr. Stevens 52,500 shares; and all
directors and executive officers as a group
786,488 shares.
|
|
(3)
|
|
The shares of common stock shown in
the table include the following numbers of shares of restricted
stock for which the indicated persons have sole voting power,
but not sole investment power: Mr. Henley
90,644 shares; Mr. Berry
36,604 shares; Mr. Bakewell 0 shares;
Mr. Griffin 34,544 shares;
Mr. Steiger 23,363 shares;
Mr. Bono 31,470 shares;
Mr. Blackford 8,614 shares;
Ms. Diersen 6,790 shares;
Mr. Emerson 5,400 shares;
Mr. Hamilton 5,400 shares;
Mr. Miclot 5,400 shares;
Ms. Paul 8,614 shares;
Mr. Quillinan 5,400 shares;
Mr. Stevens 5,400 shares; and all
directors and executive officers as a group
307,791 shares.
|
|
(4)
|
|
The percentage of outstanding
shares of common stock beneficially owned by each person is
calculated based on the 38,764,321 outstanding shares of common
stock as of February 28, 2010, plus the shares of common
stock that such person has the right to acquire as of such date
or within sixty days thereafter (i.e., April 29,
2010) upon the exercise of options granted by us.
|
|
(5)
|
|
Mr. Bakewell resigned from his
position as our Executive Vice President and Chief Financial
Officer effective December 11, 2009.
|
|
(6)
|
|
Pursuant to an amendment to
Schedule 13G filed by FMR LLC (FMR) with the SEC on
February 16, 2010, Fidelity Management & Research
Company (Fidelity), a wholly-owned subsidiary of FMR and an
investment advisor, is the beneficial owner of
3,381,287 shares of common stock, as a result of acting as
an investment advisor to various investment companies. Edward C.
Johnson 3d (Johnson), chairman of FMR, and FMR, through its
control of Fidelity and the Fidelity Funds, each has sole power
to dispose of 3,381,287 shares of common stock owned by the
Fidelity Funds. Members of the Johnson family are the
predominant owners, directly or through trusts, of Series B
voting common shares of FMR, representing 49% of the voting
power of FMR. The Johnson family group and all other
Series B shareholders have entered into a
shareholders voting agreement under which all
Series B voting common shares will be voted in accordance
with the majority vote of Series B voting common shares.
Accordingly, through their ownership of voting common shares and
the execution of the shareholders voting agreement,
members of the Johnson family may be deemed to form a
controlling group with respect to FMR. Neither FMR nor Johnson
has the sole power to vote or direct the voting of the shares
owned directly by Fidelity Funds, which power resides with the
Fidelity Funds Boards of Trustees. Notwithstanding the
power to vote shares owned directly by Fidelity Funds, FMR
reports that it has sole voting power with respect to
2,400 shares of common stock in the amended Schedule 13G.
|
|
(7)
|
|
Pursuant to a Schedule 13G
filed by T. Rowe Price Associates, Inc. (Price Associates) with
the SEC on February 11, 2010, Price Associates, in its
capacity as investment advisor, beneficially owns
3,055,300 shares of common stock. Price Associates has sole
voting power with respect to 318,700 shares and shared
investment power with respect to 3,055,300 shares.
|
|
(8)
|
|
Pursuant to a Schedule 13G
filed by Wellington Management Company, LLP (Wellington) with
the SEC on February 12, 2010, Wellington, in its
capacity as investment advisor, beneficially owns
2,646,029 shares of common stock, which are held of record
by clients of Wellington. Wellington has shared voting power
with respect to 1,612,729 shares and shared investment
power with respect to 2,646,029 shares.
|
|
(9)
|
|
Pursuant to an amendment to
Schedule 13G jointly filed by Neuberger Berman Group LLC,
Neuberger Berman LLC, Neuberger Berman Management LLC and
Neuberger Berman Equity Funds (Neuberger) with the SEC on
February 16, 2010, Neuberger Berman Group LLC, and
Neuberger Berman Management LLC serve as
sub-advisor
and investment manager, respectively, of Neuberger Berman Group
LLCs various registered mutual funds which hold such
shares of common stock in the ordinary course of their business
and not with the purpose nor with the effect of changing or
influencing the control of the issuer. The holdings of Neuberger
Berman Fixed Income LLC and NB Alternative Fund Management
LLC, affiliates of Neuberger Berman LLC, are also aggregated to
comprise the reported holdings of shares of common stock.
Neuberger Berman Group LLC, Neuberger Berman LLC, Neuberger
Berman Management LLC and certain affiliated persons directly
own no shares of common stock. As investment advisors, certain
affiliated persons that are controlled by Neuberger Berman Group
LLC have investment and voting powers with respect to the shares
|
6
|
|
|
|
|
of common stock held. Neuberger has
shared voting power with respect to 1,926,534 shares and
shared investment power with respect to 2,410,034 shares.
|
|
(10)
|
|
Pursuant to a Schedule 13G
filed by Kornitzer Capital Management, Inc. (KCM) with the SEC
on January 22, 2010, KCM, in its capacity as investment
advisor, beneficially owns 2,376,480 shares of common
stock. KCM has sole voting power with respect to
2,376,480 shares, sole investment power with respect to
2,315,026 shares and shared dispositive power with respect
to 61,454 shares.
|
|
(11)
|
|
Pursuant to an amendment to
Schedule 13G filed by BlackRock, Inc. (BlackRock) with the
SEC on January 29, 2010, BlackRock completed its
acquisition of Barclays Global Investors, NA and certain of its
affiliates (collectively, BGI Entities) on December 1,
2009. BlackRock and its subsidiaries (including the BGI
Entities), in the subsidiaries capacity as investment
advisors, beneficially own 2,269,102 shares of common
stock. BlackRock has sole voting power with respect to
2,269,102 shares and sole investment power with respect to
2,269,102 shares.
|
|
(12)
|
|
Pursuant to a Schedule 13G
filed by Wells Fargo & Company (Wells Fargo) with the
SEC on January 29, 2009, Wells Fargo and its subsidiaries,
in the subsidiaries respective capacities as investment
advisors, banks and a broker dealer, beneficially own
2,261,810 shares of common stock. Wells Fargo has sole
voting power with respect to 2,132,556 shares, sole
investment power with respect to 2,233,122 shares, and
shared investment power with respect to 25,688 shares.
|
Section 16(a)
Beneficial Ownership Reporting Compliance
Section 16(a) of the Securities Exchange Act of 1934
requires that our directors and executive officers and the
beneficial owners of more than 10% of the our registered equity
securities (the reporting persons) file with the SEC initial
reports of, and subsequent reports of changes in, their
beneficial ownership of our equity securities. The reporting
persons are required to furnish copies of all such
Section 16(a) reports to us. Based solely on our review of
the copies of such Section 16(a) reports and written
representations from certain reporting persons furnished to us,
we believe that the reporting persons complied with all
applicable Section 16(a) filing requirements during 2009.
7
BOARD OF
DIRECTORS
General
Our Board of Directors currently consists of nine directors. Our
directors are David D. Stevens (chairman), Gary D. Blackford,
Carmen L. Diersen, Martin J. Emerson, Lawrence W. Hamilton, Gary
D. Henley, John L. Miclot, Amy S. Paul, and Robert J.
Quillinan. The directors are elected at each annual meeting of
stockholders and serve for a term of one year until the next
annual meeting of stockholders and until their respective
successors are elected and qualified, subject to their prior
death, resignation, retirement, disqualification, or removal
from office. Each of our directors except Ms. Diersen was
elected by our stockholders at the 2009 annual meeting of
stockholders. Ms. Diersen was appointed by our Board of
Directors on November 12, 2009.
Director
Independence
It is the policy of our Board of Directors that a majority of
the directors be independent as defined in the listing standards
of the Nasdaq Stock Market (Nasdaq). Our Board of Directors has
determined that eight directors Gary D. Blackford,
Carmen L. Diersen, Martin J. Emerson, Lawrence W. Hamilton, John
L. Miclot, Amy S. Paul, Robert J. Quillinan, and David D.
Stevens are independent as defined in Nasdaqs
listing standards.
Board
Leadership Structure
Our Board of Directors has chosen to separate the Chief
Executive Officer and Board Chairman positions. Our Board of
Directors is led by an independent Chairman, David D. Stevens.
Our Chief Executive Officer, Gary D. Henley, is the only
member of our Board of Directors who is not an independent
director as defined in the listing standards of Nasdaq. We
believe that this leadership structure enhances the
accountability of the Chief Executive Officer to our Board of
Directors and strengthens our Board of Directors
independence from management. In addition, separating these
roles allows Mr. Henley to focus his efforts on managing
our business, while our Board of Directors benefits from
Mr. Henleys experience, expertise, and judgment.
Risk
Oversight
Our Board of Directors is responsible for overseeing our risk
management process. Our Board of Directors focuses on our
general risk management strategy, the most significant risks to
us, and ensures that appropriate risk mitigation strategies are
implemented by management. Our Board of Directors is also
apprised of particular risk management matters in connection
with its general oversight and approval of corporate matters.
Under our Audit Committees charter, our Audit Committee
discuses with management and the independent auditor our major
financial risk exposures and the steps that management has taken
to monitor and control such exposures, including our risk
assessment and risk management policies and guidelines.
Our management is responsible for
day-to-day
risk management. Our finance and accounting, legal, and
compliance areas serve as the primary monitoring and testing
function for company-wide policies and procedures, and manage
the
day-to-day
oversight of our risk management strategy for our ongoing
business. This oversight includes identifying, evaluating, and
addressing potential risks that may exist at the enterprise,
strategic, financial, operational, compliance, and reporting
levels.
The other committees of our Board of Directors also consider and
address risk as they perform their respective committee
responsibilities. All committees report to the full Board of
Directors as appropriate, including when a matter rises to the
level of a material or enterprise level risk.
We believe the division of risk management responsibilities
described above is an effective approach for addressing the
risks facing us.
Meetings
Attended by Directors
Our Board of Directors holds meetings on a quarterly basis and
on other occasions as necessary or appropriate. Our Board of
Directors met six times in 2009. Our Board of Directors has
three standing committees the Audit
8
Committee, the Compensation Committee, and the Nominating,
Compliance and Governance Committee. The Audit Committee, the
Compensation Committee, and the Nominating, Compliance and
Governance Committee met five, eight, and five times,
respectively, in 2009. During the time period he or she served,
each director attended 100% of the total number of meetings of
our Board of Directors and its committees on which he or she
served in 2009.
Our independent directors have regularly scheduled meetings at
which only they are present. Our independent directors met four
times in 2009. Pursuant to our Corporate Governance Principles,
the chairman of our Nominating, Compliance and Governance
Committee or another independent director selected by a majority
of the independent directors presides at these meetings.
Our directors are encouraged to attend our annual meeting of
stockholders absent exceptional cause. Seven of our eight
directors who were serving at the time attended the 2009 annual
meeting of stockholders.
Board of
Directors Committees
Our Board of Directors delegates certain of its functions to its
standing Audit Committee, Compensation Committee, and
Nominating, Compliance and Governance Committee. Information
regarding the responsibilities of these committees and their
members is provided below.
Audit Committee. The Audit Committee oversees
our accounting and financial reporting processes and the audits
of our financial statements. In this role, the Audit Committee
monitors and oversees the integrity of our financial statements
and related disclosures, the qualifications, independence, and
performance of our independent auditor, the performance of our
internal auditing function, and our compliance with applicable
legal requirements and our business conduct policies. The Audit
Committee has a written charter, which was revised by our Board
of Directors on April 21, 2005. A copy of the charter is
posted on our website at
http://www.wmt.com/Corporate/Audit_Committee_Charter_Revise_April_21_2005.pdf.
The information on our website, however, is not a part of this
Proxy Statement. The Audit Committee is composed of three
directors who are appointed by our Board of Directors upon the
recommendation of the Nominating, Compliance and Governance
Committee. The members of the Audit Committee are Robert J.
Quillinan (chairman), Gary D. Blackford, and Martin J. Emerson,
all of whom are independent as defined in Nasdaqs listing
standards and meet the independence criteria set forth in the
SECs rules. Our Board of Directors has determined that
each member of the Audit Committee is an audit committee
financial expert as defined in the SECs regulations. The
report of the Audit Committee appears on page 12 of this
Proxy Statement.
Compensation Committee. The Compensation
Committee oversees our compensation and benefit programs,
including director compensation, executive compensation, equity
compensation, incentive compensation, selection and retention of
key management, and succession planning. The Compensation
Committee has a written charter, which was revised by our Board
of Directors on October 23, 2006 and amended on
July 27, 2009. A copy of the charter is posted on our
website at
http://www.wmt.com/Corporate/Compensation_Committee_Charter_07272009.pdf.
The information on our website, however, is not a part of this
Proxy Statement. The Compensation Committee is composed of three
directors who are appointed by our Board of Directors upon the
recommendation of the Nominating, Compliance and Governance
Committee. The members of the Compensation Committee are
Lawrence W. Hamilton (chairman), Martin J. Emerson, and David D.
Stevens, all of whom are independent as defined in Nasdaqs
listing standards and meet the independence criteria set forth
in the SECs rules. The report of the Compensation
Committee appears beginning on page 13 of this Proxy
Statement.
Nominating, Compliance and Governance
Committee. The Nominating, Compliance and
Governance Committee oversees our corporate compliance and
governance processes. In this role, the Nominating, Compliance
and Governance Committee identifies and recommends individuals
qualified to become a member of our Board of Directors, makes
recommendations regarding the establishment and membership of
the committees of our Board of Directors, develops and reviews
corporate governance principles applicable to us, and leads the
annual review of the performance of our Board of Directors and
its committees. The Nominating, Compliance and Governance
Committee has a written charter, which was revised by our Board
of Directors on October 27, 2009. A copy of the charter is
posted on our website at
http://www.wmt.com/Corporate/Corporate_Governance_Committee_CharterV6.pdf.
The information on our website, however, is not a part of this
Proxy Statement. The Nominating,
9
Compliance and Governance Committee is composed of three
directors who are appointed by our Board of Directors. The
members of the Nominating, Compliance and Governance Committee
are John L. Miclot (chairman), Carmen L. Diersen, and Amy S.
Paul, all of whom are independent as defined in Nasdaqs
listing standards and meet the independence criteria set forth
in the SECs rules. During 2009, Lawrence W. Hamilton
served on the Nominating, Compliance and Governance Committee
and met the independence requirements of the Nasdaqs
listing standards and the SECs rules.
Director
Nominations
Our Board of Directors will consider all potential candidates
for nomination by our Board of Directors for election as
directors who are recommended by our stockholders, directors,
officers, and employees. All director recommendations must be
made in accordance with the provisions of Article II,
Section 5 of our bylaws, which sets forth requirements
concerning the information about the candidate to be provided
and the timing for the submission of the recommendations. All
director recommendations should be sent to the Nominating,
Compliance and Governance Committee,
c/o Corporate
Secretary, Wright Medical Group, Inc., 5677 Airline Road,
Arlington, Tennessee 38002. The Nominating, Compliance and
Governance Committee will screen all potential director
candidates in the same manner, regardless of the source of their
recommendation. The Nominating, Compliance and Governance
Committees review typically will be based on the written
materials provided with respect to a potential director
candidate. The Nominating, Compliance and Governance Committee
will evaluate and determine whether a potential candidate meets
our minimum qualifications and specific qualities and skills for
directors and whether requesting additional information or an
interview is appropriate.
Our Board of Directors and the Nominating, Compliance and
Governance Committee believe that our Board of Directors, as a
whole, should possess a diverse combination of perspectives,
expertise, and experience necessary to oversee our current and
future needs. Our Board of Directors has adopted the following
series of minimum qualifications and specific qualities and
skills for our directors, which will serve as the basis upon
which potential director candidates are evaluated by the
Nominating, Compliance and Governance Committee:
|
|
|
|
|
Directors should possess the highest personal and professional
ethics, integrity, and values.
|
|
|
|
Directors should have an inquisitive and objective perspective,
practical wisdom, and mature judgment.
|
|
|
|
Directors should have expertise and experience at policy-making
levels in areas that are relevant to our business.
|
|
|
|
Directors should have, or demonstrate an ability and willingness
to acquire in short order, a clear understanding of the
fundamental aspects of our business.
|
|
|
|
Directors should be committed to representing the long-term
interests of our stockholders.
|
|
|
|
Directors should be willing to devote sufficient time to carry
out their duties and responsibilities effectively and should be
committed to serving on our Board of Directors for an extended
period of time.
|
|
|
|
Directors should offer their resignation in the event of any
significant change in their personal circumstances, including a
change in their principal job responsibilities.
|
|
|
|
Directors, who also serve as the chief executive officer, chief
operating officer, or chief financial officer of another public
company should not serve on more than two boards of public
companies in addition to our Board of Directors, and other
directors should not serve on more than four boards of public
companies in addition to our Board of Directors.
|
In making our determinations regarding director nominees, our
Board of Directors will consider whether a potential candidate
has previously served as our director. Our Board of Directors
does not believe, however, that directors should expect to be
automatically renominated on an annual basis. Instead, the
annual self-assessment of the performance of our Board of
Directors and its committees is an important determinant of
director tenure.
Each current director and candidate for reelection in
Proposal 1 (election of directors) brings a strong and
unique set of experience, qualifications, attributes and skills
in a wide variety of areas, including board service, executive
management, sales, marketing and international business. Set
forth below are the specific experience,
10
qualifications, attributes and skills of the nominees for
reelection to our Board of Directors that led to the conclusion
that the nominee should serve as a member of our Board of
Directors.
David D. Stevens has served on our Board of Directors since
2004, longer than any of the other director nominees. With this
experience, he brings valuable insight into our business and its
development since 2004. In addition, Mr. Stevens has
extensive experience serving in executive and director roles of
public companies, which we believe makes him well suited to lead
our Board of Directors as our Board of Directors chairman.
Gary D. Blackford gained executive experience with a
wound-management company and experience as a director with other
companies. We believe his experience provides valuable insight
into the market for our biologics line, and his experience
leading companies contributes to the effectiveness of our Board
of Directors.
Carmen L. Diersen has finance, business development and
management experience in the medical device industry and has
been a certified public accountant since 1983. We believe that
her experience adds to our Board of Directors overall
expertise in finance and business development as it relates to
the medical device industry.
Martin J. Emerson serves and has served as director and Chief
Executive Officer of several medical device companies, which we
believe allows him to contribute insight into our industry.
Mr. Emerson also has management experience with
international operations of medical device and other companies,
which allows him to provide guidance on our international
operations.
Lawrence W. Hamilton has significant management experience in
human resources. We believe that Mr. Hamiltons
experience in managing employees and establishing compensation
policies and guidelines provides us with a valuable resource for
our compensation and human resources functions.
Gary D. Henley has extensive knowledge of our business and the
medical device industry. As our Chief Executive Officer, we
believe that Mr. Henleys perspective into our
business is an invaluable resource for our Board of Directors.
John L. Miclot has served in executive roles in several medical
device companies and Mr. Miclots deep knowledge of
medical device companies provides us with insight into our
business and markets.
Amy S. Paul has over two decades of experience in the medical
device industry, having served in executive roles in marketing
and sales functions. We believe that Ms. Pauls
executive experience in sales and marketing in the medical
device industry provides us with leadership in our most critical
functions.
Robert J. Quillinan brings over 30 years of experience in
accounting, audit, and related functions.
Mr. Quillinans experience preparing financial
statements and SEC reports gives our Board of Directors and our
Audit Committee, for which he is chairman, expertise in
financial reporting, including the establishment and review of
internal controls over financial reporting.
Corporate
Governance Principles
Our Board of Directors has adopted Corporate Governance
Principles to guide our Board of Directors in carrying out its
governance duties along with the provisions of our Articles of
Incorporation, bylaws, and all applicable rules, regulations,
and laws. The Corporate Governance Principles are posted on our
website at
http://www.wmt.com/Corporate/Corporate_Governance_PrinciplesV6.pdf.
The information on our website, however, is not a part of this
Proxy Statement. In addition to other matters, our Corporate
Governance Principles require that any director up for election
at our annual meeting of stockholders, who fails to receive at
least a majority of the votes cast for election, shall offer to
resign from our Board of Directors. The Nominating, Compliance
and Governance Committee then makes a recommendation to our
Board of Directors whether to accept, reject, or take other
action regarding the offered resignation. Our Board of Directors
must review the recommendation of the Nominating, Compliance and
Governance Committee and act promptly to accept, reject, or take
other action it deems appropriate under the circumstances. The
affected director does not take part in the deliberations or
actions of the Nominating, Compliance and Governance Committee
or our Board of Directors in this matter. If our Board of
Directors chooses not to accept the resignation of the director,
then the director will continue to serve until his or her
successor is duly elected, or until the director resigns, is
removed, or dies. If our Board of Directors accepts the
11
resignation, then our Board of Directors will fill the resulting
vacancy pursuant to our Articles of Incorporation and bylaws,
and all applicable rules, regulations, and laws.
Policies
and Procedures for Monitoring, Reviewing, Approving, or
Ratifying Transactions with Related Persons
Our Board of Directors has adopted a written Related Persons
Transactions Policy (the Policy) for monitoring, reviewing,
approving, and ratifying transactions with related persons. The
Policy applies to all financial transactions, arrangements, or
relationships or any series of similar transactions,
arrangements, or relationships in which we were, are, or will be
a participant and in which a related person had or will have a
direct or indirect material interest.
Transactions that are subject to the Policy must be approved by
the Audit Committee. The Audit Committee is authorized to
approve those transactions with related persons that are in, or
are not inconsistent with, our best interests and our
stockholders best interests and that are consistent with
our Code of Business Conduct. The Audit Committee chairman,
acting alone, may approve those transactions with related
persons that meet the foregoing criteria and that are valued at
$25,000 or less. All approvals made by the Audit Committee
chairman are required to be reported to the entire Audit
Committee at the next available opportunity.
The Audit Committee or its chairman will consider all relevant
factors, including as applicable, (i) the benefits of the
transaction to us, (ii) whether the transaction is material
to us, (iii) the effect, if any, of the transaction on a
directors independence in the event the related person is
a director or an immediate family member or affiliate of a
director, (iv) the availability of other sources for
comparable products or services, (v) the terms of the
transaction and whether they are fair and reasonable to us,
(vi) the terms available to or from unrelated third parties
or to employees generally, (vii) the role of the related
person in arranging the transaction, (viii) the interests
of the related person, and (ix) whether the potential
transaction with a related person is consistent with our Code of
Business Conduct. The Audit Committee will annually review and
consider any previously approved or ratified transaction with a
related person that remains ongoing to determine whether the
transaction requires additional or continuing approval if
conditions should be imposed with respect to the transaction.
We are not currently and have not been engaged in any
transactions with related persons since January 1, 2009.
Stockholder
Communications
Stockholders may communicate with our Board of Directors or any
individual director regarding any matter relating to us that is
within the responsibilities of our Board of Directors.
Stockholders, when acting solely in such capacity, should send
their communications to our Board of Directors or an individual
director
c/o Corporate
Secretary, Wright Medical Group, Inc., 5677 Airline Road,
Arlington, Tennessee 38002. The Corporate Secretary will discuss
with the Chairman of our Board of Directors or the individual
director whether the subject matter of a stockholder
communication is within the responsibilities of our Board of
Directors. The Corporate Secretary will forward a stockholder
communication to the Chairman of our Board of Directors or the
individual director if such person determines that the
communication meets this standard.
Audit
Committee Report
Management is responsible for our accounting and financial
reporting processes, including our internal control over
financial reporting, and for preparing our consolidated
financial statements. KPMG LLP (KPMG), our independent auditor,
is responsible for performing an audit of our consolidated
financial statements in accordance with the standards of the
Public Company Accounting Oversight Board and for expressing an
opinion on the conformity of our audited consolidated financial
statements to accounting principles generally accepted in the
United States of America. In this context, the responsibility of
the Audit Committee of our Board of Directors is to oversee our
accounting and financial reporting processes and the audits of
our consolidated financial statements.
In the performance of its oversight function, the Audit
Committee reviewed and discussed with management and KPMG our
audited consolidated financial statements as of and for the year
ended December 31, 2009. The Audit Committee discussed
with KPMG the matters required to be discussed by the Statement
on Auditing
12
Standards No. 61, as amended (AICPA, Professional
Standards, Vol. 1. AU Section 380), as adopted by the
Public Company Accounting Oversight Board in Rule 3200T.
The Audit Committee has received and reviewed the written
disclosures and the letter from KPMG required by the applicable
requirements of the Public Company Accounting Oversight Board
regarding KPMGs communications with the Audit Committee
concerning independence, and has discussed with KPMG their
independence from the Company and management.
Based on the review and discussions referred to in the paragraph
above, the Audit Committee recommended to our Board of Directors
that the Companys audited consolidated financial
statements be included in the Annual Report on
Form 10-K
for the year ended December 31, 2009, to be filed with the
SEC.
* * *
The foregoing report is provided by the members of the Audit
Committee of our Board of Directors.
Robert J. Quillinan (chairman)
Gary D. Blackford
Martin J. Emerson
Compensation
Committee Report
The Compensation Committee of our Board of Directors has the
primary authority for determining our compensation philosophy
and establishing compensation for our executive officers. The
Compensation Committee sets performance goals and objectives for
the President and Chief Executive Officer (CEO) and the other
executive officers, evaluates their performance with respect to
those goals and sets their compensation based upon the
evaluation of their performance. In evaluating executive officer
compensation, the Compensation Committee considers
recommendations from our CEO with respect to goals and
compensation of the other executive officers and assesses the
information that it receives. The Compensation Committee
recommends the compensation of the CEO for approval by the
independent directors of our Board of Directors. The
Compensation Committee also periodically reviews director
compensation. From time to time we may engage consultants with
specific expertise related to executive officer or director
compensation and benefits. All decisions with respect to
executive officer and director compensation are approved by the
Compensation Committee.
The Compensation Committee has reviewed and discussed the
Compensation Discussion and Analysis for the year ended
December 31, 2009 with management. In reliance upon the
reviews and discussions referred to above, the Compensation
Committee recommended to our Board of Directors, and our Board
of Directors has approved, that the following Compensation
Discussion and Analysis be included in the Proxy Statement for
the Annual Meeting of Stockholders to be held on May 13,
2010 to be filed with the SEC.
* * *
The foregoing report is provided by the members of the
Compensation Committee of our Board of Directors.
Lawrence W. Hamilton (chairman)
Martin J. Emerson
David D. Stevens
Compensation
Discussion and Analysis
In the following Compensation Discussion and Analysis, we
describe the material elements of compensation awarded to our
CEO, our chief financial officer, our former chief financial
officer who resigned effective December 11, 2009, and our
three other most highly compensated executive officers during
2009. We focus primarily on the 2009 information contained in
the tables and related footnotes and narrative under the heading
Executive Compensation below, but also describe
compensation actions taken during other periods to the extent it
enhances the understanding of our executive compensation
disclosure for 2009. In this discussion, we refer to each
named executive officer identified in the tables as
an executive officer.
13
General Philosophy. We compensate our
executive officers through a mix of base salary, performance
incentive bonuses, long-term equity incentives, and employee
benefits and perquisites designed to:
|
|
|
|
|
attract and retain high caliber executive officers and motivate
them to achieve superior performance for the benefit of our
stockholders;
|
|
|
|
motivate our executive officers to achieve our key strategic and
financial performance measures; and
|
|
|
|
enhance the incentives for executive officers to increase our
stock price and maximize stockholder value.
|
We believe that a portion of our executive officers
compensation potential on an annual basis should be at risk
based on our performance. If our performance does not meet the
criteria established by the Compensation Committee, incentive
compensation will be adjusted accordingly. The Compensation
Committee oversees our general programs of compensation and
benefits for all employees and determines the compensation of
our executive officers and directors. Our compensation setting
process consists of establishing (i) a base salary,
(ii) a performance incentive bonus, and
(iii) long-term equity compensation for each executive
officer. The Compensation Committee designs the performance
incentive bonus to reward executive officers for our performance
through linking their compensation to revenue and earnings
growth targets, as well as certain other corporate objectives.
We utilize equity-based awards, currently consisting of stock
options and restricted stock, to provide the greatest long-term
potential value to our executive officers and to firmly align
such executive officers interests with those of our
stockholders.
The total cash compensation (i.e., base salary plus
performance incentive bonus) paid to our executive officers is
intended to be competitive with the total cash compensation paid
to executive officers in similar positions at companies engaged
primarily in the orthopaedic medical device industry with
revenues similar to ours, as well as comparable to other
companies with performance similar to ours. The Compensation
Committee reviews the targeted total compensation (i.e.,
the aggregate level of compensation that we will pay if
performance goals are fully met) to ensure the total
compensation is aligned with our goals of comparability and
incentivizing performance. We also provide our executive
officers with a variety of other benefits that we make available
generally to all salaried employees.
The Role of the Compensation Committee. The
Compensation Committee has the primary authority to determine
our compensation philosophy and to establish compensation for
our executive officers. In determining the appropriate level of
compensation, the Compensation Committee reviews a variety of
sources to determine and set compensation.
The Compensation Committee reviews the performance and
compensation for our CEO annually and recommends the
compensation level for approval by the independent directors of
our Board of Directors.
The performance of our executive management team as a group is
reviewed annually by the Compensation Committee. Our CEO assists
the Compensation Committee by providing annual recommendations
regarding the compensation of all other executive officers. Each
executive officer participates in an annual performance review
with the CEO to provide input about the executive officers
contributions to our success for the period being assessed. With
respect to equity compensation awarded to executive officers
other than the CEO, the Compensation Committee grants options
and/or
restricted stock, based generally upon the recommendation of the
CEO and a comparison of our peer group companies.
The Compensation Committee also has the power and authority to
hire outside advisors or consultants to assist the Compensation
Committee in fulfilling its responsibilities. Given the
Compensation Committees access to pertinent data as a
result of working with the consulting firm Watson Wyatt during
the fourth quarter of 2008, a compensation consultant was not
retained in connection with our 2009 compensation decisions.
Our executive compensation decisions are congruent with
Sections 162(m) and 409A of the Internal Revenue Code of
1986, as amended (the Code), and compensation
charges under Financial Accounting Standards Board (FASB)
Accounting Standards Codification (ASC) Section 718,
Compensation - Stock Compensation. However, the
Compensation Committee from time to time may approve payment of
compensation that does not qualify for the exclusion from the
limitation on deductibility of Section 162(m) if the
Compensation Committee determines that such payments are
consistent with our overall objective to attract, motivate, and
retain our executives.
14
Total Compensation. The total compensation
package offered to each executive officer is comprised of four
elements, which are described in more detail below:
|
|
|
|
|
base salary;
|
|
|
|
performance incentive bonus;
|
|
|
|
long-term equity incentive awards; and
|
|
|
|
employee benefits and perquisites.
|
In allocating compensation across these elements, the
Compensation Committee does not follow any strict policy or
guidelines. To determine whether our executive compensation is
comparable to our competitors and other companies with
performance similar to ours, the Compensation Committee compares
the compensation of executive officers at similar companies,
taking into consideration the companys size, industry, and
geographic locality, as well as, the comparable named executive
officers level of responsibility and years of experience.
The criteria used to select companies similar to us include
companies: (i) in the medical equipment and device
industry; (ii) with revenues between $170 million and
$760 million; (iii) whose current enterprise market
value is between $250 million and $2 billion; and
(iv) whose number of employees is between 400 and 3,600.
These companies are considered comparable to us and generally
recruit individuals to fill executive positions that have
similar skills and background to those we recruit. The
comparative data that we used in reviewing executive officer
compensation consisted of data from the
EQUILARINSIGHTtm
Public Medical Companies database. The list of such companies is
comprised of the following companies (with us listed simply to
show our relative position among the peer companies) based on
information available at the time of the compensation review:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
|
Market Cap
|
|
Number of
|
Name (Symbol)
|
|
(In
millions)(1)
|
|
(In
millions)(2)
|
|
Employees(1)
|
|
American Medical Systems, Inc. (AMMD)
|
|
$
|
520
|
|
|
$
|
1,470
|
|
|
|
1,221
|
|
Conmed Corporation (CNMD)
|
|
|
695
|
|
|
|
694
|
|
|
|
3,500
|
|
EV3, Inc. (EVVV)
|
|
|
449
|
|
|
|
1,810
|
|
|
|
1,350
|
|
Exactech, Inc. (EXAC)
|
|
|
177
|
|
|
|
250
|
|
|
|
408
|
|
Haemonetics Corporation (HAE)
|
|
|
598
|
|
|
|
1,400
|
|
|
|
2,016
|
|
Hanger Orthopedic Group, Inc. (HGR)
|
|
|
760
|
|
|
|
570
|
|
|
|
3,636
|
|
Integra Lifesciences Holdings Corporation (IART)
|
|
|
682
|
|
|
|
1,200
|
|
|
|
3,000
|
|
Orthofix International NV (OFIX)
|
|
|
546
|
|
|
|
610
|
|
|
|
1,484
|
|
Symmetry Medical Inc. (SMA)
|
|
|
366
|
|
|
|
320
|
|
|
|
2,357
|
|
Thoratec Corporation (THOR)
|
|
|
374
|
|
|
|
1,900
|
|
|
|
1,258
|
|
Wright Medical Group, Inc. (WMGI)
|
|
|
488
|
|
|
|
623
|
|
|
|
1,320
|
|
|
|
|
(1) |
|
Information obtained from each companies annual report on
Form 10-K
for the year ended: American Medical System, Inc., Symmetry
Medical Inc., and Thoratec Corporation
January 2, 2010; Conmed Corporation, EV3, Inc., Exactech,
Inc., Hanger Orthopedic Group, Inc., Integra Lifesciences
Holdings Corporation, Orthofix International NV, and Wright
Medical Group, Inc. December 31, 2009; and
Haemonetics Corporation March 28, 2009. |
|
(2) |
|
Market capitalization was determined as of March 11, 2010. |
We can review in detail only those individuals for whom
compensation information is publicly disclosed. This is
typically only the five most highly compensated officers at each
company. Generally, this correlates to our CEO, Senior Vice
President and Chief Financial Officer (CFO), and certain other
executive officers.
The overall result of this review provides the starting point
for the analysis of the Compensation Committee. The Compensation
Committee looks more extensively at a number of other factors,
including the total compensation, the mean, minimum, and maximum
for each executive officer position. The Compensation Committee
strongly believes in retaining the best talent among our
executive management team. In the case of our CEO, the
15
Compensation Committee also considered our performance since he
began working for us, and the anticipated level of difficulty of
replacing him with someone of comparable experience and skill.
The Compensation Committee believes that the compensation of our
executive officers those having the greatest ability
to influence our performance should include greater
levels of performance-based incentive compensation, while other
levels of management should receive a greater portion of their
compensation in base salary. The Compensation Committees
review of the comparable companies chosen, although each had a
different compensation structure, indicated that all appear to
provide their executive officers with average base salaries of
approximately 10% to 43% of overall compensation, average
targeted bonus compensation of up to 33% of overall compensation
and average equity compensation of approximately 34% to 71% of
overall compensation.
We have entered into an employment agreement with one of our
executive officers Gary D. Henley. The term of
Mr. Henleys employment agreement began on
April 2, 2009 and ends on April 2, 2012.
We have not entered into an employment agreement with Lance A.
Berry, William L. Griffin, Jr., Edward A. Steiger, or
Frank S. Bono. We entered into separation pay agreements with
each of Messrs. Berry, Bakewell, Griffin, Steiger, and
Bono, effective April 1, 2009. Our separation pay agreement
with Mr. Bakewell was terminated effective
December 11, 2009 when Mr. Bakewell resigned from his
position as our Executive Vice President and Chief Financial
Officer.
Base Salaries. We want to provide our
executive officers with a level of assured cash compensation in
the form of base salary to compensate them for the services they
provide and their level of professional experience and
knowledge. The Compensation Committee reviews executive officer
compensation annually. In establishing base salaries, the
Compensation Committee seeks relevant compensation information
including: (i) scope of the position;
(ii) responsibilities of the position;
(iii) experience and length of service with us, the
industry, and the community; (iv) effort and performance;
(v) team building skills; (vi) observance of our
ethics and compliance programs; (vii) salaries paid by
competitive companies to officers in similar positions; and
(viii) overall macroeconomic trends. The Compensation
Committee considers the input of the CEO with respect to the
base salaries of our other executive officers. Increases in base
salary from year to year are based upon the performance of the
executive officers, comparisons of our compensation to our
competitors compensation for similar positions and
responsibilities, as well as relevant economic market
considerations, as assessed, reviewed and approved by the
Compensation Committee. The Compensation Committee assesses
these factors with respect to the CEO. The Compensation
Committee recommends the compensation of the CEO for approval by
the independent directors of our Board of Directors. The
Compensation Committee estimates that we provide our executive
officers with average base salaries of approximately 21% to 35%
of overall compensation. The Compensation Committee estimates
that the salary levels of our executive officers approximate the
50th percentile of the salary levels in effect for comparable
executive officer positions at companies in our peer group. It
is the Compensation Committees goal that the total
compensation levels of our executive officers (cash compensation
plus the value of restricted shares) range between the 50th and
75th percentile of the total compensation levels in effect for
comparable executive officers positions at our peer group
companies. The Compensation Committee estimates that the total
compensation levels of our executive officers range between the
30th and 75th percentile for comparable executive officer
positions at companies in our peer group. This range, which is
lower than the Compensation Committees goal, reflects the
impact in 2009 of the
pay-for-performance
nature of our executive performance incentive plans, which are
described in greater detail below. Our executive officers have a
significant level of valuable industry specific knowledge and
experience. We believe they are a key factor in our future
success.
An employment agreement establishes the initial annual base
salary of Mr. Henley and provides that the Compensation
Committee will review compensation annually and may make such
increases in base salary as are merited based on the executive
officers performance and are consistent with our
compensation policies. The base
16
salaries of our other executive officers are set annually by the
Compensation Committee, typically on April 1. The base
salaries of our executive officers are set forth below.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Annual Base Salary
|
|
Annual Base Salary
|
|
Annual Base Salary
|
|
|
as of
|
|
as of
|
|
as of
|
|
|
January 1,
|
|
April 1,
|
|
April 1,
|
Name
|
|
2009
|
|
2009
|
|
2010
|
|
Gary D. Henley
|
|
$
|
488,000
|
|
|
$
|
510,000
|
|
|
$
|
520,200
|
|
Lance A. Berry
|
|
|
216,000
|
|
|
|
246,200
|
|
|
|
300,900
|
|
John K. Bakewell
|
|
|
299,900
|
|
|
|
307,400
|
|
|
|
N/A
|
|
William L. Griffin, Jr.
|
|
|
300,000
|
|
|
|
312,000
|
|
|
|
318,240
|
|
Edward A. Steiger
|
|
|
230,000
|
|
|
|
236,900
|
|
|
|
257,040
|
|
Frank S. Bono
|
|
|
282,800
|
|
|
|
291,300
|
|
|
|
314,160
|
|
The increases in base salaries from 2009 to 2010 reflect merit
increases of 2%, reflecting the difficult market and economic
conditions. Mr. Berrys annual base salary was
increased to $295,000 effective December, 2009, in connection
with his promotion to Chief Financial Officer. Messrs. Bono
and Steiger also received promotional increases of 5.7% and
6.4%, respectively, effective January 1, 2010 as a result
of increasing responsibility. These salaries reflect levels that
the Compensation Committee concluded were appropriate based upon
the executive officers general experiences and the review
of comparable salaries at comparable companies.
Performance Incentive Bonus. We implemented an
Executive Performance Incentive Plan (the 2005 Bonus Plan) for
all of our United States of America-based officers, including
our executive officers, in 2005. Each of Messrs. Henley,
Berry, Bono, Griffin, and Steiger participated in the 2005 Bonus
Plan. Mr. Bakewell participated in the 2005 Bonus Plan
until he resigned from his position as our Executive Vice
President and Chief Financial Officer effective
December 11, 2009. The 2005 Bonus Plan, which is
administered by the Compensation Committee, provides that the
Compensation Committee will establish a method each year for
determining the total amount of performance incentive bonuses
available to be paid to all officers under the 2005 Bonus Plan
(Bonus Pool). The Bonus Pool is established based upon specific
measures of our financial performance, which may include sales,
cash flow, operating income, pre-tax income, net income, and
earnings per share. For 2009, the Bonus Pool was established
based upon our performance relative to a specific operating
income target. One of our objectives is to consistently achieve
market leading revenue growth while achieving operating income
growth in excess of that revenue growth. Specifically, for 2009
the Compensation Committee established objectives of revenue
growth of 10% and net income growth of 2%. The 2005 Bonus Plan
also provides for the Compensation Committee to establish
individual performance goals, which include financial and
operational performance measures for each executive officer
based upon the executive officers responsibility. Each
executive officers bonus payment under the 2005 Bonus Plan
for a particular quarter is determined by multiplying the
executive officers target bonus amount (the executive
officers incentive target times the executive
officers base salary) for the quarter by a payout
percentage determined based on the achievement of corporate
financial performance goals. The Compensation Committee, in its
sole and absolute discretion, may determine that the amount of
an executive officers actual performance incentive bonus
is less than or more than the amount earned by the executive
officer under the 2005 Bonus Plan. The amount of the performance
incentive bonus payable to an executive officer may vary from
zero to 200% of the executive officers annual target.
On March 20, 2010, the Compensation Committee of our Board
of Directors adopted the 2010 Executive Performance Incentive
Plan, the material terms of which are presented for approval of
our stockholders in Proposal 3 Approval of the
material terms of the 2010 Executive Performance Incentive Plan.
Each of Messrs. Henley, Berry, Bono, Griffin, and Steiger
are eligible to participate in the 2010 Executive Performance
Incentive Plan, which is administered by the Compensation
Committee. Under the 2010 Executive Performance Incentive Plan,
the Compensation Committee must establish performance goals
based upon performance measures such as sales revenue, operating
income before or after taxes, net income before or after taxes,
net income before securities transactions, net or operating
income excluding non-recurring charges, return on assets, return
on equity, return on capital, market share, earnings per share,
cash flow, revenue, revenue growth, expenses, stock price,
dividends, total stockholder return, price/earnings ratio,
market capitalization, book value, product quality, customer
retention, unit sales, strategic business objectives or any
other performance measure deemed appropriate
17
by the Compensation Committee in its discretion. The target
performance bonus is stated as a percentage of base salary for
each participant and represents the amount of cash that a
participant will receive if all performance goals for each
performance measure are met or exceeded. Partial payments of the
target performance bonus may be paid only if minimum performance
thresholds are achieved. A participant may not be paid for
performance below the minimum performance threshold of any
component of the performance measures. If the performance goals
for a performance year are exceeded, the Compensation Committee
may pay additional bonus in excess of the target performance
bonus. However, no participant may be paid an amount that
exceeds twice the target performance bonus unless otherwise
determined by the Compensation Committee. In no event may any
payment under the 2010 Executive Performance Incentive Plan to a
participant exceed $1,500,000 for any performance year.
For 2010, the Compensation Committee established objectives of
net income, revenue growth, and free cash flow for our executive
officers. Achievement of the free cash flow objective is limited
to the achievement of the net income objective. Each executive
officers bonus payment under the 2010 Executive
Performance Incentive Plan for a particular quarter is
determined by multiplying the executive officers target
bonus amount (the executive officers incentive target
times the executive officers base salary) for the quarter
by a payout percentage determined based on the achievement of
corporate financial performance goals. The Compensation
Committee, in its sole and absolute discretion, may determine
that the amount of an executive officers actual
performance incentive bonus is less than or more than the amount
earned by the executive officer under the 2010 Executive
Performance Incentive Plan. However, the Compensation Committee
has indicated that it will not make any discretionary awards to
executive officers if performance targets are not met. The
amount of the performance incentive bonus payable to an
executive officer may vary from zero to 200% of the executive
officers annual target.
The Compensation Committee established the following targeted
bonus levels for our executive officers:
|
|
|
|
|
|
|
|
|
|
|
2009 Target
|
|
2010 Target
|
Position
|
|
(% of base salary)
|
|
(% of base salary)
|
|
CEO
|
|
|
75
|
%
|
|
|
75
|
%
|
Former CFO
|
|
|
50
|
%
|
|
|
N/A
|
|
CFO and Other executive officers
|
|
|
45
|
%
|
|
|
45
|
%
|
Our performance goals are not calculated using generally
accepted accounting principles (GAAP) measures. Instead, our
performance goals are calculated using non-GAAP measures as more
fully described in our
Form 8-Ks
that are filed in connection with our quarterly earnings
releases. For the year ended December 31, 2009, our
non-GAAP
financial measures did not include: foreign currency impact on
net sales, restructuring charges,
non-cash
stock-based compensation expense, non-cash inventory
step-up
amortization, costs associated with U.S. governmental
inquiries, charges to write off cumulative translation
adjustment balances, charges to write down a significant
international receivable, and income tax effects of the
foregoing.
Our executive officers have performance goals for their
incentive bonuses based upon corporate objectives which are
described in the table below.
|
|
|
|
|
|
|
|
|
|
|
2009 Target
|
|
2010 Target
|
Performance Goal
|
|
(% of bonus)
|
|
(% of bonus)
|
|
Adjusted Net Income
Growth(1)
|
|
|
40
|
%
|
|
|
50
|
%
|
Revenue Growth
|
|
|
40-50
|
%
|
|
|
25
|
%
|
Free Cash Flow
|
|
|
10-20
|
%
|
|
|
25
|
%
|
|
|
|
(1)
|
|
Adjusted Net Income as described in
the 2005 Bonus Plan and 2010 Executive Performance Incentive
Plan represents net income less certain income or expenses that,
in the Compensation Committees discretion, are excluded
from our
non-GAAP
financial measures (such as restructuring charges, U.S.
governmental inquiry charges, and non-cash,
stock-based
compensation expense) for the determination of target
achievement. All references to Adjusted Net Income in the
context of the 2005 Bonus Plan and the 2010 Executive
Performance Incentive Plan refer to the above-described
calculation.
|
18
Our executive officers bonus objectives for 2010 include
the following global objectives:
|
|
|
Performance Goal
|
|
100% of target
|
|
Revenue Growth
|
|
10%
|
Adjusted Net Income Growth
|
|
12%
|
Free Cash Flow (as a percentage of sales)
|
|
2.0%
|
Our executive officers will earn bonuses for free cash flow only
to the extent that the adjusted net income growth target is
achieved. For each measure, no bonus payment will be made until
minimum thresholds are attained. Our executive officers may
receive 200% of their targeted bonus only if each of the
performance measures for 2010 (revenue growth, adjusted net
income growth, and free cash flow) exceed their targets by 30%.
This percentage of overachievement was subjectively determined
to be an appropriate stretch goal.
The performance incentive bonus paid to each executive officer
for 2009 under the 2005 Bonus Plan is set forth below.
|
|
|
|
|
|
|
Performance
|
Name
|
|
Incentive Bonus
|
|
Gary D. Henley
|
|
$
|
70,272
|
|
Lance A. Berry
|
|
|
18,662
|
|
John K. Bakewell
|
|
|
28,790
|
|
William L. Griffin, Jr.
|
|
|
25,920
|
|
Edward A. Steiger
|
|
|
19,872
|
|
Frank S. Bono
|
|
|
24,434
|
|
The Compensation Committee estimates that we provide our
executive officers with targeted bonus compensation of 13% to
16% of overall compensation. The
pay-for-performance
aspect of our 2005 Bonus Plan is apparent in the payments
actually made in 2009. Each of Messrs. Henley, Berry, Bono
and Bakewell had a reduction in annual bonus in 2009 of 75% from
the 2008 levels, and Messrs. Griffin and Steiger received
only 20% of target bonus for 2009.
Long-Term Equity Incentive Awards. Long-term
incentives comprise the largest portion of each executive
officers compensation package, consistent with our
philosophy and principles discussed above. Our Compensation
Committees objective is to provide executive officers with
long-term incentive award opportunities that are at the 50th to
75th percentile of executives in comparable positions at
companies in our peer group. The Compensation Committee
estimates that the total compensation levels of our executive
officers range between the 30th and 75th percentile for
comparable executive officer positions at companies in our peer
group. Mr. Henley is at the low end of this range due to
prior year low equity awards. Mr. Berry is below the
50th percentile because he has only recently been promoted
to his role as our CFO.
Through the grant of these equity incentives, we seek to align
the long-term interests of our executive officers with the
long-term interests of our stockholders by creating a strong and
direct linkage between compensation and long-term stockholder
return. We may grant long-term, equity-based incentive awards to
our executive officers under our 2009 Equity Incentive Plan. Our
Compensation Committee administers the 2009 Equity Incentive
Plan. Under the 2009 Equity Incentive Plan, we may grant awards
in the form of incentive stock options, nonqualified stock
options, stock appreciation rights, restricted stock, restricted
stock units, performance share units, and stock bonuses. Based
on an assessment of competitive factors, the Compensation
Committee determines an award that is suitable for providing an
adequate incentive for the performance and retention of each
executive officer.
Beginning in 2006, the accounting treatment for stock options
changed as a result of Statement of Financial Accounting
Standards No. 123(R) (now FASB ASC Topic 718), making the
accounting treatment of stock options less attractive. As a
result, the Compensation Committee assessed the desirability of
granting shares of restricted stock or restricted stock units to
employees, particularly our executive officers, and concluded
that restricted stock would provide an equally motivating form
of incentive compensation while permitting us to issue fewer
shares, thereby reducing potential dilution. The Compensation
Committee may award a limited number of stock options to
executive officers upon starting employment, in other special
situations, and as part of their annual compensation.
19
However, the primary form of equity compensation is the issuance
of shares of restricted stock. The restricted stock has
historically vested in equal annual installments over four
years. In the future, we many issue other forms of equity
compensation allowed under the 2009 Equity Incentive Plan.
The Compensation Committee may award stock options to closely
align the interests of the executive officers with those of our
stockholders. To encourage retention, the stock options may be
granted with a vesting period of one or more years. The
Compensation Committee has taken the position that stock options
should be granted with an exercise price that is equal to the
fair market value of the common stock on the grant date,
calculated as the closing price per share of stock on the
trading day immediately prior to the grant date. The actual
value of stock option compensation, therefore, depends on the
market value of the common stock increasing after the grant date.
The Compensation Committee has adopted a general policy related
to equity awards under which:
(i) non-performance
based awards will not fully vest prior to a minimum of three
years (including cliff-vesting awards); (ii) the
Compensation Committee will not waive vesting periods for any
awards except in the case of death, disability, retirement or
change in control; and (iii) the above restrictions will
apply to a total of 90% of the shares of common stock authorized
under the 2009 Equity Incentive Plan.
Guidelines for the number of restricted stock awards and stock
options granted to each executive officer are determined using a
procedure approved by the Compensation Committee based upon
several factors, including the executive officers level of
responsibility, salary grade, performance, and the value of the
stock at the time of grant. With the exception of promotions and
new hires, we generally grant these awards effective as of the
date of our annual meeting of stockholders. This timing enables
us to consider our prior performance as well as the performance
of the potential recipients, and our expectations for the
current year. Also, it follows our annual performance
evaluations. The awards also are made as early as practicable in
the year in order to optimize the
time-period
for the incentives associated with the awards. The Compensation
Committees schedule is determined several months in
advance, and the proximity of any awards to earnings
announcements or other market events is coincidental. For 2009,
we granted restricted stock, restricted stock units and stock
options with a grant date value of 300% of our CEOs base
salary (prior to his 2009 base salary increase) and 140% to 200%
of our other executive officers base salaries (prior to
their 2009 base salary increases).
The benchmark for these grants is the average level of annual
restricted stock awards and stock option grants for similar
positions at our peer group companies, adjusted using the above
factors and taking into consideration such equivalency factors
as our number of shares outstanding and market capitalization,
compared to the peer group companies.
Each restricted stock award allows the executive officer to
acquire shares of common stock upon vesting. Each stock option
allows the executive officer to acquire shares of common stock
at the fair market value on the grant date over a specified
period of time, up to ten years. Stock option awards will
provide a return to the executive officer only if the market
price of the shares appreciates over the term of the award.
In 2009, our Board of Directors adopted Executive Officer Stock
Ownership Guidelines, which require our executive officers to
acquire and hold shares of common stock equal in value to a
multiple of their annual base salary. Our Board of Directors and
the Compensation Committee generally encourage our executive
officers to have a financial stake in us to align the interests
of our stockholders and management, and view restricted stock
awards and stock options as a means of furthering this goal. The
guidelines are described in the heading Executive Officer
Stock Ownership Guidelines below.
To address stockholders potential concerns regarding the
number of options, restricted shares and restricted stock units
we grant in a given year, the Compensation Committee set an
annual cap on these awards for each of the next three years,
beginning on January 1, 2011. During this period we will
not grant a number of shares subject to awards under our 2009
Equity Incentive Plan to employees and non-employee directors,
in the aggregate, greater than the Risk Metrics Group (RMG)
threshold percentage for our GICS peer group (3510-Health Care
Equipment & Services) of shares of our common stock
that we believe will be outstanding over such
3-year
period. This would reflect limiting awards to no greater than
the RMG 2010 threshold for year 1, the RMG 2011 threshold for
year 2, and the RMG 2012 threshold for year 3. This limitation
does not apply to awards under plans assumed in acquisitions or
issuances under tax-qualified employee stock purchase plans.
Solely for the purposes of calculating
20
the burn rate, each stock option will be counted
once and each share subject to restricted stock or restricted
stock unit will be counted twice (equivalent to two shares).
The long-term equity incentive awards granted in 2009 to each of
our executive officers is set forth below.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Grant Date
|
|
|
|
|
Grant Date
|
|
Number of
|
|
Fair Value of
|
|
|
Number of
|
|
Fair Value of
|
|
Shares of
|
|
Restricted
|
|
|
Options
|
|
Options
|
|
Restricted Stock
|
|
Stock
|
Name
|
|
Granted
|
|
Granted
|
|
Granted
|
|
Granted
|
|
Gary D. Henley
|
|
|
57,638
|
|
|
$
|
350,946
|
|
|
|
70,976
|
|
|
$
|
1,097,999
|
|
Lance A. Berry
|
|
|
6,378
|
|
|
|
38,834
|
|
|
|
27,854
|
|
|
|
451,501
|
|
John K. Bakewell
|
|
|
12,949
|
|
|
|
78,844
|
|
|
|
11,000
|
|
|
|
170,170
|
|
William L. Griffin, Jr.
|
|
|
11,811
|
|
|
|
71,915
|
|
|
|
34,544
|
|
|
|
534,396
|
|
Edward A. Steiger
|
|
|
6,791
|
|
|
|
41,349
|
|
|
|
18,363
|
|
|
|
284,076
|
|
Frank S. Bono
|
|
|
11,142
|
|
|
|
67,841
|
|
|
|
21,220
|
|
|
|
328,273
|
|
Our Compensation Committee estimates that we provide our
executive officers with equity compensation of approximately 49%
to 63% of overall compensation.
Other Elements of Compensation and
Perquisites. In order to attract and retain
employees while paying market levels of compensation, we provide
our executive officers the following benefits and perks.
Medical Insurance. We provide to each
executive officer and the executive officers spouse and
children such health, dental, and vision insurance coverage as
we may from time to time make available to our other employees.
We pay a portion of the premiums for this insurance for all
employees.
Life and Disability Insurance. We provide to
each executive officer such life
and/or
disability insurance, as we, in our sole discretion, may from
time to time make available to our other executive employees of
the same level of employment.
Housing Allowance & Relocation
Costs. In order to attract and retain management
talent, we provide relocation benefits, including a housing
allowance, to certain executive officers upon their employment
with us. The allowance is intended to partially defray the
additional cost of housing while the employee relocates as well
as actual expenses related to the sale and purchase of a home,
household moving expenses and similar related items. We provide
the same relocation benefits to all senior management employees.
Defined Contribution Plan. We, and our
designated affiliates, offer the Section 401(k)
Savings/Retirement Plan (401(k) Plan), a tax-qualified
retirement plan, to our eligible employees. The 401(k) Plan
permits eligible employees to defer from 1% to 100% of their
annual eligible compensation, subject to certain limitations
imposed by the Code. The employees elective deferrals are
immediately vested and non-forfeitable in the 401(k) Plan. We
currently match up to 4% of contributions to the 401(k) Plan.
Stock Purchase Plan. Our 2002 Employee Stock
Purchase Plan (ESPP), which qualifies under Section 423 of
the Code, permits participants to purchase our common stock on
favorable terms. ESPP participants are granted a purchase right
to acquire shares of common stock at a price that is 85% of the
stock price on either the first day of the plan period or the
stock price on the last day of the plan period, whichever is
lower. The purchase dates occur on the last business day of June
and December of each year. To pay for the shares, each
participant may authorize periodic payroll deductions from their
cash compensation, subject to certain limitations imposed by the
Code. All payroll deductions collected from the participant in a
period are automatically applied to the purchase of common stock
on that periods purchase date provided the participant
remains an eligible employee and has not withdrawn from the ESPP
prior to that date. Our ESPP is available only to
U.S. employees. Shares of stock purchased pursuant to the
ESPP are generally subject to a holding period lasting between
one and one and one-half years after such stock is purchased,
during which time the shares may not be sold, exchanged,
pledged, hypothecated, or otherwise transferred, except in the
case of demonstrated financial emergency.
21
Other. We make available certain other
perquisites or fringe benefits to certain executive officers,
such as travel insurance, airline club dues, professional
society dues and food, reimbursement of financial planning,
insurance, and recreational fees incidental to official company
functions, including board meetings.
Severance Benefits. We believe that companies
should provide their executive officers with reasonable
severance benefits, which should reflect the fact that it may be
difficult for them to find comparable employment within a short
period of time, that the executive officers will be better able
to focus on their respective duties without the worry and
uncertainty related to being terminated, and that executive
officers interests should be aligned with our
stockholders interests in connection with a potential
change in control. Further, severance benefits help clarify what
will happen in the event of our executive officers
termination from employment. To that end, our employment
agreement with Mr. Henley includes provisions for
separation pay, and we have entered into separation pay
agreements with our other executive officers,
Messrs. Berry, Griffin, Steiger and Bono. The separation
pay agreements became effective April 1, 2009, and their
terms continue until their third anniversaries. The terms will
be extended automatically for one additional year unless we or
the executive officer provide notice of termination of the
separation pay agreement. In the event that the executive
officer is terminated for cause or the executive officer
terminates employment other than for good reason we shall have
no obligations other than payment of accrued obligations
described below. In the event of an involuntary termination of
the executive officer, we will be obligated to pay a separation
payment and accrued obligations and provide benefits to the
executive officer as described below.
|
|
|
|
|
Accrued Obligations. Accrued obligations
include (i) any accrued base salary through the date of
termination, (ii) any annual cash incentive compensation
awards earned but not yet paid, (iii) the value of any
accrued vacation, (iv) reimbursement for any unreimbursed
business expenses, and, (v) only in the case of an
involuntary termination after a change in control or a
termination at any time by reason of death, an annual incentive
payment at target for the year that includes the date of
termination, prorated for the portion of the year that the
executive officer was employed.
|
|
|
|
Separation Payment upon Involuntary
Termination. The total separation payment for
Mr. Henley is the amount equal to 24 months multiplied
by 1.75 times Mr. Henleys monthly base pay. The total
separation payment for Messrs. Berry, Griffin, Steiger and
Bono is the amount equal to 12 months multiplied by 1.45
times their monthly base pay. Half of the total separation
payment amount will be payable at or within a reasonable time
after the date of termination. The remaining half of the total
separation payment amount will be payable in installments
beginning six months after the date of termination, with a final
installment of the balance of the remaining half of the total
separation payment to be made on or before March 15 of the
calendar year following the year of termination.
|
|
|
|
Benefits upon Involuntary Termination. The
executive officer will also receive benefits that include
(i) health and dental coverage under the Consolidated
Omnibus Budget Reconciliation Act (COBRA), which we must pay for
a period not exceeding 18 months, (ii) outplacement
assistance for a period of 24 months for Mr. Henley
and 12 months for Messrs. Berry, Griffin, Steiger and
Bono, subject to termination if the executive officer accepts
employment with another employer, (iii) financial planning
services for a period of 24 months for Mr. Henley and
12 months for Messrs. Berry, Griffin, Steiger and
Bono, (iv) payment to continue insurance coverage equal to
the annual supplemental executive officer insurance benefit
provided to the executive officer prior to the date of
termination, and (v) reasonable attorneys fees and
expense if any such fees or expenses are incurred to enforce the
separation pay agreement.
|
For purposes of the separation pay agreements, involuntary
termination will occur if we terminate the employment of the
executive officer other than for cause, disability, voluntary
retirement or death of the executive officer or the executive
officer resigns for good reason. A termination of the executive
officer before a change in control by reason of the executive
officers retirement on or after age 65 does not
constitute an involuntary termination.
The definition of cause includes (i) willful failure of the
executive officer to substantially perform the executive
officers duties that amounts to an intentional and
extended neglect of the executive officers duties,
(ii) only prior to a change in control, continued,
documented poor performance after giving the executive officer
sufficient time to improve, (iii) the determination by our
Board of Directors that the executive officer has engaged or
22
is about to engage in conduct materially injurious to us,
(iv) the executive officers conviction or entering of
a guilty or no contest plea to a felony charge, or (v) the
executive officers participation in the activities
proscribed by the confidentiality, non-solicitation, and
non-competition covenants described below or a material breach
of any of the other covenants contained in the separation pay
agreement.
Prior to a change in control, the definition of good reason
includes (i) the assignment to the executive officer of any
duties materially inconsistent with the range of duties and
responsibilities appropriate to a senior executive of us,
(ii) a material reduction in the executive officers
overall standing and responsibilities, (iii) a material
reduction in the executive officers aggregate annualized
compensation and benefits opportunities, (iv) our failure
to pay the executive officer any portion of the executive
officers compensation and benefits within 30 days
after they become due, (v) any purported termination of the
executive officers employment that is not made pursuant to
a notice of termination that reasonably details the basis for
termination, (vi) the failure by us to obtain an agreement
from any our successors requiring such successor to assume and
agree to perform our obligations under the separation pay
agreement, (vii) the failure by us to provide
indemnification and directors and officers insurance protection
contemplated by the agreement, or (viii) the failure by us
to comply with any material provision of the separation pay
agreement.
After a change in control, the definition of good reason
includes, (i) a material and adverse change in the
executive officers title, authority as an executive
officer, duties, responsibilities or reporting lines as in
effect immediately prior to the change in control, (ii) a
material reduction in the executive officers aggregate
annualized compensation opportunities, or (iii) the
relocation of the executive officers principal place of
employment to a location that is more than 40 miles from
the executive officers principal place of employment
immediately prior to the change in control.
Under the employment agreement for Mr. Henley and the
separation pay agreement for all other executive officers, the
executive officer makes certain covenants that impose future
obligations on the executive officer regarding confidentiality
of information, transfer of inventions, non-solicitation of our
employees for a period of 12 to 24 months, and
noncompetition with our business for a period of 12 to
24 months. If we determine that a breach of any of these
covenants has occurred, then our obligations to make payments or
provide benefits shall cease immediately and permanently, and
the executive officer shall repay an amount equal to 90% of the
payments and benefits previously provided under the separation
pay agreement, with interest. Upon termination for any reason
other than cause, the executive officer must enter into a mutual
release of all claims within 45 days after the date of
termination before any payments will be made to the executive
officer.
If we are required to restate our balance sheet or statement of
operations affecting any reporting period that transpires during
the term of the separation pay agreement due to our material
non-compliance with any financial requirements under securities
laws, we may require the executive officer to reimburse us for
any bonus or
incentive-based
or equity-based compensation received by the executive officer
during the term of the separation pay agreement and any profits
realized from the sale of our securities by the executive
officer during the term of the separation pay agreement. If our
Board of Directors determines that such a forfeiture is
appropriate, we may withhold future amounts owed to the
executive officer as compensation, and we may commence legal
action to collect such sums as our Board of Directors determine
is owed to us.
All payments under the separation pay agreement will be net of
applicable tax withholdings. With the exception of
Mr. Henleys employment agreement, each of the
separation pay agreements contains a provision that limits
payment under the separation pay agreement to avoid taxation
under Section 4999 of the Code for parachute
payments within the meaning of Section 280G of the
Code.
Our Compensation Committee has adopted a policy concerning
gross-ups
for taxes payable by executive officers. Generally, our policy
is that executive officers should be responsible for the taxes
payable by them with respect to their compensation. However, in
unusual circumstances where our Compensation Committee believes
that accommodations must be made to recruit a new executive
officer, limited reimbursement for taxes payable may be included
in their compensation agreements. In such unusual circumstances,
the gross up will be limited to payments triggered
by both a change in control and termination of employment and
will be subject to a three year sunset provision. At the time we
hired our CEO, we agreed to provide a
gross-up
to his compensation. In continuation of this commitment,
Mr. Henleys employment agreement provides for a
gross-up
payment if it is
23
determined that any payment to Mr. Henley in the nature of
compensation under his employment agreement or otherwise would
be subject to the excise tax imposed by Section 4999 of the
Code, together with any interest or penalties imposed. Our
obligation to make the
gross-up
payment is not conditioned upon Mr. Henleys
termination of employment. The
gross-up
payment would not be deductible by us.
Change in Control Benefits. Our executive
officers and other employees have built us into the successful
enterprise that we are today, and the Compensation Committee
believes that it is important to protect them in the event of a
change in control. Further, it is our belief that the interests
of stockholders will be best served if the interests of our
executive officers are aligned with them, and providing change
in control benefits should at least reduce the reluctance of
executive officers to pursue potential change in control
transactions that may be in the best interests of stockholders.
Relative to our overall value, these potential change in control
benefits are relatively minor.
Under the terms of the employment agreement for Mr. Henley
and the separation pay agreements with our other executive
officers, these change in control benefits are double
trigger, which requires (i) a change in control and
(ii) a termination without cause for good reason within
12 months of the expiration of their separation pay
agreements before the executive officer receives their change in
control benefit. If we give notice of termination of the
separation pay agreement less than one year after a change in
control, then the term of the separation pay agreement will be
automatically extended until the later of the one year
anniversary that follows such written notice or the second
anniversary of the change in control. The change in control
benefit requires us to pay a separation payment and accrued
obligations and provide benefits to the executive officer as
described above under the heading Severance Benefits.
Subject to several exceptions, for purposes of the employment
agreement for Mr. Henley and the separation pay agreements
for our other executive officers, a change in control occurs if
(i) any person or group of persons acquires more than 50%
of our capital stock, (ii) any person or group of persons
acquires 35% or more of the voting power represented by our
capital stock in a
12-month
period, (iii) any person or group of persons acquires 40%
of our assets in a
12-month
period, (iv) a majority of our directors are replaced in
any 12-month
period by directors whose election is not endorsed by a majority
of our directors, or (v) a merger or consolidation occurs
pursuant to which 40% of our assets are to be transferred to a
different entity.
In addition to the benefits under the employment agreement for
Mr. Henley and the separation pay agreements for our other
executive officers, terminated executive officers would be
entitled to receive any benefits that they otherwise would have
been entitled to receive under our 401(k) Plan. Additionally,
upon a change in control, all unexercisable options will
immediately vest and become exercisable and all restrictions on
restricted stock will lapse. The Compensation Committee believes
that these levels of benefits are consistent with the general
practice among our peers, although we have not conducted a study
to confirm this.
24
Potential
Payments Upon Termination or Change in Control
The following table sets forth the benefits payable to our
executive officers based upon a hypothetical termination
and/or
change in control date of December 31, 2009. Our
Compensation Committee may, in its discretion, revise, amend, or
add to the benefits if it deems advisable.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Termination
|
|
|
Change in Control
|
|
|
Change in Control
|
|
|
|
|
|
without
|
|
|
with
|
|
|
without
|
|
Name
|
|
Benefit
|
|
Cause
|
|
|
Termination
|
|
|
Termination
|
|
|
Gary D. Henley
|
|
Salary
|
|
$
|
1,785,000
|
|
|
$
|
1,785,000
|
|
|
$
|
|
|
|
|
Benefits continuation
|
|
|
18,126
|
|
|
|
18,126
|
|
|
|
|
|
|
|
Outplacement benefits
|
|
|
60,000
|
|
|
|
60,000
|
|
|
|
|
|
|
|
Other termination
benefits(1)
|
|
|
13,000
|
|
|
|
13,000
|
|
|
|
|
|
|
|
Stock option
acceleration(2)
|
|
|
|
|
|
|
200,004
|
|
|
|
200,004
|
|
|
|
Restricted stock
acceleration(3)
|
|
|
|
|
|
|
1,717,176
|
|
|
|
1,717,176
|
|
|
|
Tax reimbursement
|
|
|
|
|
|
|
756,443
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
1,876,126
|
|
|
$
|
4,549,749
|
|
|
$
|
1,917,180
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Lance A. Berry
|
|
Salary
|
|
$
|
427,750
|
|
|
$
|
427,750
|
|
|
$
|
|
|
|
|
Benefits continuation
|
|
|
23,313
|
|
|
|
23,313
|
|
|
|
|
|
|
|
Outplacement benefits
|
|
|
30,000
|
|
|
|
30,000
|
|
|
|
|
|
|
|
Other termination
benefits(1)
|
|
|
8,000
|
|
|
|
8,000
|
|
|
|
|
|
|
|
Stock option
acceleration(2)
|
|
|
|
|
|
|
22,132
|
|
|
|
22,132
|
|
|
|
Restricted stock acceleration(3)
|
|
|
|
|
|
|
693,280
|
|
|
|
693,280
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
489,063
|
|
|
$
|
1,204,475
|
|
|
$
|
715,412
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
John K.
Bakewell(4)
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
William L. Griffin, Jr.
|
|
Salary
|
|
$
|
678,600
|
|
|
$
|
678,600
|
|
|
$
|
|
|
|
|
Benefits continuation
|
|
|
18,126
|
|
|
|
18,126
|
|
|
|
|
|
|
|
Outplacement benefits
|
|
|
30,000
|
|
|
|
30,000
|
|
|
|
|
|
|
|
Other termination
benefits(1)
|
|
|
8,000
|
|
|
|
8,000
|
|
|
|
|
|
|
|
Stock option
acceleration(2)
|
|
|
|
|
|
|
40,984
|
|
|
|
40,984
|
|
|
|
Restricted stock
acceleration(3)
|
|
|
|
|
|
|
654,263
|
|
|
|
654,263
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
734,726
|
|
|
$
|
1,429,973
|
|
|
$
|
695,247
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Edward A. Steiger
|
|
Salary
|
|
$
|
515,258
|
|
|
$
|
515,258
|
|
|
$
|
|
|
|
|
Benefits continuation
|
|
|
18,126
|
|
|
|
18,126
|
|
|
|
|
|
|
|
Outplacement benefits
|
|
|
30,000
|
|
|
|
30,000
|
|
|
|
|
|
|
|
Other termination
benefits(1)
|
|
|
8,000
|
|
|
|
8,000
|
|
|
|
|
|
|
|
Stock option
acceleration(2)
|
|
|
|
|
|
|
23,565
|
|
|
|
23,565
|
|
|
|
Restricted stock
acceleration(3)
|
|
|
|
|
|
|
347,795
|
|
|
|
347,795
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
571,384
|
|
|
$
|
942,744
|
|
|
$
|
371,360
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Frank S. Bono
|
|
Salary
|
|
$
|
422,385
|
|
|
$
|
422,385
|
|
|
$
|
|
|
|
|
Benefits continuation
|
|
|
23,313
|
|
|
|
23,313
|
|
|
|
|
|
|
|
Outplacement benefits
|
|
|
30,000
|
|
|
|
30,000
|
|
|
|
|
|
|
|
Other termination
benefits(1)
|
|
|
8,000
|
|
|
|
8,000
|
|
|
|
|
|
|
|
Stock option
acceleration(2)
|
|
|
|
|
|
|
38,663
|
|
|
|
38,663
|
|
|
|
Restricted stock
acceleration(3)
|
|
|
|
|
|
|
501,342
|
|
|
|
501,342
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
483,698
|
|
|
$
|
1,023,703
|
|
|
$
|
540,005
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
The amounts in the Other
termination benefits rows include the cost of financial planning
services for 24 months, an annual physical, and continued
executive insurance. Reimbursement of reasonable attorneys
fees and expenses is not included as the amount is not estimable.
|
|
(2)
|
|
Stock option acceleration is
calculated as the intrinsic value of the unvested options on
December 31, 2009. The intrinsic value is calculated as the
difference between the market value of our common stock as of
December 31, 2009, and the exercise price of the stock
option. The market value as of December 31, 2009, is deemed
to have been $18.94 per share, which is the closing sale price
of our common stock reported for transactions effected on the
Nasdaq Global Select Market on December 31, 2009.
|
25
|
|
|
(3)
|
|
Restricted stock acceleration is
calculated as the market value of the unvested awards on
December 31, 2009. The market value as of December 31,
2009, is deemed to have been $18.94 per share, which is the
closing sale price of our common stock reported for transactions
effected on the Nasdaq Global Select Market on December 31,
2009.
|
|
(4)
|
|
Mr. Bakewell resigned from his
position as our Executive Vice President and Chief Financial
Officer effective December 11, 2009, at which time his
separation pay agreement terminated.
|
For purposes of these benefits, a change in control is deemed to
occur, in general, if (i) any person or group of persons
acquires more than 50% of our capital stock, (ii) any
person or group of persons acquires 35% or more of the voting
power represented by our capital stock in a
12-month
period, (iii) any person or group of persons acquires 40%
of our assets in a
12-month
period, (iv) a majority of our directors are replaced in
any 12-month
period by directors whose election is not endorsed by a majority
of our directors, or (v) a merger or consolidation occurs
pursuant to which 40% of our assets are to be transferred to a
different entity.
Compensation of Chief Executive Officer. Gary
D. Henley became our President and Chief Executive Officer in
2006. For the year ended December 31, 2009, we paid
Mr. Henley a base salary of $510,000 pursuant to his
employment agreement with us. Mr. Henley also received a
performance incentive bonus of $70,272 under the 2005 Bonus Plan
for 2009. In addition, on May 13, 2009, we granted
Mr. Henley 70,976 shares of restricted stock and an
option to purchase 57,638 shares of common stock under the
Fifth Amended and Restated 1999 Equity Incentive Plan, as
amended (the 1999 Equity Incentive Plan). The exercise price of
the stock option is $15.47 per share, which was the fair market
value of the common stock on the grant date as determined under
the 1999 Equity Incentive Plan. Both the stock option and the
restricted stock will vest in equal annual installments over a
period of four years after the grant date. The Compensation
Committee considers that the compensation paid to
Mr. Henley for 2009 was reasonable and appropriate under
the circumstances.
CEO Succession Plan. In 2009, our Board of
Directors adopted a policy that requires our Board of Directors
to regularly approve a CEO succession plan.
Executive Officer Stock Ownership
Guidelines. In 2009, our Board of Directors
adopted Executive Officer Stock Ownership Guidelines, which
require our executive officers to acquire and hold shares of
common stock equal in value to a multiple of their annual base
salary. The CEO must maintain value equal to three times his
annual salary, and the remaining executive officers must
maintain value equal to twice their annual salary. Qualifying
shares include owned shares, unvested restricted stock, unvested
restricted stock units, and the value of any vested stock
options. There is a five-year accumulation period beginning on
the later of (i) becoming an officer subject to the share
ownership guidelines or (ii) July 1, 2010.
Compensation and Risk. We believe that our
performance-based compensation and equity programs create
appropriate incentives to increase long-term stockholder value.
These programs have been designed and administered in a manner
that discourages undue risk-taking by employees. Relevant
features of these programs include:
|
|
|
|
|
limits on annual incentive and long-term performance awards,
thereby defining and capping potential payouts;
|
|
|
|
proportionately greater award opportunity derived from the
long-term incentive program compared to annual incentive plan,
creating a greater focus on sustained company performance over
time;
|
|
|
|
the application of an annual incentive metric that aligns senior
management against the balanced objectives of increased
revenues, increasing net income, and generating cash flow;
|
|
|
|
use of three long-term incentive vehicles restricted
stock, restricted stock units and stock options that
vest over a number of years, thereby providing strong incentives
for sustained operational and financial performance;
|
|
|
|
a long-term incentive program that has overlapping vesting
periods, such that at any one time up to four separate awards
are affected by current year performance, thereby requiring
sustained high levels of performance; and
|
|
|
|
share ownership guidelines for senior executives, monitored by
the Compensation Committee, that ensure alignment with
shareholder interests over the long term.
|
In light of these features of our compensation program, we
conclude that the risks arising from our employee compensation
policies and practices are not reasonably likely to have a
material adverse effect on us.
26
EXECUTIVE
COMPENSATION
Summary
Compensation Information
The table below sets forth summary compensation information for
each of the last three fiscal years for our principal executive,
our principal financial officer, our three other most highly
compensated executive officers who were serving in such
capacities on December 31, 2009, and our principal
financial officer who served until December 11, 2009, who
we refer to collectively as our named executive officers.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock
|
|
|
Option
|
|
|
Incentive Plan
|
|
|
All Other
|
|
|
Total
|
|
Name and Principal Position
|
|
Year
|
|
|
Salary
|
|
|
Bonus
|
|
|
Awards(1)
|
|
|
Awards(1)
|
|
|
Compensation(2)
|
|
|
Compensation(3)
|
|
|
Compensation
|
|
|
Gary D. Henley
|
|
|
2009
|
|
|
$
|
504,500
|
|
|
|
|
|
|
$
|
1,097,999
|
|
|
$
|
350,946
|
|
|
$
|
70,272
|
|
|
$
|
12,800
|
|
|
$
|
2,036,517
|
|
President and Chief
|
|
|
2008
|
|
|
|
470,150
|
|
|
|
|
|
|
|
328,388
|
|
|
|
601,495
|
|
|
|
323,089
|
|
|
|
17,080
|
|
|
|
1,740,202
|
|
Executive Officer
|
|
|
2007
|
|
|
|
416,250
|
|
|
$
|
74,906
|
|
|
|
541,800
|
|
|
|
559,500
|
|
|
|
129,624
|
|
|
|
22,776
|
|
|
|
1,744,856
|
|
Lance A. Berry
|
|
|
2009
|
|
|
|
242,717
|
|
|
|
|
|
|
|
451,501
|
|
|
|
38,834
|
|
|
|
18,662
|
|
|
|
10,453
|
|
|
|
762,167
|
|
Senior Vice President and Chief Financial Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
John K.
Bakewell(4)
|
|
|
2009
|
|
|
|
289,932
|
|
|
|
|
|
|
|
170,170
|
|
|
|
78,844
|
|
|
|
28,790
|
|
|
|
26,675
|
|
|
|
594,411
|
|
Former Executive Vice
|
|
|
2008
|
|
|
|
293,675
|
|
|
|
|
|
|
|
233,520
|
|
|
|
216,538
|
|
|
|
134,629
|
|
|
|
12,810
|
|
|
|
891,172
|
|
President and Chief Financial Officer
|
|
|
2007
|
|
|
|
267,250
|
|
|
|
32,212
|
|
|
|
433,440
|
|
|
|
|
|
|
|
55,106
|
|
|
|
17,868
|
|
|
|
805,876
|
|
William L. Griffin, Jr.
|
|
|
2009
|
|
|
|
309,000
|
|
|
|
|
|
|
|
534,396
|
|
|
|
71,915
|
|
|
|
25,920
|
|
|
|
9,545
|
|
|
|
950,776
|
|
Senior Vice President, Global Operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Edward A. Steiger
|
|
|
2009
|
|
|
|
235,175
|
|
|
|
|
|
|
|
284,076
|
|
|
|
41,349
|
|
|
|
19,872
|
|
|
|
150,635
|
|
|
|
731,107
|
|
Senior Vice President, Human Resources
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Frank S. Bono
|
|
|
2009
|
|
|
|
289,175
|
|
|
|
|
|
|
|
328,273
|
|
|
|
67,841
|
|
|
|
24,434
|
|
|
|
15,754
|
|
|
|
725,477
|
|
Senior Vice
|
|
|
2008
|
|
|
|
278,350
|
|
|
|
|
|
|
|
204,330
|
|
|
|
168,419
|
|
|
|
104,499
|
|
|
|
11,850
|
|
|
|
767,448
|
|
President and Chief Technology Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
The amounts in the Stock Awards and
Option Awards columns represent grant date fair value computed
in accordance with FASB ASC Topic 718. For Stock Awards, which
consist of restricted stock, the grant date fair value per share
is equal to the closing price of our stock on the date of grant.
See note 12 to our Audited Financial Statements contained
in our Annual Report on
Form 10-K
for a discussion of assumptions used to determine fair value of
Option Awards.
|
|
(2)
|
|
The amounts in the Non-Equity
Incentive Plan Compensation column represent amounts earned by
each named executive officer under the 2005 Bonus Plan for that
year.
|
|
(3)
|
|
The amounts in the All Other
Compensation column are more fully described in the table under
All Other Compensation Supplemental.
|
|
(4)
|
|
Mr. Bakewell resigned from his
position as our Executive Vice President and Chief Financial
Officer effective December 11, 2009.
|
See Compensation Discussion and Analysis above for a complete
description of compensation plans pursuant to which the amounts
listed under the Summary Compensation Table were paid or awarded
and the criteria for such payment.
All stock options and shares of restricted stock vest upon a
change in control, as defined in the 1999 Equity Incentive Plan
and 2009 Equity Incentive Plan.
27
All Other
Compensation Supplemental
The table below sets forth other compensation information for
each of the last three fiscal years for our named executive
officers.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Housing/
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
Name and
|
|
|
|
401k
|
|
Car
|
|
|
|
Travel
|
|
Financial
|
|
Insurance
|
|
Relocation
|
|
Club
|
|
Gross
|
|
Other
|
Principal Position
|
|
Year
|
|
Match
|
|
Allowance
|
|
Vacation
|
|
Bonus
|
|
Planning
|
|
Premiums
|
|
Expenses
|
|
Dues
|
|
Up
|
|
Compensation
|
|
Gary D. Henley
|
|
|
2009
|
|
|
$
|
7,350
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
4,450
|
|
|
$
|
1,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
12,800
|
|
President and Chief
|
|
|
2008
|
|
|
|
6,900
|
|
|
$
|
2,400
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
7,780
|
|
|
|
|
|
|
|
17,080
|
|
Executive Officer
|
|
|
2007
|
|
|
|
6,750
|
|
|
|
9,600
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,336
|
|
|
$
|
90
|
|
|
|
22,776
|
|
Lance A. Berry
|
|
|
2009
|
|
|
|
7,327
|
|
|
|
|
|
|
|
|
|
|
$
|
1,500
|
|
|
|
500
|
|
|
|
1,000
|
|
|
|
|
|
|
|
|
|
|
|
126
|
|
|
|
10,453
|
|
Senior Vice President and Chief Financial Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
John K. Bakewell
|
|
|
2009
|
|
|
|
7,350
|
|
|
|
|
|
|
$
|
11,825
|
|
|
|
1,500
|
|
|
|
5,000
|
|
|
|
1,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26,675
|
|
Former Executive Vice
|
|
|
2008
|
|
|
|
6,900
|
|
|
|
2,100
|
|
|
|
|
|
|
|
1,500
|
|
|
|
|
|
|
|
1,556
|
|
|
|
|
|
|
|
|
|
|
|
754
|
|
|
|
12,810
|
|
President and Chief Financial Officer
|
|
|
2007
|
|
|
|
6,750
|
|
|
|
8,400
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,556
|
|
|
|
|
|
|
|
300
|
|
|
|
862
|
|
|
|
17,868
|
|
William L. Griffin, Jr.
|
|
|
2009
|
|
|
|
7,350
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,195
|
|
|
|
1,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,545
|
|
Senior Vice President, Global Operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Edward A. Steiger
|
|
|
2009
|
|
|
|
7,085
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,000
|
|
|
$
|
89,793
|
|
|
|
|
|
|
|
52,757
|
|
|
|
150,635
|
|
Senior Vice President, Human Resources
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Frank S. Bono
|
|
|
2009
|
|
|
|
7,350
|
|
|
|
|
|
|
|
|
|
|
|
7,500
|
|
|
|
|
|
|
|
904
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,754
|
|
Senior Vice President
|
|
|
2008
|
|
|
|
6,900
|
|
|
|
1,950
|
|
|
|
|
|
|
|
3,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,850
|
|
and Chief Technology Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Grants of
Plan-Based Awards
The table below sets forth information concerning grants of plan
based awards in 2009 to our named executive officers.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Awards:
|
|
|
|
|
|
Grant Date
|
|
|
|
|
|
Estimated Future Payouts
|
|
|
All Other
|
|
|
Number of
|
|
|
Exercise
|
|
|
Fair Value of
|
|
|
|
|
|
Under Non-Equity Incentive
|
|
|
Awards:
|
|
|
Securities
|
|
|
Price of
|
|
|
Stock and
|
|
|
|
Grant
|
|
Plans(1)
|
|
|
Number of
|
|
|
Underlying
|
|
|
Option
|
|
|
Option
|
|
Name
|
|
Date
|
|
Threshold
|
|
|
Target
|
|
|
Maximum
|
|
|
Shares of Stock
|
|
|
Options
|
|
|
Awards(2)
|
|
|
Awards(3)
|
|
|
Gary D Henley
|
|
5/13/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
57,638
|
|
|
$
|
15.47
|
|
|
$
|
350,946
|
|
|
|
5/13/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
70,976
|
|
|
|
|
|
|
|
|
|
|
|
1,097,999
|
|
|
|
|
|
$
|
30,270
|
|
|
$
|
378,375
|
|
|
$
|
756,750
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Lance A. Berry
|
|
5/13/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,378
|
|
|
|
15.47
|
|
|
|
38,834
|
|
|
|
5/13/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17,854
|
|
|
|
|
|
|
|
|
|
|
|
276,201
|
|
|
|
12/11/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,000
|
|
|
|
|
|
|
|
|
|
|
|
175,300
|
|
|
|
|
|
|
8,738
|
|
|
|
109,223
|
|
|
|
218,446
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
John K. Bakewell
|
|
5/13/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12,949
|
|
|
|
15.47
|
|
|
|
78,844
|
|
|
|
5/13/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,000
|
|
|
|
|
|
|
|
|
|
|
|
170,170
|
|
|
|
|
|
|
11,597
|
|
|
|
144,966
|
|
|
|
289,932
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
William L. Griffin, Jr.
|
|
5/13/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,811
|
|
|
|
15.47
|
|
|
|
71,915
|
|
|
|
5/13/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
34,544
|
|
|
|
|
|
|
|
|
|
|
|
534,396
|
|
|
|
|
|
|
11,124
|
|
|
|
139,050
|
|
|
|
278,100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Edward A. Steiger
|
|
5/13/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,791
|
|
|
|
15.47
|
|
|
|
41,349
|
|
|
|
5/13/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18,363
|
|
|
|
|
|
|
|
|
|
|
|
284,076
|
|
|
|
|
|
|
8,466
|
|
|
|
105,829
|
|
|
|
211,658
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Frank S. Bono
|
|
5/13/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,142
|
|
|
|
15.47
|
|
|
|
67,841
|
|
|
|
5/13/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21,220
|
|
|
|
|
|
|
|
|
|
|
|
328,273
|
|
|
|
|
|
|
10,410
|
|
|
|
130,129
|
|
|
|
260,258
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28
|
|
|
(1)
|
|
Estimated Future Payouts Under
Non-Equity Incentive Plans represent the threshold, target, and
maximum amounts that could be earned under the 2005 Bonus Plan
at targets established for each level. Each named executive
officer had a target incentive amount that could be earned if we
met the targets established. Until the threshold performance is
obtained, no incentive is earned. If the maximum performance had
been achieved, the named executive officers would have received
200% of their targeted amount.
|
|
(2)
|
|
The exercise price of each stock
option granted to our named executive officers is equal to the
fair market value, within the meaning of the 1999 Equity
Incentive Plan, of the underlying shares of common stock on the
grant date, calculated as the closing price on the trading day
immediately prior to the grant date. The closing market price on
the date of the grant of each stock option was $14.96 per share.
|
|
(3)
|
|
The grant date fair value is
computed in accordance with FASB ASC Topic 718. For Stock
Awards, which consist of restricted stock, the grant date fair
value per share is equal to the closing price of our stock on
the date of grant. See note 12 to our Audited Financial
Statements contained in our Annual Report on
Form 10-K
for a discussion of assumptions used to determine fair value of
Option Awards.
|
See Compensation Discussion and Analysis above for a complete
description. All the stock options granted to the named
executive officers were granted under the 1999 Equity Incentive
Plan. The Compensation Committee, which administers the 1999
Equity Incentive Plan, has general authority to accelerate,
extend, or otherwise modify the benefits under the stock options
in certain circumstances within overall plan and other
limitations. The Compensation Committee has no present intention
to exercise that authority with respect to these stock options.
All the shares of restricted stock were granted under our 1999
Equity Incentive Plan, with the exception of
Mr. Berrys December 11, 2009 grant, which was
made under our 2009 Equity Incentive Plan.
All stock options and shares of restricted stock vest upon a
change in control, as defined in the 2009 Equity Incentive Plan
and 1999 Equity Incentive Plan. All of the stock options and
restricted shares granted to our named executive officers in
2009 vest in equal annual installments on the first through
fourth anniversaries of the grant date.
29
Outstanding
Equity Awards
The table below sets forth information regarding the outstanding
equity awards held by our named executive officers at
December 31, 2009.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
Stock Awards
|
|
|
Number of
|
|
Number of
|
|
|
|
|
|
|
|
|
|
|
Securities
|
|
Securities
|
|
|
|
|
|
Number of
|
|
Market Value
|
|
|
Underlying
|
|
Underlying
|
|
|
|
|
|
Shares of
|
|
of Shares of
|
|
|
Unexercised
|
|
Unexercised
|
|
Option
|
|
|
|
Stock That
|
|
Stock That
|
|
|
Options
|
|
Options
|
|
Exercise
|
|
Option
|
|
Have Not
|
|
Have Not
|
Name
|
|
Exercisable
|
|
Unexercisable
|
|
Price
|
|
Expiration Date
|
|
Vested
|
|
Vested(1)
|
|
Gary D. Henley
|
|
|
225,000
|
|
|
|
75,000
|
(2)
|
|
$
|
19.52
|
|
|
|
4/4/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
25,000
|
|
|
|
25,000
|
(3)
|
|
|
24.08
|
|
|
|
5/17/2017
|
|
|
|
|
|
|
|
|
|
|
|
|
12,500
|
|
|
|
37,500
|
(4)
|
|
|
29.19
|
|
|
|
5/14/2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
57,638
|
(5)
|
|
|
15.47
|
|
|
|
5/13/2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
90,664
|
(6)
|
|
$
|
1,717,176
|
|
Lance A. Berry
|
|
|
15,450
|
|
|
|
|
|
|
|
27.30
|
|
|
|
10/23/2013
|
|
|
|
|
|
|
|
|
|
|
|
|
40,000
|
|
|
|
|
|
|
|
30.11
|
|
|
|
3/25/2014
|
|
|
|
|
|
|
|
|
|
|
|
|
50,000
|
|
|
|
|
|
|
|
23.39
|
|
|
|
4/4/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
3,751
|
|
|
|
3,750
|
(2)
|
|
|
19.52
|
|
|
|
4/4/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
2,500
|
|
|
|
7,500
|
(4)
|
|
|
29.19
|
|
|
|
5/14/2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,378
|
(5)
|
|
|
15.47
|
|
|
|
5/13/2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
36,604
|
(7)
|
|
|
693,280
|
|
John K. Bakewell
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
William L. Griffin, Jr.
|
|
|
25,000
|
|
|
|
75,000
|
(8)
|
|
|
29.88
|
|
|
|
7/22/2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,811
|
(5)
|
|
|
15.47
|
|
|
|
5/13/2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
34,544
|
(9)
|
|
|
654,263
|
|
Edward A. Steiger
|
|
|
12,500
|
|
|
|
37,500
|
(10)
|
|
|
22.07
|
|
|
|
11/17/2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,791
|
(5)
|
|
|
15.47
|
|
|
|
5/13/2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18,363
|
(11)
|
|
|
347,795
|
|
Frank S. Bono
|
|
|
37,500
|
|
|
|
37,500
|
(12)
|
|
|
25.44
|
|
|
|
7/24/2017
|
|
|
|
|
|
|
|
|
|
|
|
|
3,500
|
|
|
|
10,500
|
(4)
|
|
|
29.19
|
|
|
|
5/14/2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,142
|
(5)
|
|
|
15.47
|
|
|
|
5/13/2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26,470
|
(13)
|
|
|
501,342
|
|
|
|
|
(1)
|
|
Calculated as the market value on
December 31, 2009, which is deemed to have been $18.94 per
share, the closing sale price of our common stock reported for
transactions effected on the Nasdaq Global Select Market on
December 31, 2009.
|
|
(2)
|
|
These options vest and become
exercisable on 4/4/2010.
|
|
(3)
|
|
These options vest and become
exercisable in two equal installments on 5/17/2010 and 5/17/2011.
|
|
(4)
|
|
These options vest and become
exercisable in three equal installments on 5/14/2010, 5/14/2011,
and 5/14/2012.
|
|
(5)
|
|
These options vest and become
exercisable in four equal installments on 5/13/2010, 5/13/2011,
5/13/2012 and 5/13/2013.
|
|
(6)
|
|
11,250 of these shares of
restricted stock vest in two equal installments on 5/17/2010 and
5/17/2011. 8,438 of these shares of restricted stock vest in
three equal installments on 5/14/2010, 5/14/2011 and 5/14/2012.
70,976 of these shares of restricted stock vest in four equal
installments on 5/13/2010, 5/13/2011, 5/13/2012 and 5/13/2013.
|
|
(7)
|
|
5,000 of these shares of restricted
stock vest in two equal installments on 5/17/2010 and 5/17/2011.
3,750 of these shares of restricted stock vest in three equal
installments on 5/14/2010, 5/14/2011 and 5/14/2012. 17,854 of
these shares of restricted stock vest in four equal installments
on 5/13/2010, 5/13/2011, 5/13/2012 and 5/13/2013. 10,000 of
these shares of restricted stock vest in four equal installments
on 12/11/2010, 12/11/2011, 12/11/2012 and 12/11/2013.
|
|
(8)
|
|
These options vest and become
exercisable in three equal installments on 7/22/2010, 7/22/2011,
and 7/22/2012.
|
|
(9)
|
|
These shares of restricted stock
vest in four equal installments on 5/13/2010, 5/13/2011,
5/13/2012 and 5/13/2013.
|
30
|
|
|
(10)
|
|
These options vest and become
exercisable in three equal installments on 11/17/2010,
11/17/2011, and 11/17/2012.
|
|
(11)
|
|
18,363 of these shares of
restricted stock vest in four equal installments on 5/13/2010,
5/13/2011, 5/13/2012 and 5/13/2013.
|
|
(12)
|
|
These options vest and become
exercisable in two equal installments on 7/24/2010 and 7/24/2011.
|
|
(13)
|
|
5,250 of these shares of restricted
stock vest in three equal installments on 5/14/2010, 5/14/2011
and 5/14/2012. 21,220 of these shares of restricted stock vest
in four equal installments on 5/13/2010, 5/13/2011, 5/13/2012
and 5/13/2013.
|
Option
Exercises and Stock Vested During 2009
The following table provides information on stock option
exercises and vesting of restricted stock during 2009 for the
named executive officers.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
Stock Awards
|
|
|
Number of Shares
|
|
Value Realized
|
|
Number of Shares
|
|
Value Realized
|
Name
|
|
Acquired on Exercise
|
|
Upon Exercise
|
|
Acquired on Vesting
|
|
on Vesting
|
|
Gary D. Henley
|
|
|
|
|
|
|
|
|
|
|
8,437
|
|
|
$
|
125,655
|
|
Lance A. Berry
|
|
|
|
|
|
|
|
|
|
|
3,750
|
|
|
|
55,850
|
|
John K. Bakewell
|
|
|
9,249
|
|
|
$
|
18,353
|
|
|
|
6,500
|
|
|
|
96,790
|
|
William L. Griffin, Jr.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Edward A. Steiger
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Frank S. Bono
|
|
|
|
|
|
|
|
|
|
|
1,750
|
|
|
|
26,180
|
|
31
DIRECTOR
COMPENSATION
Director
Compensation
We compensate our directors for their services as members of our
Board of Directors and committees with a combination of annual
retainers and stock options. Directors who are not employees are
eligible to receive compensation for their services as
directors, while directors who are our employees are ineligible
to receive separate director compensation. The following table
sets forth a summary of the compensation we paid to our
non-employee directors in 2009:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fees Earned or
|
|
Stock
|
|
Option
|
|
|
Name
|
|
Paid in Cash
|
|
Awards(1)
|
|
Awards(2)
|
|
Total
|
|
Gary D. Blackford
|
|
$
|
45,000
|
|
|
$
|
83,538
|
|
|
$
|
60,888
|
|
|
$
|
189,426
|
|
Carmen L.
Diersen(3)
|
|
|
5,400
|
|
|
|
125,072
|
|
|
|
112,191
|
|
|
|
242,663
|
|
Martin J. Emerson
|
|
|
50,000
|
|
|
|
83,538
|
|
|
|
60,888
|
|
|
|
194,426
|
|
Lawrence W. Hamilton
|
|
|
45,825
|
|
|
|
83,538
|
|
|
|
60,888
|
|
|
|
190,251
|
|
John L. Miclot
|
|
|
43,750
|
|
|
|
83,538
|
|
|
|
60,888
|
|
|
|
188,176
|
|
Amy S. Paul
|
|
|
39,000
|
|
|
|
83,538
|
|
|
|
60,888
|
|
|
|
183,426
|
|
Robert J. Quillinan
|
|
|
60,000
|
|
|
|
83,538
|
|
|
|
60,888
|
|
|
|
204,426
|
|
David D. Stevens
|
|
|
92,500
|
|
|
|
83,538
|
|
|
|
60,888
|
|
|
|
236,926
|
|
|
|
|
(1)
|
|
The amounts in the Stock Awards
column represent grant date fair value computed in accordance
with FASB ASC Topic 718. For Stock Awards, which consist of
restricted stock, the grant date fair value per share is equal
to the closing price of our stock on the date of grant.
|
|
|
|
As of December 31, 2009, the
directors had the following number of shares of restricted stock
outstanding: Mr. Blackford 8,614;
Ms. Diersen 6,790; Mr. Emerson
5,400; Mr. Hamilton 5,400;
Mr. Miclot 5,400; Ms. Paul
8,614; Mr. Quillinan 5,400; and
Mr. Stevens 5,400.
|
|
(2)
|
|
The amounts in the Option Awards
column represent grant date fair value computed in accordance
with FASB ASC Topic 718. See note 12 to our Audited
Financial Statements contained in our Annual Report on
Form 10-K
for a discussion of assumptions used to determine fair value of
Option Awards.
|
|
|
|
As of December 31, 2009, the
directors had the following number of stock options outstanding:
Mr. Blackford 25,000;
Ms. Diersen 15,000;
Mr. Emerson 52,500;
Mr. Hamilton 40,000;
Mr. Miclot 40,000; Ms. Paul
25,000; Mr. Quillinan 40,000; and
Mr. Stevens 70,000.
|
|
(3)
|
|
Ms. Diersen was appointed by
our Board of Directors on November 12, 2009.
|
Eligible directors are paid an annual retainer of $35,000. All
directors are reimbursed for their
out-of-pocket
expenses incurred in connection with attending meetings of our
Board of Directors and its committees. In addition, upon their
initial election to our Board of Directors, eligible directors
are granted a stock option to purchase 15,000 shares of
common stock and a restricted stock award worth approximately
$125,000 on the date of grant. Directors reelected to office
shall be granted an option to purchase 10,000 shares of
common stock and a restricted stock award worth approximately
$83,500 on the date of grant. The stock options for all
directors, except Ms. Diersen, were granted pursuant to the
1999 Equity Incentive Plan, and Ms. Diersens stock
options were granted pursuant to the 2009 Equity Incentive Plan.
Stock options were granted with an exercise price equal to the
fair market value of the common stock on the grant date as
determined under the respective plan. The stock options vest and
become exercisable in equal annual installments over a period of
four years after the grant date for the initial
15,000 share stock option and for the subsequent
10,000 share stock option. The restricted stock awards were
granted pursuant to the 2009 Equity Incentive Plan and vest in
equal annual installments over a period of four years after the
grant date for the initial $125,000 restricted stock award and
in a single installment one year after the grant date for the
subsequent $83,500 restricted stock award. Future equity awards
will be granted to eligible directors under our 2009 Equity
Incentive Plan.
32
In addition to the compensation discussed above, eligible
directors are paid in accordance with the following:
|
|
|
|
|
The non-executive Chairman of our Board of Directors is paid a
supplemental annual retainer of $50,000.
|
|
|
|
Audit Committee The members of the Audit Committee
are paid a supplemental annual retainer of $25,000 for the
chairman and $10,000 for the other members.
|
|
|
|
Compensation Committee The members of the
Compensation Committee are paid a supplemental annual retainer
of $10,000 for the chairman and $5,000 for the other members.
|
|
|
|
Nominating, Compliance and Governance Committee The
members of the Nominating, Compliance and Governance Committee
are paid a supplemental annual retainer of $10,000 for the
chairman and $5,000 for the other members.
|
Our Board of Directors has adopted Director Stock Ownership
Guidelines whereby each non-employee director is required to
hold 25,000 shares, vested options, or vested restricted
shares. Each director shall be given three years to achieve the
threshold ownership. Once the threshold is reached, a director
would be permitted to sell shares; provided, that the threshold
is maintained. When a director leaves our Board of Directors,
the director may sell any vested shares he or she possesses.
Compensation
Committee Interlocks and Insider Participation
Lawrence W. Hamilton, Martin J. Emerson, and David D. Stevens,
our current directors, served as members of the Compensation
Committee of our Board of Directors in 2009. No member of the
Compensation Committee is or was an officer or employee of ours
or any of our subsidiaries. In addition, no executive officer of
ours served during 2009 as a director or a member of the
compensation committee of any entity that had an executive
officer serving as our director or a member of our Compensation
Committee.
33
PROPOSAL 1
ELECTION OF DIRECTORS
Director
Nominees
Upon the recommendation of the Nominating, Compliance and
Governance Committee, our Board of Directors has nominated the
individuals listed below for election as our directors. Each
nominee is an existing director and, except Carmen L. Diersen,
was elected by our stockholders at the 2009 annual meeting of
stockholders. Ms. Diersen was appointed by our Board of
Directors on November 12, 2009. Each nominee has consented
to serve on our Board of Directors. Our Board of Directors does
not know of any reason why any nominee would not be able to
serve as a director. However, if any nominee was to become
unable to serve as a director, our Board of Directors may
designate a substitute nominee, in which case the persons named
as proxies will vote for such substitute nominee.
David D. Stevens. Mr. Stevens,
age 56, has been one of our directors since 2004. He is
currently the independent director serving as the Chairman of
our Board of Directors. He has been a private investor since
2006. Mr. Stevens was the Chief Executive Officer of
Accredo Health Group, Inc., a subsidiary of Medco Health
Solutions, Inc., from 2005 to 2006. He was the Chairman of the
Board and Chief Executive Officer of Accredo Health, Inc. from
1996 to 2005. Mr. Stevens was the President and Chief
Operating Officer of Southern Health Systems, Inc. from 1983 to
1996. He is a director of Medco Health Solutions, Inc. and
Thomas & Betts Corporation, both public companies.
Gary D. Blackford. Mr. Blackford,
age 52, has been one of directors since 2008. Since 2007,
Mr. Blackford has served as Chairman of the Board of
Directors of Universal Hospital Services, Inc. In addition to
his role as Chairman, Mr. Blackford has been the President,
Chief Executive Officer and a member of the Board of Directors
of Universal Hospital Services, Inc. since 2003. From 2001 to
2002, Mr. Blackford was Chief Executive Officer for
Curative Health Services. From 1999 to 2001, Mr. Blackford
served as Chief Executive Officer for ShopforSchool, Inc. He was
the Chief Operating Officer for Value Rx from 1995 to 1998 and
the Chief Operating Officer and Chief Financial Officer of
MedIntel Systems Corporation from 1993 to 1994.
Mr. Blackford is a director of Universal Hospital Services,
Inc., a public reporting company, and served on the Board of
Directors of Compex Technologies, Inc., a public reporting
company, from 2005 until its acquisition by Encore Medical
Corporation.
Carmen L. Diersen. Ms. Diersen,
age 49, has been one of our directors since December, 2009
when she was appointed by our Board of Directors.
Ms. Diersen currently serves as the Chief Financial Officer
of Spine Wave, Inc., a developer of advanced materials,
techniques and implant systems for spinal surgery. From 2004 to
2006, she served as the Executive Vice President and Chief
Financial Officer of American Medical Systems, Inc. From 1992 to
2004, Ms. Diersen held positions of increasing domestic and
international responsibility in finance, business development,
and general management at Medtronic, Inc., including Vice
President of Finance and Administration and Vice President of
Business Development, Americas and Asia Pacific. From 1982 to
1992, Ms. Diersen was at Honeywell, Inc. Ms. Diersen
has served on the Board of Directors of SonoSite, Inc. and
served on the Board of Directors of Memry Corporation from 2004
to 2008 when the company was sold. Ms. Diersen has been a
Certified Public Accountant since 1983 and received a B.S. in
Accounting from the University of North Dakota and an MBA in
General Management from the University of Minnesota, Carlson
School of Management.
Martin J. Emerson. Mr. Emerson,
age 46, has been one of our directors since 2006. He
currently serves as President, Chief Executive Officer, and
Director of Galil Medical, a private medical device company. He
was the President and Chief Executive Officer and a director of
American Medical Systems Holdings, Inc., a medical device
company, from 2005 to January 2008, where he also served as the
President and Chief Operating Officer from 2004 to 2005, the
Executive Vice President of Global Sales and Marketing and Chief
Operating Officer from 2003 to 2004, and a Vice President and
the General Manager of International from 2000 to 2002.
Mr. Emerson has over twenty-three years of experience in
the medical device industry. He was the General Manager and
Finance Director in Singapore for Boston Scientific Corporation
from 1998 to 2000. Mr. Emerson was the Vice President and
Regional Financial Officer in Singapore for MasterCard
International Incorporated from 1997 to 1998. He also held
management positions with Baxter International Inc. from 1985 to
1997, most recently as the Vice President of Finance of its
Hospital Business division. Mr. Emerson is a director of
Incisive Surgical, Inc., a private company.
34
Lawrence W. Hamilton. Mr. Hamilton,
age 52, has been one of our directors since 2007.
Mr. Hamilton served as the Senior Vice President, Human
Resources at Tech Data Corporation, a distributor of information
technology, from 1996 to 2006, and as the Vice President, Human
Resources from 1993 to 1996. Mr. Hamilton served in a
variety of human resource management positions with
Bristol-Myers Squibb Company from 1985 to 1993, including Vice
President, Human Resources and Administration at Linvatec Corp.,
an arthroscopic and endoscopic division of Bristol-Myers Squibb
Company, from 1991 to 1993. Mr. Hamilton is a certified
Senior Professional in Human Resources and recently received the
Certified Compensation Professional designation from the
American Compensation Association.
Gary D. Henley. Mr. Henley, age 61,
has been one of our directors and our President and Chief
Executive Officer since 2006. He has twenty-five years of
experience in the orthopaedic medical device industry.
Mr. Henley was an executive with Orthofix International
N.V., a diversified orthopaedic products company, from 1997 to
2006, most recently serving as the President of its Americas
Division. He was the President of the Endoscopy Video Division
of Smith & Nephew Richards, Inc., from 1987 until
1996. Mr. Henley was the President and Chief Executive
Officer of Cecorp, Inc., a maker of surgical visualization
devices for the arthroscopic and endoscopic markets, from 1982
to 1987.
John L. Miclot. John L. Miclot, age 51,
has been one of our directors since 2007. He is currently the
President and Chief Executive Officer of CCS Medical, Inc., a
provider of products and services for patients with chronic
diseases. Prior to joining CCS Medical, he was the President and
Chief Executive Officer of Respironics, Inc., a provider of
sleep and respiratory products, from 2003 until 2008.
Mr. Miclot served in various positions at Respironics, Inc.
from 1998 to 2003, including Chief Strategic Officer and
President of the Homecare Division. His previous employer,
Healthdyne Technologies, Inc., a medical device company, was
acquired by Respironics, Inc. in 1998. Mr. Miclot served in
various positions at Healthdyne Technologies, Inc., including
Senior Vice President, Sales and Marketing, from 1995 to 1998.
He began his career at DeRoyal Industries, Inc., Baxter
International Inc., and Ohmeda Medical, Inc. Mr. Miclot is
a director of ev3 Inc., a NASDAQ publicly traded company,
chairman of the Board of Directors of Breathe Technologies,
Inc., a private company, as well as a director of the Pittsburgh
Zoo & PPG Aquarium and Burger King Cancer Caring
Center, both charitable institutions.
Amy S. Paul. Ms. Paul, age 58, has
been one of our directors since May 2008. Ms. Paul retired
in 2008 following a
26-year
career with C.R. Bard, Inc., a medical device company, most
recently serving as the Group Vice President-International since
2003. She served in various positions at C.R. Bard, Inc. from
1982 to 2003, including President of Bard Access Systems, Inc.,
President of Bard Endoscopic Technologies, Vice President and
Business Manager of Bard Ventures, Vice President of Marketing
of Bard Cardiopulmonary Division, Marketing Manager for Davol
Inc., and Senior Product Manager for Davol Inc.
Robert J. Quillinan. Mr. Quillinan,
age 62, has been one of our directors since 2006. He
retired in 2003 following a
23-year
career with Coherent, Inc., a leading supplier of lasers,
precision optics, and related accessories used in commercial and
scientific research applications. At Coherent, Inc.,
Mr. Quillinan served as Executive Vice President of Mergers
and Acquisitions from 2002 to 2003, Executive Vice President and
Chief Financial Officer from 1983 to 2002, Vice President and
Treasurer from 1982 to 1983, and Corporate Controller from 1980
to 1982. He was the Director of Financial Services for Synertek,
Inc. from 1978 to 1980 and an audit manager for Main,
LaFrentz & Co. from 1971 to 1978. Mr. Quillinan
is a director of Iverson Genetic Diagnostics, Inc., a private
company, and was a director of Reliant Technologies, Inc., a
private company, from 2005 until 2008.
Board of
Directors Recommendation
OUR BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE FOR
EACH OF THE NOMINEES FOR DIRECTOR LISTED ABOVE. Each
proxy solicited on behalf of our Board of Directors will be
voted FOR the election of the director nominees unless
the stockholder instructs otherwise in the proxy.
35
PROPOSAL 2
APPROVAL OF AN AMENDMENT TO OUR
2009 EQUITY INCENTIVE PLAN
Introduction
The 2009 Equity Incentive Plan originally was adopted by our
Board of Directors and approved by the stockholders on
May 13, 2009. Under the 2009 Equity Incentive Plan, we are
authorized to grant equity-based awards in the form of stock
options, stock appreciation rights, restricted stock, restricted
stock units, performance share units, and stock bonuses to our
and our subsidiaries employees (including executive
officers), directors, and consultants. The purpose of the 2009
Equity Incentive Plan is to provide a means for us to attract
able persons to become and remain employees and directors of and
consultants to us and our subsidiaries by providing them with
long-term, equity based incentive compensation. The objectives
of the 2009 Equity Incentive Plan are to strengthen the
commitment of employees, directors, and consultants to our
welfare and to promote an identity of interest between them and
our stockholders.
Summary
of Proposed Amendment
The Compensation Committee of our Board of Directors has
reviewed the 2009 Equity Incentive Plan and has concluded that
it would be in our best interests and the best interest of our
stockholders for the 2009 Equity Incentive Plan to be amended to
increase by 700,000 the number of shares of our common stock
available for awards thereunder. The Compensation Committee has
adopted an amendment to the 2009 Equity Incentive Plan to effect
these changes, subject to approval by our stockholders in a
manner that complies with applicable law, the rules and
regulations of the SEC, and the rules and regulations of Nasdaq.
If approved by our stockholders, the amendment of the 2009
Equity Incentive Plan will become effective as of May 13,
2010, the date of the annual meeting.
At present, we are authorized to grant equity-based awards under
the 2009 Equity Incentive Plan for up to 750,000 shares
plus the number of shares of common stock granted under the 1999
Equity Incentive Plan that are not exercised or are forfeited,
lapsed, or expired, or otherwise terminate without delivery of
any shares of common stock subject thereto, to the extent such
common stock would otherwise again have been available under the
1999 Equity Incentive Plan. At February 28, 2010, we had
granted stock options to approximately three employees,
directors and independent distributors. At February 28,
2010, we had granted restricted stock to approximately
189 employees, directors and independent distributors. At
February 28, 2010, we had granted restricted stock units to
approximately 25 employees, directors and independent
distributors. We thus far have not granted any stock
appreciation rights, performance share units, or stock bonuses
under the 2009 Equity Incentive Plan. At February 28, 2010,
we had not issued shares of common stock pursuant to stock
option exercises, and there were outstanding stock options to
purchase 32,800 shares of common stock (the
weighted-average exercise price for which is $17.98 and the
weighted-average remaining term for which is 9.8 years) and
unvested restricted shares and restricted stock units of
509,515. As a result, at February 28, 2010, there were
974,442 remaining shares of common stock available for future
awards under the 2009 Equity Incentive Plan, our only active
equity incentive plan.
Based on our current compensation policies, the Compensation
Committee believes that in the near future there will not be a
sufficient number of shares of common stock available for future
awards under the 2009 Equity Incentive Plan to enable us to
continue to achieve our objectives. Therefore, as contemplated
in the amendment, the maximum number of shares of common stock
for which we may grant awards under the 2009 Equity Incentive
Plan will be increased by 700,000 shares from 750,000 to
1,450,000 shares, of which full value awards are limited to
1,450,000 shares, plus the number of shares of common stock
granted under the 1999 Equity Incentive Plan that are not
exercised or are forfeited, lapsed, or expired, or otherwise
terminate without delivery of any shares of common stock subject
thereto, to the extent such common stock would otherwise again
have been available under the 1999 Equity Incentive Plan. The
additional shares represent a 93% increase in the number of
authorized shares under the 2009 Equity Incentive Plan, but
constitute only 2% of the 38,764,321 shares of common stock
that were outstanding on February 28, 2010. The additional
700,000 shares, together with the existing
974,442 shares at February 28, 2010, of which 319,039
may be granted as full value awards, are expected to provide us
with a sufficient number of available shares of common stock to
make awards under the 2009 Equity Incentive Plan for the
foreseeable future.
36
To address stockholders potential concerns regarding the
number of options, restricted shares and restricted stock units
we grant in a given year, the Compensation Committee set an
annual cap on these awards for each of the next three years,
beginning on January 1, 2011. During this period we will
not grant a number of shares subject to awards under our 2009
Equity Incentive Plan to employees and non-employee directors,
in the aggregate, greater than the RMG threshold percentage for
our GICS peer group (3510-Health Care Equipment &
Services) of shares of our common stock that we believe will be
outstanding over such
3-year
period. This would reflect limiting awards to no greater than
the RMG 2010 threshold for year 1, the RMG 2011 threshold for
year 2, and the RMG 2012 threshold for year 3. This limitation
does not apply to awards under plans assumed in acquisitions or
issuances under tax-qualified employee stock purchase plans.
Solely for the purposes of calculating the burn
rate, each stock option will be counted once and each
share subject to restricted stock or restricted stock unit will
be counted twice (equivalent to two shares).
Summary
of 2009 Equity Incentive Plan
The following is a summary of the detailed provisions of the
2009 Equity Incentive Plan as proposed to be amended. The
statements contained herein are qualified in their entirety by
reference to the 2009 Equity Incentive Plan, which sets forth
the 2009 Equity Incentive Plan as so amended, a copy of which is
attached as Appendix A to this Proxy Statement.
General. The 2009 Equity Incentive Plan
authorizes us to grant to eligible persons the following types
of equity-based awards: options to purchase common stock that
qualify as incentive stock options within the
meaning of Section 422 of the Code; options to purchase
common stock that do not qualify as incentive stock options
under the Code, which are also referred to as nonqualified
stock options; stock appreciation rights (SARs); shares of
restricted stock; restricted stock units; performance share
units; and stock bonuses.
Eligible Persons. Approximately 650 non-union
employees and directors of and consultants to us and our related
entities are eligible to receive equity-based awards under the
2009 Equity Incentive Plan. Under present law, incentive stock
options may be granted only to employees.
Shares Available. As contemplated by the
amendment, the aggregate number of shares of common stock which
may be made subject to all awards granted under the 2009 Equity
Incentive Plan is 1,450,000 shares, plus the number of
shares of common stock granted under the 1999 Equity Incentive
Plan that are not exercised or are forfeited, lapsed, or
expired, or otherwise terminate without delivery of any shares
of common stock subject thereto, to the extent such common stock
would otherwise again have been available under the 1999 Equity
Incentive Plan. Any and all shares of stock that may be made
subject to Awards are authorized to be issued pursuant to
Incentive Stock Options. Shares issued as full value awards
(that is, awards other than stock options or stock appreciation
rights) may not exceed 1,450,000 shares, plus the number of
full value awards allowed under the 1999 Equity Incentive Plan
that are not exercised or are forfeited, lapsed, or expired, or
otherwise terminate without delivery of any shares of common
stock subject thereto, to the extent such common stock would
otherwise again have been available under the 1999 Equity
Incentive Plan. The awards granted under the 2009 Equity
Incentive Plan and the foregoing share limitations are subject
to equitable adjustment or substitution, as determined by the
Compensation Committee, in its sole discretion, in the event of
certain changes in our outstanding shares of common stock or its
capital structure resulting from stock dividends, stock splits,
reverse stock splits, recapitalizations, reorganizations,
mergers, consolidations, combinations, exchanges, or other
relevant changes in capitalization. In the event that any stock
option, SAR, restricted stock, restricted stock unit, or
performance share unit expires or is surrendered, terminated, or
forfeited, the shares of common stock no longer subject to such
award will be released and thereafter available for new awards
to be granted under the 2009 Equity Incentive Plan.
At February 28, 2010, we had granted stock options and
stock bonuses to approximately three employees, directors and
independent distributors. At February 28, 2010, we had
granted full value awards to approximately 214 employees,
directors and independent distributors. We thus far have not
granted any stock appreciation rights, performance share units,
or stock bonuses under the 2009 Equity Incentive Plan. At
February 28, 2010, there were outstanding stock options to
purchase 32,800 shares of common stock (the
weighted-average exercise price for which is $17.98 and the
weighted-average remaining term for which is 9.8 years) and
unvested restricted shares and restricted stock units of
509,515. At February 28, 2010, we had transferred
766,757 shares from the 1999 Equity
37
Incentive Plan, of which 78,554 were full value awards. As a
result, at February 28, 2010 and as contemplated by the
amendment, there will be 1,674,442 remaining shares of common
stock available for future awards under the 2009 Equity
Incentive Plan, of which full value awards will be limited to
1,019,039 shares.
Administration. The Compensation Committee of
our Board of Directors is authorized to administer the 2009
Equity Incentive Plan. The Compensation Committee has the
authority, subject to the provisions of the 2009 Equity
Incentive Plan, to establish, adopt, or revise such rules and
regulations and to make all such determinations relating to the
administration of the 2009 Equity Incentive Plan as it may deem
necessary or advisable. The Compensation Committee has the
power, subject to the provisions of the 2009 Equity Incentive
Plan, to select the eligible persons to participate in the 2009
Equity Incentive Plan; determine the nature and extent of the
awards to be made to each participant; determine the time or
times when awards will be made to participants; establish the
performance goals and determine the period of time within which
performance is measured with respect to performance share units;
determine the period of time during which shares of restricted
stock are subject to restrictions; determine the conditions for
the payment of awards; and prescribe the forms of agreements and
documents evidencing the awards.
Types of
Equity-Based Awards.
Stock Options. The Compensation
Committee may grant awards of stock options to eligible persons
under the 2009 Equity Incentive Plan. Nonqualified stock options
may be granted to all eligible persons, but incentive stock
options may be granted only to employees of ours and our related
entities.
The Compensation Committee may set the exercise price of stock
options, provided that the exercise price is not less than the
fair market value of the underlying common stock on the date of
grant. Stock options will vest and become exercisable in such a
manner and on such date or dates as are determined by the
Compensation Committee. The stock options will expire after a
period not exceeding 10 years from the date of grant, as
determined by the Compensation Committee, subject to earlier
termination in the event that the participants employment
or service with us or a related entity ceases before the end of
the option period. If an incentive stock option is granted to a
participant who owns or is deemed to own more than 10% of the
combined voting power of all classes of our stock, the option
period may not exceed five years and the exercise price may not
be less than 110% of the fair market value of the underlying
common stock on the date of grant. Each stock option is to be
evidenced by a stock option agreement containing such
provisions, consistent with the 2009 Equity Incentive Plan, as
are determined by the Compensation Committee.
Stock Appreciation Rights. The
Compensation Committee may grant awards of stock appreciation
rights to eligible persons, alone or in tandem with stock
options, pursuant to the 2009 Equity Incentive Plan. A SAR
confers on the participant the right to receive the value equal
to the excess of the fair market value of one share of common
stock on the date of exercise over the exercise price of the
SAR. We may pay an exercised SARs excess value in the form
of cash, shares of common stock, or a combination of both as
determined by the Compensation Committee. If, on the day that an
unexercised SAR is scheduled to expire, the fair market value of
the common stock exceeds the exercise price of the SAR, the SAR
will be deemed to have been exercised by the participant on such
last day, and we will make the appropriate payment therefore.
Each SAR is to be subject to such terms and conditions as are
imposed by the Compensation Committee and are not inconsistent
with the 2009 Equity Incentive Plan.
Restricted Stock. The Compensation
Committee may grant awards of restricted stock to eligible
persons under the 2009 Equity Incentive Plan. Upon the award of
the restricted stock, we issue such stock to be held in a
restricted book entry account in the name of the participant.
The participants rights to the restricted stock are
subject to certain transferability and forfeiture restrictions
during a restricted period which commences on the date of grant
of the restricted stock and expires from time to time in
accordance with a schedule established by the Compensation
Committee. While the restrictions are in place, the participant
generally has the rights and privileges of a stockholder as to
the restricted stock, including the right to vote the restricted
stock and to receive dividends thereon. Upon the expiration of
the restricted period, the restrictions are of no further force
or effect with respect to the restricted stock, and we will
remove the restrictions of such restricted book entry account.
Each restricted stock award is to be evidenced by an agreement
between us and the participant setting forth the applicable
restrictions.
38
Restricted Stock Units. The
Compensation Committee may grant awards of restricted stock
units to eligible persons pursuant to the 2009 Equity Incentive
Plan. A restricted stock unit is a hypothetical investment equal
to one share of common stock. We do not issue any shares of
common stock when a restricted stock unit award is made, and the
participant is not considered a stockholder of ours. The
participants rights with respect to the restricted stock
units are subject to certain forfeiture provisions during a
restricted period which commences as of the date of grant of the
restricted stock units and expires from time to time in
accordance with a schedule established by the Compensation
Committee. Upon the expiration of the restricted period, we
deliver to the participant one share of common stock for each
restricted stock unit for which the restrictions have expired.
The terms and conditions of each grant of restricted stock units
are to be reflected in a written award agreement.
Performance Share Units. The
Compensation Committee is authorized to establish performance
share unit programs and may grant awards of performance share
units to eligible persons in accordance with such programs under
the 2009 Equity Incentive Plan. The Compensation Committee
determines the number of performance share units to be granted
to each eligible person who is selected to receive such an
award. At the beginning of each performance measurement period,
referred to in the 2009 Equity Incentive Plan as an award
period, the Compensation Committee establishes written
performance goals based on our financial objectives for such
award period and a schedule relating the accomplishment of the
performance goals to the performance share units to be earned by
the participants. The performance goals may include absolute or
relative growth in earnings per share or rate of return on
stockholders equity or any other measurement of corporate
performance and may be determined on an individual basis or by
categories of participants. The Compensation Committee may
adjust the performance goals during the award period to account
for certain events affecting us. At the completion of the award
period, the Compensation Committee calculates the number of
shares of common stock earned with respect to each
participants performance share unit award by multiplying
the number of performance share units granted to the participant
by a performance factor representing the degree of attainment of
the performance goals. Payment of earned performance share units
is made in the form of shares of common stock or, at the
Compensation Committees discretion, cash if requested by
the participant.
Stock Bonuses. The Compensation
Committee may issue unrestricted shares of common stock to
eligible persons pursuant to the 2009 Equity Incentive Plan. The
Compensation Committee may grant the stock awards as or in
payment of a bonus to the participant, to provide incentives for
the participant, or to recognize the participants special
achievements or contributions.
Transferability. A participants rights
and interest under the 2009 Equity Incentive Plan, including
amounts payable, may not be sold, assigned, donated, transferred
or otherwise disposed of, mortgaged, pledged or encumbered
except, in the event of a participants death, to a
designated beneficiary to the extent permitted in the 2009
Equity Incentive Plan, or in the absence of such designation, by
will or the laws of descent and distribution. The Compensation
Committee, however, may allow for the transfer of awards other
than incentive stock options to other persons or entities.
Change of Control Provisions. The award
agreements entered into under the 2009 Equity Incentive Plan may
provide for change in control provisions. In the absence of such
provisions, in the event of any of the following: (i) we
are merged or consolidated with another corporation or entity
and, in connection therewith, consideration is received by our
stockholders in a form other than stock or other equity
interests of the surviving entity, (ii) all or
substantially all of our assets are acquired by another person,
or (iii) the reorganization or liquidation of us, the
Compensation Committee may in its discretion and upon at least
ten days advance notice to the affected persons, cancel any
outstanding awards and pay to the holders in cash the value of
such awards based upon the price per share of stock received or
to be received by our other stockholders in such event.
Amendment and Termination. Our Board of
Directors may terminate the 2009 Equity Incentive Plan at any
time. Our Board of Directors or the Compensation Committee may
suspend and, if suspended, reinstate the 2009 Equity Incentive
Plan in whole or in part at any time and from time to time. Any
amendment of the 2009 Equity Incentive Plan must be approved by
our stockholders to the extent that such approval is required by
the 2009 Equity Incentive Plan, applicable law, the rules and
regulations of the SEC, or the rules and regulations of any
national securities exchange on which the common stock is then
listed.
39
Federal
Income Tax Consequences
The following is a summary of the material anticipated United
States federal income tax consequences of the 2009 Equity
Incentive Plan to us and the participants. The summary is based
on current federal income tax law, which is subject to change,
and does not address state, local, or foreign tax consequences
or considerations.
Stock Options. The grant of a stock option
that does not have a readily ascertainable value will not result
in taxable income at the time of the grant for either us or the
optionee. Upon exercising an incentive stock option, the
optionee will have no taxable income (except that the
alternative minimum tax may apply) and we will receive no
deduction. Upon exercising a nonqualified stock option, the
optionee will recognize ordinary income in the amount by which
the fair market value of the common stock at the time of
exercise exceeds the stock option exercise price, and we will be
entitled to a deduction for the same amount. The optionees
income is subject to withholding tax as wages.
The tax treatment of the optionee upon a disposition of shares
of common stock acquired through the exercise of a stock option
is dependent upon the length of time that the shares have been
held and on whether such shares were acquired by exercising an
incentive stock option or a nonqualified stock option. If an
employee exercises an incentive stock option and holds the
shares for two years from the date of grant and one year after
exercise, then any gain or loss realized based on the exercise
price of the stock option will be treated as long-term capital
gain or loss. Shares obtained upon exercise of an incentive
stock option that are sold without satisfying these holding
periods will be treated as shares received from the exercise of
a nonqualified stock option. Generally, upon the sale of shares
obtained by exercising a nonqualified stock option, the optionee
will treat the gain realized on the sale as a capital gain.
Generally, there will be no tax consequence to us in connection
with the disposition of shares of common stock acquired under a
stock option, except that we may be entitled to a deduction in
the case of a disposition of shares acquired upon exercise of an
incentive stock option before the applicable holding periods
have been satisfied.
Stock Appreciation Rights. The grant of a SAR
will not result in taxable income to the participant at the time
of the award. Upon exercising the SAR, the participant will
recognize ordinary income in the amount by which the fair market
value of the common stock or the amount of cash, as the case may
be, exceeds the SAR exercise price, if any. We will be entitled
to a deduction for the same amount. The participants
income is subject to withholding tax as wages. Upon a
disposition of shares of common stock acquired through the
exercise of the SAR, the participant may recognize capital gain
or loss, the character of which is dependent upon the length of
time that the shares have been held. Generally, there will be no
tax consequences to us in connection with the disposition of
shares of common stock acquired under a SAR.
Restricted Stock. An award of shares of common
stock that is limited in terms of transferability and is subject
to a substantial risk of forfeiture (i.e., restricted
stock) will not result in taxable income to the participant at
the time of the grant. Prior to the lapse of either of the
restrictions on the restricted stock, any dividends on such
shares will be paid currently and will be treated as ordinary
compensation income to the participant, subject to withholding.
Upon the lapse of either of the restrictions, the participant
will recognize ordinary compensation income in the amount of the
fair market value of the shares of common stock at the time that
the restriction lapses, less the amount paid for the shares, if
any.
Alternatively, within 30 days after transfer of the
restricted stock, a participant may make an election under
Section 83(b) of the Code, which would allow the
participant to include in income in the year that the restricted
common stock is awarded an amount equal to the fair market value
of the restricted stock on the date of such award determined as
if the restricted common stock were not subject to restrictions.
The employer is then entitled to a compensation-paid deduction
in the same amount. The election is required to be written and
delivered to the employer within that
30-day
period. The participant is also required to confirm the election
with the filing of the participants federal income tax
return for the year in which the award is made. Failure to
satisfy either of these requirements may invalidate the intended
election. In the event of a valid Section 83(b) election,
the participant will not recognize income at the time that the
restrictions actually lapse. In addition, any appreciation or
depreciation in the value of the stock and any dividends paid on
the stock after a valid Section 83(b) election are not
deductible by the employer as compensation paid. For purposes of
determining the period of time that the participant holds the
restricted stock, the holding period begins on the award date
when a participant makes a Section 83(b) election. Further,
any dividends received after the Section 83(b) election is
made will constitute ordinary dividend income to
40
the participant and will not be deductible by the employer. If
the restricted stock subject to the Section 83(b) election
is subsequently forfeited, however, the participant is not
entitled to a deduction or tax refund.
We will be entitled to a deduction for the year in which the
participant recognizes ordinary income with respect to the
restricted stock in an amount equal to such income.
Restricted Stock Units. The grant of a
restricted stock unit will not result in taxable income to the
participant at the time of the grant. At the time that we make a
payment with respect to the restricted stock unit, the
participant will recognize ordinary compensation income in an
amount equal to the fair market value of the shares of common
stock received or in the amount of the cash received, as the
case may be. Wage withholding rules will apply. We will be
entitled to a deduction at the time of payment in an amount
equal to such income.
Performance Share Units. The grant of a
performance share unit will not result in taxable income to the
participant at the time of the grant. At the time that we make a
payment with respect to the performance share units, the
participant will recognize ordinary compensation income in an
amount equal to the fair market value of the shares of common
stock received or in the amount of the cash received, as the
case may be. Wage withholding rules will apply. We will be
entitled to a deduction at the time of payment in an amount
equal to such income.
Stock Bonuses. A participant who receives a
stock bonus will recognize ordinary compensation income upon
receipt of the stock in an amount equal to the fair market value
of the stock on the date of grant. Wage withholding rules will
apply. We will be entitled to a deduction at the time of grant
in an amount equal to such income.
Effect of Section 162(m) of the
Code. Section 162(m) of the Code limits to
$1,000,000 per person the annual amount that we may deduct for
compensation paid to any of our most highly compensated
employees. Compensation payable as a result of the attainment of
performance goals may be excluded from this limit. To qualify as
performance-based compensation, the 2009 Equity Incentive Plan
and the awards made thereunder must meet certain requirements.
For example, stock options and SARs granted with an exercise
price not less than the fair market value of the underlying
shares of common stock are considered performance-based
compensation, so long as the 2009 Equity Incentive Plan and the
stock option or SAR meet certain requirements, because the
amount of compensation is attributable to an increase in the
price of the common stock. Restricted stock awards may or may
not qualify as performance-based compensation, depending on
whether the vesting of the restricted stock is based on the
attainment of performance-based goals.
Common
Stock Price
The last sale price of our common stock on March 23, 2010,
as reported by the Nasdaq Global Select Market, was $17.16 per
share.
41
Award
Grants
Past Award Grants. The following table sets
forth information regarding the number of equity-based awards
that were made, in the aggregate, under the 1999 Equity
Incentive Plan and the 2009 Equity Incentive Plan during 2009,
to (i) each of our named executive officers, (ii) all
current executive officers as a group, (iii) all current
directors, who are not executive officers, as a group, and
(iv) all employees, who are not executive officers, as a
group. There is no applicable disclosure to be made with regard
to any associate of our current directors, director nominees,
and executive officers or any other recipient of 5% or more of
the stock options.
|
|
|
|
|
|
|
|
|
|
|
Number of Shares of Common
|
|
|
Number of Shares of Restricted
|
|
|
|
Stock Underlying
|
|
|
Stock or Phantom
|
|
Name or Category
|
|
Options on Exercise
|
|
|
Stock Units on Vesting
|
|
|
Gary D. Henley
|
|
|
57,638
|
|
|
|
70,976
|
|
Lance A. Berry
|
|
|
6,378
|
|
|
|
27,854
|
|
John K. Bakewell
|
|
|
12,949
|
|
|
|
11,000
|
|
William L. Griffin
|
|
|
11,811
|
|
|
|
34,544
|
|
Edward A. Steiger
|
|
|
6,791
|
|
|
|
18,363
|
|
Frank S. Bono
|
|
|
11,142
|
|
|
|
21,220
|
|
All current executive officers as a group
|
|
|
100,817
|
|
|
|
186,647
|
|
All current directors, who are not executive officers, as a group
|
|
|
85,000
|
|
|
|
44,590
|
|
All employees, who are not executive officers, as a group
|
|
|
82,414
|
|
|
|
516,326
|
|
Future Award Grants. The granting of
equity-based awards under the 2009 Equity Incentive Plan is at
the discretion of the Compensation Committee. The Compensation
Committee has not yet determined any additional awards that will
be granted under the 2009 Equity Incentive Plan to the persons
and groups of persons identified in the preceding table. See
Executive Compensation Grant of Plan Based
Awards for information regarding the stock options,
restricted stock, and restricted stock units granted in 2009 to
our executive officers named in the Summary Compensation Table.
Board of
Directors Recommendation
OUR BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE FOR
THE APPROVAL OF AN AMENDMENT TO OUR 2009 EQUITY INCENTIVE
PLAN. Each proxy solicited on behalf of our Board of
Directors will be voted FOR the approval of an amendment
to our 2009 Equity Incentive Plan unless the stockholder
instructs otherwise in the proxy.
42
PROPOSAL 3
APPROVAL OF THE MATERIAL TERMS OF OUR 2010 EXECUTIVE
PERFORMANCE INCENTIVE PLAN
Introduction
On March 20, 2010, the Compensation Committee of our Board
of Directors adopted the 2010 Executive Performance Incentive
Plan. For purposes of Section 162(m) of the Code, the
material terms of the 2010 Executive Performance Incentive Plan
must be approved by our stockholders to enable us to fully
deduct for tax purposes compensation that is intended to qualify
as performance-based compensation.
Purpose
of the Proposal
Our Board of Directors is requesting that stockholders approve
the material terms of the 2010 Executive Performance Incentive
Plan to enable us to fully deduct for tax purposes payments
under the 2010 Executive Performance Incentive Plan that are
intended to qualify as performance-based
compensation. Under Section 162(m), the federal
income tax deductibility of compensation paid to our CEO and our
three other most highly compensated officers (other than our CEO
and principal financial officer) determined pursuant to the
executive compensation disclosure rules under the Securities
Exchange Act of 1934 (Covered Employees) may be limited to the
extent such compensation exceeds $1,000,000 in any taxable year.
However, we may deduct compensation paid to our Covered
Employees in excess of that amount if it qualifies as
performance-based compensation. In addition to certain other
requirements, for awards under the 2010 Executive Performance
Incentive Plan to constitute performance-based compensation, the
material terms of the 2010 Executive Performance Incentive Plan
must be disclosed to and approved by our stockholders. Under the
Section 162(m) regulations, the material terms of the 2010
Executive Performance Incentive Plan are (i) the maximum
amount of compensation that may be paid to a participant under
the 2010 Executive Performance Incentive Plan during a specified
period, (ii) the employees eligible to receive compensation
under the 2010 Executive Performance Incentive Plan, and
(iii) the business criteria on which performance goals are
based. Accordingly, our Board of Directors is asking
stockholders to approve the material terms of the 2010 Executive
Performance Incentive Plan for Section 162(m) purposes.
The deductibility of awards granted to Covered Employees after
our annual meeting will potentially be limited unless the
maximum award limits, eligibility provisions and business
criteria in the 2010 Executive Performance Incentive Plan are
approved by stockholders.
The material terms of the 2010 Executive Performance Incentive
Plan are disclosed below as follows: (i) the maximum amount
of compensation is described in the section entitled
Summary of the 2010 Executive Performance
Incentive Plan Maximum Award, (ii) the
eligible employees are described in the section entitled
Summary of the 2010 Executive Performance
Incentive Plan Individuals Who May
Participate, and (iii) the business criteria are
described in the section entitled Summary of
the 2010 Executive Performance Incentive Plan
Administration of the 2010 Executive Performance Incentive Plan
and Performance Goals. The following summary of the 2010
Executive Performance Incentive Plan, including its material
terms, does not purport to be a complete description of all the
provisions of the 2010 Executive Performance Incentive Plan and
should be read in conjunction with, and is qualified in its
entirety by reference to, the complete text of the 2010
Executive Performance Incentive Plan, which is appended to this
proxy statement as Appendix B.
Summary
of the 2010 Executive Performance Incentive Plan
The 2010 Executive Performance Incentive Plan provides for
objective performance-based awards for selected senior
executives, subject to a maximum limit, as described in more
detail below. Amounts paid under the 2010 Executive Performance
Incentive Plan are intended to qualify as performance-based
compensation, which is excluded from the $1,000,000 limit on
deductible compensation set forth in Section 162(m) of the
Code.
Administration of the 2010 Executive Performance Incentive
Plan and Performance Goals. The Compensation
Committee administers and interprets the 2010 Executive
Performance Incentive Plan, and any determination made by the
Compensation Committee will be final and conclusive. The
Compensation Committee may employ such legal counsel,
consultants and agents (including counsel or agents who are
employees of the
43
Company or its subsidiaries) as it may deem desirable for the
administration of the 2010 Executive Performance Incentive Plan
and may rely upon any opinion received from any such counsel or
consultant or agent and any computation received from such
consultant or agent. All expenses incurred in the administration
of the 2010 Executive Performance Incentive Plan, including,
without limitation, for the engagement of any counsel,
consultant, or agent, will be paid by the Company.
The Compensation Committee has the sole and absolute authority
to designate the participants in the 2010 Executive Performance
Incentive Plan from the pool of employees qualified to
participate in the 2010 Executive Performance Incentive Plan.
Within 90 days of the start of each calendar year, but in
no case later than the date which is 25% of the period being
measured, the Compensation Committee must establish the
performance objectives for all applicable measuring periods
during the year. The Compensation Committee must determine the
time periods (e.g., quarterly or full-year) for which
performance goals will be measured. The Compensation Committee
or its designee must communicate performance goals, financial
performance measures, the relative weighting of each measure,
and the performance minimum threshold, target bonus, and maximum
bonus to each participant. However, the weighting of measures of
cash flow shall not be greater than the weighted of measures of
net income.
Performance goals must be based upon performance measures such
as sales revenue, operating income before or after taxes, net
income before or after taxes, net income before securities
transactions, net or operating income excluding non-recurring
charges, return on assets, return on equity, return on capital,
market share, earnings per share, cash flow, revenue, revenue
growth, expenses, stock price, dividends, total stockholder
return, price/earnings ratio, market capitalization, book value,
product quality, customer retention, unit sales, strategic
business objectives or any other performance measure deemed
appropriate by the Compensation Committee in its discretion.
The Compensation Committee must determine a target performance
bonus, stated as a percentage of base salary, for each
participant. The target performance bonus represents the amount
of cash that a participant will receive if all performance goals
for each performance measure are met or exceeded.
The Compensation Committee must determine minimum performance
thresholds for each of the performance measures. Partial
payments of the target performance bonus may be paid only if the
minimum performance thresholds are achieved. A participant may
not be paid for performance below the minimum performance
threshold of any component of the performance measures.
If the performance goals for a performance year are exceeded,
the Compensation Committee may pay additional bonus in excess of
the target performance bonus. However, no participant may be
paid an amount that exceeds twice the target performance bonus
unless otherwise determined by the Compensation Committee.
Payments under the 2010 Executive Performance Incentive Plan
will be prorated for each component of the performance measures
between the minimum performance threshold and the target
performance goal and between the target performance goal and the
maximum performance bonus.
Financial results will be determined as soon as practicable
after the end of each quarter and the end of the performance
year. The Compensation Committee will review, approve and
certify payments for each quarter and for the performance year.
The Compensation Committee will determine in its sole discretion
the payments to be made to participants under the 2010 Executive
Performance Incentive Plan. Payments will be calculated based on
the participants basis for award calculation, which is the
participants base salary in effect at the end of the
quarter or performance year, prorated to cover the period under
consideration, plus any lump sum merit increases that may have
been granted to the participant during the performance year,
prorated to cover the period under consideration. All other
compensatory incentives, premiums, bonuses or payments will be
excluded from the basis for award calculation.
Payments under the 2010 Executive Performance Incentive Plan
based on quarterly results for the first, second, or third
quarter will be made in the following calendar quarter and may
not exceed 20% of a participants target bonus for the
performance year. Payments based on financial results of the
fourth quarter and for the performance year will be made after
the end of the performance year and will include
make-up
payments and overachievement payments based on the full year
financial results. Payments under the 2010 Executive Performance
Incentive Plan
44
will be made to participants as soon as practicable after the
Compensation Committee certifies that one or more of the
applicable performance objectives have been attained and
certified the amount of the payment. All payments under the 2010
Executive Performance Incentive Plan will be in cash, and
delivery must occur on or prior to March 15 of the performance
year following the performance year for which payments are to be
made. Any withholding of federal, state, or local taxes will be
deducted from all payments under the 2010 Executive Performance
Incentive Plan.
Subject to certain exceptions, a participant must be employed as
of the last day of a performance year to be entitled to a
payment under the 2010 Executive Performance Incentive Plan. A
participants payments under the 2010 Executive Performance
Incentive Plan will be prorated if the participant leaves his or
her position due to disability, dies, or takes a military leave.
Newly hired individuals may become participants if they are
hired on or prior to September 30 of a performance year.
Individuals who transfer within the Company or its subsidiaries
may also become participants. All payments made to such newly
hired or transferred individuals will be prorated for the period
of participation in the 2010 Executive Performance Incentive
Plan.
Maximum Award. In no event may any payment
under the 2010 Executive Performance Incentive Plan to a
participant exceed $1,500,000 for any performance year.
Individuals Who May Participate. The
Compensation Committee has the sole and absolute authority to
designate the participants in the 2010 Executive Performance
Incentive Plan. To be eligible to participate in the 2010
Executive Performance Incentive Plan, an individual must be a
regular full-time or part-time executive employed by the Company
or its subsidiaries and be designated as an officer of us or our
subsidiaries by our Board of Directors of such entity. In
addition, an individual must (i) be employed by us or one
of our subsidiaries for at least three months during the
performance year with a hire date on or prior to September 30
and must be an employee on December 31 of the performance year,
(ii) have met minimum job expectations and have performed
satisfactorily, as determined by the participants
manager/supervisor in conjunction with our Human Resource
Department; (iii) not have participated in another formal
non-equity incentive plan during the same period in the
performance year, other than individuals who have transferred
within us or our subsidiaries; and (iv) be employed in the
United States, Canada or in a European country in the business
unit designated by us as EMEA.
If a participant does not maintain an acceptable level of
overall performance, the participant may, at the sole discretion
of the Compensation Committee, be suspended from the 2010
Executive Performance Incentive Plan.
As of March 20, 2010, approximately 20 employees were
eligible to participate in the 2010 Executive Performance
Incentive Plan.
Transfer Restrictions; No Right to Continued
Employment. A participants rights and
interest under the 2010 Executive Performance Incentive Plan,
including amounts payable, may not be sold, assigned, donated,
or transferred or otherwise disposed of, mortgaged, pledged or
encumbered except, in the event of a participants death,
to a designated beneficiary to the extent permitted by the 2010
Executive Performance Incentive Plan, or in the absence of such
designation, by will or the laws of descent and distribution.
Neither the 2010 Executive Performance Incentive Plan nor any
action taken under the 2010 Executive Performance Incentive Plan
may be construed as giving any participant any right to be
retained in the employ or service of the Company or its
subsidiaries.
Term and Amendment. The 2010 Executive
Performance Incentive Plan became effective on March 20,
2010 and will expire on May 13, 2015.
Our Board of Directors of the Compensation Committee may at any
time amend, suspend, discontinue, or terminate the 2010
Executive Performance Incentive Plan; provided, however, that no
such amendment, suspension, discontinuance or termination shall
adversely affect any then existing rights of any participant in
any respect of any performance year that has already begun.
45
Executive
Performance Incentive Plan Payments
Past Payments. The following table sets forth
information regarding the amount of cash paid under the 2005
Bonus Plan during 2009, to (i) each of our named executive
officers, (ii) all current executive officers as a group,
(iii) all current directors, who are not executive
officers, as a group, and (iv) all employees, who are not
executive officers, as a group. There is no applicable
disclosure to be made with regard to any associate of our
current directors, director nominees, and executive officers or
any other recipient.
|
|
|
|
|
Name or Category
|
|
Amount of Award
|
|
|
Gary D. Henley
|
|
$
|
70,272
|
|
Lance A. Berry
|
|
|
18,662
|
|
William L. Griffin
|
|
|
25,920
|
|
Edward A. Steiger
|
|
|
19,872
|
|
Frank S. Bono
|
|
|
24,434
|
|
John K. Bakewell
|
|
|
28,790
|
|
All current executive officers as a group
|
|
|
179,082
|
|
All current directors, who are not executive officers, as a group
|
|
|
0
|
|
All officers, who are not executive officers, as a group
|
|
|
219,414
|
|
Future Payments. Future payments under the
2010 Executive Performance Incentive Plan is at the discretion
of the Compensation Committee. See Board of
Directors Compensation Committee Report
Performance Incentive Bonus for information
regarding the amounts that may be paid in 2010 to our executive
officers.
Board of
Directors Recommendation
OUR BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE FOR
THE APPROVAL OF THE MATERIAL TERMS OF OUR 2010 EXECUTIVE
PERFORMANCE INCENTIVE PLAN. Each proxy solicited on behalf
of our Board of Directors will be voted FOR the approval
of the material terms of the 2010 Executive Performance
Incentive Plan unless the stockholder instructs otherwise in the
proxy.
46
PROPOSAL 4
RATIFICATION OF SELECTION OF INDEPENDENT AUDITOR
General
The Audit Committee of our Board of Directors has selected KPMG
LLP (KPMG) as the independent auditor to perform the audit of
our consolidated financial statements for 2010. KPMG has audited
our consolidated financial statements since 2002. KPMG is a
registered public accounting firm.
Our Board of Directors is asking the stockholders to ratify the
selection of KPMG as our independent auditor for 2010. Although
not required by law, Nasdaqs listing standards, or our
bylaws, our Board of Directors is submitting the selection of
KPMG to the stockholders for ratification as a matter of good
corporate practice. Even if the selection is ratified, the Audit
Committee, in its discretion, may select a different registered
public accounting firm at any time during the year if it
determines that such a change would be in the best interests of
us and our stockholders.
Representatives of KPMG are expected to be present at the
meeting. They will have an opportunity to make a statement if
they desire and will be available to respond to appropriate
questions from our stockholders.
Board of
Directors Recommendation
OUR BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE FOR
THE RATIFICATION OF THE SELECTION OF KPMG AS OUR INDEPENDENT
AUDITOR FOR 2010. Each proxy solicited on behalf of our
Board of Directors will be voted FOR the ratification of
the selection of KPMG as our independent auditor for 2010 unless
the stockholder instructs otherwise in the proxy. If the
stockholders do not ratify the selection, the matter will be
reconsidered by the Audit Committee and our Board of Directors.
Audit and
Non-Audit Services
The Audit Committee is directly responsible for the appointment,
compensation, and oversight of our independent auditor. In
addition to retaining KPMG to audit our consolidated financial
statements for 2009, the Audit Committee retained KPMG to
provide other auditing and advisory services in 2009. The Audit
Committee understands the need for KPMG to maintain objectivity
and independence in its audits of our financial statements. The
Audit Committee has reviewed all non-audit services provided by
KPMG in 2009 and has concluded that the provision of such
services was compatible with maintaining KPMGs
independence in the conduct of its auditing functions.
To help ensure the independence of the independent auditor, the
Audit Committee has adopted a policy for the pre-approval of all
audit and non-audit services to be performed for us by our
independent auditor. Pursuant to this policy, all audit and
non-audit services to be performed by the independent auditor
must be approved in advance by the Audit Committee. The Audit
Committee may delegate to one or more of its members the
authority to grant the required approvals, provided that any
exercise of such authority is presented to the full Audit
Committee at its next regularly scheduled meeting.
The table below sets forth the aggregate fees billed by KPMG for
audit and non-audit services provided to us in 2008 and 2009.
|
|
|
|
|
|
|
|
|
Fees
|
|
2009
|
|
|
2008
|
|
|
Audit Fees
|
|
$
|
981,000
|
|
|
$
|
1,015,000
|
|
Audit-Related Fees
|
|
|
43,000
|
|
|
|
32,000
|
|
Tax Fees:
|
|
|
|
|
|
|
|
|
Tax Compliance Fees
|
|
|
20,000
|
|
|
|
20,000
|
|
All Other Tax Fees
|
|
|
52,000
|
|
|
|
77,000
|
|
|
|
|
|
|
|
|
|
|
Total Tax Fees
|
|
|
72,000
|
|
|
|
97,000
|
|
All Other Fees
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
1,096,000
|
|
|
$
|
1,144,000
|
|
|
|
|
|
|
|
|
|
|
47
In the above table, in accordance with the SECs
definitions and rules, audit fees are fees for
professional services for the audit of a companys
financial statements included in the annual report on
Form 10-K,
for the review of a companys financial statements included
in the quarterly reports on
Form 10-Q,
and for services that are normally provided by the accountant in
connection with statutory and regulatory filings or engagements;
audit-related fees are fees for assurance and
related services that are reasonably related to the performance
of the audit or review of a companys financial statements;
tax fees are fees for tax compliance, tax advice,
and tax planning; and all other fees are fees for
any services not included in the first three categories.
Other
Independence Measures
We have taken additional steps to ensure the independence of our
independent auditor. The Audit Committee requires that the lead
and concurring partners assigned to the audit of our
consolidated financial statements be rotated off the independent
auditors audit engagement at least every five years. Our
Board of Directors, upon the recommendation of the Audit
Committee, also has adopted a policy restricting the hiring of
employees or former employees of the independent auditor, who
participated in any capacity in the audit of our consolidated
financial statements.
48
EXECUTIVE
OFFICERS
Executive
Officers and Other Officers
The table below sets forth certain information concerning our
executive officers and other officers.
|
|
|
|
|
|
|
Name
|
|
Age
|
|
Position(s)
|
|
Executive Officers:
|
|
|
|
|
|
|
Gary D. Henley
|
|
|
61
|
|
|
President & Chief Executive Officer
|
Lance A. Berry
|
|
|
37
|
|
|
Senior Vice President & Chief Financial Officer
|
Frank S. Bono
|
|
|
47
|
|
|
Senior Vice President & Chief Technology Officer
|
William L. Griffin, Jr.
|
|
|
61
|
|
|
Senior Vice President, Global Operations
|
Edward A. Steiger
|
|
|
58
|
|
|
Senior Vice President, Human Resources
|
Eric A. Stookey
|
|
|
39
|
|
|
Senior Vice President & Chief Commercial Officer
|
Other Officers:
|
|
|
|
|
|
|
Timothy E. Davis, Jr.
|
|
|
40
|
|
|
Senior Vice President, Corporate Development
|
Rhonda L. Fellows
|
|
|
54
|
|
|
Senior Vice President, Government Affairs, National Accounts
& Reimbursements
|
William J. Flannery
|
|
|
56
|
|
|
Vice President, Logistics & Materials
|
Cary P. Hagan
|
|
|
43
|
|
|
Senior Vice President, Sales & Marketing EMEA
|
Karen L. Harris
|
|
|
48
|
|
|
Senior Vice President, Sales & Marketing Japan,
Latin America & Pacific Rim
|
Kyle M. Joines
|
|
|
42
|
|
|
Vice President, Manufacturing
|
Joyce B. Jones
|
|
|
56
|
|
|
Vice President & Treasurer
|
Lisa L. Michels
|
|
|
35
|
|
|
Vice President & Chief Compliance Officer
|
Alicia M. Napoli
|
|
|
55
|
|
|
Vice President, Clinical & Regulatory
|
John T. Treace
|
|
|
38
|
|
|
Senior Vice President, Global Marketing & U.S. Sales
|
Jennifer S. Walker
|
|
|
42
|
|
|
Vice President & Corporate Controller
|
Gary D. Henley has been one of our directors and our President
and Chief Executive Officer since 2006. He has 26 years of
experience in the orthopaedic medical device industry.
Mr. Henley was an executive officer with Orthofix
International N.V., a diversified orthopaedic products company,
from 1997 to 2006, most recently serving as the President of its
Americas Division. He was the President of the Endoscopy Video
Division of Smith & Nephew Richards, Inc. from 1987
until 1996. Mr. Henley was the President and Chief
Executive Officer of Cecorp, Inc., a maker of surgical
visualization devices for the arthroscopic and endoscopic
markets, from 1982 to 1987.
Lance A. Berry has been our Senior Vice President and Chief
Financial Officer since December, 2009. He joined us in 2002,
and, until his appointment as Chief Financial Officer, served as
Vice President and Corporate Controller. Prior to joining us,
Mr. Berry served as audit manager with the Memphis office
of Arthur Andersen LLP from 1995 to 2002. Mr. Berry
received his Masters degree in Accounting from the University of
Mississippi. Mr. Berry is a certified public accountant,
inactive.
Frank S. Bono served as our Senior Vice President, Research and
Development from 2007 until January, 2010, and now serves as our
Senior Vice President and Chief Technology Officer.
Mr. Bono has over 18 years of experience in the
orthopaedic medical device industry. He was employed by
Medtronic Spinal and Biologics, Inc. in various product
development positions from 2003 to 2007, serving as Vice
President Product Development and most recently as Vice
President Ventures Technology Development. Mr. Bono was the
Vice President Product Development of Spine Wave, Inc., a
minimally invasive spinal implant company, from 2002 to 2003.
Mr. Bono was employed by DePuy, Inc., a subsidiary of
Johnson & Johnson, holding various technical positions
in both total joint
49
and spinal reconstruction from 1992 to 2002, where he ultimately
served as the Vice President of Research and Development for the
Core Spinal Product line.
William F. Griffin, Jr. has been our Senior Vice President,
Global Operations since 2008. Prior to joining us,
Mr. Griffin had global responsibility for all operations at
Smith & Nephew, Inc. since 2002. From 1997 until 2002,
he held positions at Johnson & Johnson Medical,
including most recently serving as its Vice President and
General Manager. Mr. Griffin began his career in the
medical device industry with Becton, Dickinson and Company where
he spent 23 years with the final position of Vice President
of Global Supply Chain Services.
Edward A. Steiger has been our Senior Vice President, Human
Resources since January, 2010, and was previously our Vice
President, Human Resources since 2008. He has eight years of
experience in the medical device industry and 35 years of
experience related to various aspects of human resources. Prior
to joining us, Mr. Steiger was employed by Sempra Energy as
Vice President, Human Resources for its global businesses from
2003 to 2008. From 1998 to 2003, Mr. Steiger worked for
Monsanto Company, most recently as its Vice President, Global
Staffing. From 1992 to 1997, Mr. Steiger was Vice
President, Human Resources for Tastemaker, a specialty
chemical/flavor partnership between Mallinckrodt Inc. and
Hercules Incorporated. From 1985 to 1992, Mr. Steiger held
a number of key positions at Allergan, Inc. a global eye care
pharmaceutical and medical device company
Eric A. Stookey has been our Senior Vice President and Chief
Commercial Officer since January, 2010. Mr. Stookey has
served us in various other marketing and sales positions since
1995, including as our Vice President, North American Sales from
2007 to January, 2010, as our Vice President
U.S. Sales from 2005 until 2007, as our Senior Director of
Sales Central Region from 2003 to 2005 and as our
Director of Marketing for Large Joint Reconstruction Products
from 2001 to 2003. He was employed by DePuy Orthopedics, Inc.
from 1993 to 1995.
Timothy E. Davis, Jr. has been our Senior Vice President,
Business Development since January, 2010 and previously served
as our Vice President, Business Development since 2006. He was a
partner with MB Venture Partners, LLC, a medical technology and
life sciences venture capital firm specializing in
musculoskeletal diseases, from 2004 to 2006. Mr. Davis was
the Vice President of Vector Fund Management, a healthcare
and life sciences venture capital firm, from 1997 to 2004. He
was a Senior Consultant at Gemini Consulting Group, a healthcare
consulting firm, from 1995 to 1997 and a Sales Specialist at
Parke-Davis Company, a pharmaceutical company, from 1992 to 1994.
Rhonda L. Fellows has been our Senior Vice President, Government
Affairs, National Accounts and Reimbursements since January,
2010, and previously served as our Senior Vice President,
Government Affairs and Reimbursement since 2007. Prior to
joining us, she worked for Orthofix International N.V., a
diversified orthopaedic products company, from 1998 to 2007,
most recently serving as Senior Vice President, Government
Affairs and HIPAA Privacy Officer. Ms. Fellows served as
National Accounts Manager for Medtronic, Inc., a medical
technology company, from 1991 to 1996, until her division was
sold to Empi Inc., a manufacturer and provider of non-invasive
medical products, where she served from 1996 to 1997.
William J. Flannery has been our Vice President, Logistics and
Materials since 2004. He served as our Senior
Director Materials and Purchasing from 1994 to 2004.
Mr. Flannery has 30 years of experience in the
orthopaedic medical device industry. He was employed by United
States Surgical Corporation, a manufacturer of products used to
perform minimally invasive surgical procedures, in various
operational positions from 1978 to 1994, where he ultimately
served as the Senior Director of Materials.
Cary P. Hagan has been our Senior Vice President, Sales and
Marketing EMEA since January, 2010. He served as our
Vice President, OrthoRecon Marketing from 2006 until January,
2010, as our Senior Director Biologics Marketing and
Business from 2003 to 2006, as the Product Manager for Biologics
from 1996 to 2003, and in various other marketing and sales
roles since 1989.
Karen L. Harris has been our Senior Vice President,
Sales & Marketing Japan, Latin
America & Pacific Rim Sales and Marketing since
January, 2010, and previously served as our Vice President,
International Sales and Distribution since 1998. She served as
our Vice President European Business Development
from 1997 to 1998. Ms. Harris was employed by MicroAire
Surgical Instruments, Inc., in various sales and marketing
positions from 1990 to 1997, most recently serving as the
Director of International Sales and Marketing.
50
Kyle M. Joines has been our Vice President, Manufacturing since
2004. He served as our Senior Director Manufacturing
from 2001 to 2004, the Director Manufacturing from
1998 to 2001, and in various other production positions from
1993 to 1998. Mr. Joines was employed by Precision
Castparts Corp., a global manufacturer of complex metal
components and products, from 1990 to 1992, where he ultimately
served as the Foundry Coordinator.
Joyce B. Jones has been our Vice President and Treasurer since
2002. She served as our Vice President Finance and
Controller from 1998 to 2002 and in various other finance and
accounting positions from 1989 to 1998. Ms. Jones was the
Corporate Controller of Insituform Technologies, Inc., a
provider of specialized pipeline rehabilitation technologies and
services, from 1986 to 1989.
Lisa L. Michels has been our Vice President and Chief Compliance
Officer since 2008. Prior to joining us, she worked for
Smith & Nephew Inc. from 2006 to 2008, most recently
as the Group Director of Regulatory Affairs. Ms. Michels
was also employed by Baxter International, Inc. from 2004 to
2006 and by GE Medical Systems, a division of General Electric
Company, from 1999 to 2004 where she served in various
regulatory and compliance positions.
Alicia M. Napoli has been our Vice President, Clinical and
Regulatory since 2008. Ms. Napoli was previously Sr.
Director of Regulatory and Clinical Affairs at Covidien Ltd. She
led global submissions and clinical trials for its Imaging
Solutions and Pharmaceutical business sector, including drug and
device registrations throughout the world. She spent her first
twenty years in progressive quality systems and regulatory
compliance positions at Baxter International Inc. and
Mallinckrodt Inc.
John T. Treace has been our Senior Vice President, Global
Marketing and U.S. Sales since January, 2010.
Mr. Treace previously served as our Vice President,
Biologics and Extremities Marketing since 2005. He served as our
Vice President and General Manager Biologics and
Extremity Marketing from 2003 to 2005 and the Senior
Director Biologics Marketing from 2001 to 2003.
Mr. Treace was the Director of Marketing of Medtronic
Xomed, Inc., and its predecessor, Xomed Surgical Products, Inc.,
from 1996 to 2000. He was the Director of Marketing of TreBay
Medical Corp. from 1994 to 1996.
Jennifer S. Walker has been our Vice President and Corporate
Controller since December 2009. She served as our Assistant
Controller from 2001 to 2009 and in various other finance and
accounting positions from 1996 to 2001. Prior to joining us,
Ms. Walker was employed by Arthur Andersen LLP.
Ms. Walker is a certified public accountant.
Code of
Business Conduct
We have adopted a Code of Business Conduct which applies to all
of our directors, officers, employees and agents, as well as
those of our subsidiaries. The Code of Business Conduct
satisfies the SECs requirements for a code of
ethics and Nasdaqs requirements for a code of
conduct. The Code of Business Conduct is posted on our
website at
http://www.wmt.com/corporate/codeofconduct.pdf.
The information on our website, however, is not a part of this
Proxy Statement. The Code of Business Conduct may be waived for
any director or officer only by our Board of Directors upon the
recommendation of both our Nominating, Compliance and Governance
Committee and our ethics officer. Our Board of Directors has no
present intention to permit any waiver of the Code of Business
Conduct for any director or officer.
51
OTHER
MATTERS
As of the date hereof, our Board of Directors knows of no
business that will be presented at the meeting other than the
proposals described in this Proxy Statement. If any other
proposal properly comes before the stockholders for a vote at
the meeting, the proxy holders will vote the shares of common
stock represented by proxies that are submitted to us in
accordance with their best judgment.
ADDITIONAL
INFORMATION
Solicitation
of Proxies
We will solicit proxies on behalf of our Board of Directors by
mail, telephone, facsimile, or other electronic means or in
person. We have retained MacKenzie Partners, Inc. to assist in
soliciting proxies for a fee of $7,500 plus the reimbursement of
its distribution costs and other costs and expenses. We will pay
the proxy solicitation costs. We will supply copies of the proxy
solicitation materials to brokerage firms, banks, and other
nominees for the purpose of soliciting proxies from the
beneficial owners of the shares of common stock held of record
by such nominees. We request that such brokerage firms, banks,
and other nominees forward the proxy solicitation materials to
the beneficial owners and will reimburse them for their
reasonable expenses.
Mailing
Address of Principal Executive Office
The mailing address of our principal executive office is Wright
Medical Group, Inc., 5677 Airline Road, Arlington, Tennessee
38002.
Stockholder
Proposals for Inclusion in Proxy Statement for 2011 Annual
Meeting of Stockholders
To be considered for inclusion in our proxy statement for the
2011 Annual Meeting of Stockholders, a stockholder proposal must
be received by us no later than the close of business on
December 13, 2010. Stockholder proposals must be sent to
Corporate Secretary, Wright Medical Group, Inc., 5677 Airline
Road, Arlington, Tennessee 38002. We will not be required to
include in our proxy statement any stockholder proposal that
does not meet all the requirements for such inclusion
established by the SECs proxy rules and Delaware corporate
law.
Other
Stockholder Proposals for Presentation at 2011 Annual Meeting of
Stockholders
For any proposal that is not submitted for inclusion in our
proxy statement for the 2011 Annual Meeting of Stockholders, but
is instead sought to be presented directly at the meeting, the
SECs rules permit management to vote proxies in its
discretion if: (i) we receive notice of the proposal before
the close of business on February 26, 2011, and advise
stockholders in the proxy statement about the nature of the
matter and how management intends to vote on such matter; or
(ii) we do not receive notice of the proposal prior to the
close of business on February 26, 2011. Notices of
intention to present proposals at the 2011 Annual Meeting of
Stockholders should be sent to Corporate Secretary, Wright
Medical Group, Inc., 5677 Airline Road, Arlington, Tennessee
38002.
By Order of our Board of Directors,
Thomas L. McAllister
Secretary
Arlington, Tennessee
April 15, 2010
52
APPENDIX A
WRIGHT MEDICAL GROUP, INC.
AMENDED AND RESTATED 2009 EQUITY INCENTIVE PLAN
RECITALS
WHEREAS, the 2009 Equity Incentive Plan (the Plan)
originally was adopted by our Board of Directors and approved by
the stockholders on May 13, 2009;
WHEREAS, it is now desired to amend and restate the Plan in its
entirety to increase by 700,000 the number of shares of our
common stock, par value $0.01 per share, available for awards
under the Plan.
WHEREAS, Section 15 of the Plan provides that the Plan may
be amended at any time, in whole or in part, by action of the
Companys Board of Directors or its Compensation
Committee; and
NOW, THEREFORE, pursuant to the authority granted by the
Compensation Committee, the Plan is hereby amended and restated,
effective as of May 13, 2010, as follows:
1. Purpose.
(a) The purpose of the Plan is to provide a means through
which the Company may attract able persons to become and remain
directors of the Company or any Related Entity and enter and
remain in the employ of the Company or any Related Entity and to
provide a means whereby employees, directors and consultants of
the Company and any Related Entity can acquire and maintain
Stock ownership, or be paid incentive compensation measured by
reference to the value of Stock, thereby strengthening their
commitment to the welfare of the Company and promoting an
identity of interest between stockholders and these employees,
directors and consultants.
(b) So that the appropriate incentive can be provided, the
Plan provides for granting Incentive Stock Options, Nonqualified
Stock Options, Stock Appreciation Rights, Restricted Stock,
Restricted Stock Units, Performance Share Units and Stock Bonus,
or any combination of the foregoing.
2. Definitions. The
following definitions shall be applicable throughout the Plan:
(a) Award means, individually or collectively,
any Incentive Stock Option, Nonqualified Stock Option, Stock
Appreciation Right, Restricted Stock, Restricted Stock Unit,
Performance Share Unit or Stock Bonus granted under the Plan.
(b) Award Period means a period of time within
which performance is measured for the purpose of determining
whether a Performance Share Unit has been earned.
(c) Board means our Board of Directors of the
Company.
(d) Cause means the Company or a Related Entity
having cause to terminate a Participants employment or
service in accordance with the provisions of any existing
employment, consulting or any other agreement between the
Participant and the Company or a Related Entity or, in the
absence of such an employment, consulting or other agreement,
upon (i) the determination by the Committee that the
Participant has ceased to perform the Participants duties
to the Company or a Related Entity (other than as a result of
the Participants incapacity due to physical or mental
illness or injury), which failure amounts to intentional and
extended neglect of the Participants duties, (ii) the
Committees determination that the Participant has engaged
or is about to engage in conduct injurious to the Company or a
Related Entity, or (iii) the Participant having plead no
contest to a charge of a felony or having been convicted of a
felony.
(e) Code means the Internal Revenue Code of
1986, as amended. Reference in the Plan to any section of the
Code shall be deemed to include any amendments or successor
provisions to such section and any regulations under such
section.
(f) Committee means the full Board, the
Compensation Committee of the Board or such other committee as
the Board may appoint to administer the Plan.
(g) Common Stock means the common stock, par
value $0.01 per share, of the Company.
A-1
(h) Company means Wright Medical Group, Inc., a
Delaware corporation, and any successor thereto.
(i) Date of Grant means the date on which the
granting of an Award is authorized, or such other date as may be
specified in such authorization.
(j) Disability means the complete and permanent
inability by reason of illness or accident to perform the duties
of the occupation at which a Participant was employed or served
when such disability commenced or, if the Participant was
retired when such disability commenced, the inability to engage
in any substantial gainful activity, in either case as
determined by the Committee based upon medical evidence
acceptable to it.
(k) Eligible Person means any (i) person
regularly employed by the Company or any Related Entity;
provided, however, that no such employee covered by a collective
bargaining agreement shall be an Eligible Person unless and to
the extent that such eligibility is set forth in such collective
bargaining agreement or in an agreement or instrument relating
thereto; (ii) director of the Company or any Related
Entity; or (iii) consultant to the Company or any Related
Entity.
(l) Exchange Act means the Securities Exchange
Act of 1934, as amended.
(m) Fair Market Value on a given date means
(i) if the Stock is listed on a national securities
exchange, the closing price of a share of Stock reported as
having occurred on the primary exchange with which the Stock is
listed and traded on the date prior to such date, or, if there
is no such sale on that date, then on the last preceding date on
which such a sale was reported; (ii) if the Stock is not
listed on any national securities exchange but is quoted on an
automated quotation system, the closing price of a share of
Stock reported on the date prior to such date, or, if there is
no such sale on that date, then on the last preceding date on
which a sale was reported; or (iii) if the Stock is not
listed on a national securities exchange nor quoted on an
automated quotation system, the amount determined pursuant to
one of the methods set forth in Treas. Reg.
§ 1.409A-1(b)(5)(iv)(B)(2), as elected by the
Committee.
(n) Full Value Award means any Award, other
than Options or Stock Appreciation Rights, which is settled by
the issuance of Common Stock.
(o) Holder means a Participant who has been
granted an Award.
(p) Incentive Stock Option means an Option
granted by the Committee to a Participant under the Plan which
is designated by the Committee as an Incentive Stock Option
pursuant to Section 422 of the Code.
(q) Non-Employee Director means a
non-employee director within the meaning of
Rule 16b-3
of the Exchange Act or any successor rule or regulation.
(r) Nonqualified Stock Option means an Option
granted under the Plan which is not designated as an Incentive
Stock Option.
(s) Normal Termination means termination of
status as an Eligible Person:
(i) upon retirement pursuant to the retirement plan of the
Company or any Related Entity, as may be applicable at the time
to the Participant in question;
(ii) on account of Disability;
(iii) with the written approval of the Committee;
(iv) voluntary on the part of the Participant; or
(v) by the Company or any Related Entity without Cause.
(t) Option means an Award granted under
Section 7 of the Plan.
(u) Option Period means the period described in
Section 7(c).
(v) Option Price means the exercise price set
for an Option described in Section 7(a).
(w) Participant means an Eligible Person who
has been selected by the Committee to participate in the Plan
and to receive an Award.
A-2
(x) Performance Goals means the performance
objectives of the Company or a Related Entity during an Award
Period or Restricted Period established for the purpose of
determining whether, and to what extent, Awards will be earned
for an Award Period or Restricted Period.
(y) Performance Share Unit means a hypothetical
investment equal to one share of Stock granted in connection
with an Award made under Section 9 of the Plan.
(z) Plan means the Wright Medical Group, Inc.
2009 Equity Incentive Plan, as may be amended
and/or
restated from time to time.
(aa) Qualified Committee means a committee
composed of at least two Qualified Directors.
(bb) Qualified Director means a person who is
(i) an Non-Employee Director and (ii) an outside
director within the meaning of Section 162(m) of the
Code.
(cc) Related Entity means, when referring to a
subsidiary, any business entity (other than the Company) which,
at the time of the granting of an Award, is in an unbroken chain
of entities ending with the Company, if stock or voting
interests possessing 50% or more of the total combined voting
power of all classes of stock or other ownership interests of
each of the entities other than the Company is owned by one of
the other entities in such chain and, when referring to a parent
entity, the term Related Entity shall mean any
entity in an unbroken chain of entities ending with the Company
if, at the time of the granting of the Award, each of the
entities other than the Company owns stock or other ownership
interests possessing 50% or more of the total combined voting
power of all classes of stock (or other ownership interests) in
one of the other entities in such chain. In addition, with
respect to an Incentive Stock Option, the definition of
Related Entity as used in this Plan shall apply by
only considering entities that are corporations.
(dd) Restricted Period means, with respect to
any share of Restricted Stock or any Restricted Stock Unit, the
period of time determined by the Committee during which such
Award is subject to the restrictions set forth in
Section 10.
(ee) Restricted Stock means an Award of
Restricted Stock granted under Section 10 of the Plan.
(ff) Restricted Stock Unit means a hypothetical
investment equal to one share of Stock granted in connection
with an Award made under Section 10 of the Plan.
(gg) Securities Act means the Securities Act of
1933, as amended.
(hh) Stock means the Common Stock or such other
authorized shares of stock of the Company as from time to time
may be authorized for use under the Plan.
(ii) Stock Appreciation Right or
SAR means an Award granted under Section 8 of
the Plan.
(jj) Stock Bonus means an Award granted under
Section 11 of the Plan.
(kk) Stock Option Agreement means the agreement
between the Company and a Participant who has been granted an
Option pursuant to Section 7 which defines the rights and
obligations of the parties as required in Section 7(d).
(ll) Vested Unit shall have the meaning
ascribed thereto in Section 10(e).
3. Effective Date, Duration and Shareholder
Approval. The Plan shall be effective as of
May 13, 2009. The effectiveness of the Plan and the
validity of any and all Awards granted hereunder is contingent
upon approval of the Plan by the stockholders of the Company in
a manner which complies with (i) Section 422(b)(1)
and, to the extent provided in Section 16 herein,
Section 162(m) of the Code and (ii) if listed, the
requirements of the national securities exchange with which the
Stock is listed. Unless and until the stockholders approve the
Plan in compliance with the applicable requirements, no Award
granted hereunder shall be effective. The expiration date of the
Plan, after which no Awards may be granted hereunder, shall be
May 13, 2019; provided, however, that the administration of
the Plan shall continue in effect until all matters relating to
the payment of Awards previously granted have been settled.
A-3
4. Administration. The Plan
shall be administered by the full Board or the Committee,
provided that the Committee shall be composed of at least two
persons, each member of which, at the time he takes any action
with respect to an Award under the Plan, shall be a Non-Employee
Director; and further provided, that to the extent that the
Company determines that an Award is intended to comply with
Section 162(m) of the Code, the Plan shall be administered
by a Qualified Committee. The majority of the members of the
Committee shall constitute a quorum. The acts of a majority of
the members present at any meeting at which a quorum is present
or acts approved in writing by a majority of the Committee shall
be deemed the acts of the Committee. Subject to the provisions
of the Plan, the Committee shall have exclusive power to:
(a) select the Eligible Persons to participate in the Plan;
(b) determine the nature and extent of the Awards to be made to
each Participant;
(c) determine the time or times when Awards will be made to
Participants;
(d) determine the duration of each Award Period and Restricted
Period;
(e) determine the conditions to which the payment of Awards may
be subject;
(f) establish the Performance Goals for each Award Period;
(g) prescribe the form of Stock Option Agreement or other form
or forms evidencing Awards; and
(h) cause records to be established in which there shall be
entered, from time to time as Awards are made to Participants,
the date of each Award, the number of Incentive Stock Options,
Nonqualified Stock Options, SARs, Restricted Stock Units,
Performance Share Units, shares of Restricted Stock and Stock
Bonuses awarded by the Committee to each Participant, the
expiration date, the Award Period and the duration of any
applicable Restricted Period.
The Committee shall have the authority, subject to the
provisions of the Plan, to establish, adopt, or revise such
rules and regulations and to make all such determinations
relating to the Plan as it may deem necessary or advisable for
the administration of the Plan. The Committees
interpretation of the Plan or any documents evidencing Awards
granted pursuant thereto and all decisions and determinations by
the Committee with respect to the Plan shall be final, binding,
and conclusive on all parties unless otherwise determined by the
Board.
5. Grant of Awards; Shares Subject to the
Plan. The Committee may, from time to time,
grant Awards of Options, Stock Appreciation Rights, Restricted
Stock Units, Performance Share Units, shares of Restricted
Stock, Stock Bonuses to one or more Eligible Persons; provided,
however, that:
(a) Subject to Section 13, the aggregate number of shares
of Stock which may be made subject to all Awards shall be equal
to the sum of (i) 1,450,000 shares of Common Stock
plus (ii) the number of shares of Stock granted under the
Companys Fifth Amended and Restated 1999 Equity Incentive
Plan, as amended, that are not exercised or are forfeited, lapse
or expire, or otherwise terminate without delivery of any Stock
subject thereto, to the extent such Stock would otherwise again
have been available for issuance under such Fifth Amended and
Restated 1999 Equity Incentive Plan, as amended. The number of
Full Value Awards may not exceed the sum of
(i) 1,450,000 shares of Common Stock plus
(ii) the number of shares of Full Value Awards permitted
under the Companys Fifth Amended and Restated 1999 Equity
Incentive Plan, as amended, that have not been granted to an
Eligible Person, to the extent such Stock would otherwise again
have been available for issuance under such Fifth Amended and
Restated 1999 Equity Incentive Plan. Any and all shares of Stock
that may be made subject to Awards are authorized to be issued
pursuant to Incentive Stock Options;
(b) Such shares shall be deemed to have been used in payment of
Awards whether they are actually delivered or the Fair Market
Value equivalent of such shares is paid in cash. In the event
any Option, SAR not attached to an Option, Restricted Stock,
Restricted Stock Unit or Performance Share Unit shall be
surrendered, terminate, expire, or be forfeited, the number of
shares of Stock no longer subject thereto shall thereupon be
released and shall thereafter be available for new Awards under
the Plan;
A-4
(c) Stock delivered by the Company in settlement of Awards under
the Plan may be authorized and unissued Stock or Stock held in
the treasury of the Company or may be purchased on the open
market or by private purchase; and
(d) The Committee may, in its sole discretion, require a
Participant to pay consideration for an Award in an amount and
in a manner as the Committee deems appropriate.
6. Eligibility. Participation
shall be limited to Eligible Persons who have received written
notification from the Committee, or from a person designated by
the Committee, that they have been selected to participate in
the Plan.
7. Discretionary Grant of Stock
Options. The Committee is authorized to grant
one or more Incentive Stock Options or Nonqualified Stock
Options to any Eligible Person; provided, however, that no
Incentive Stock Options shall be granted to any Eligible Person
who is not an employee of the Company or a Related Entity. Each
Option granted shall be subject to the following conditions, or
to such other conditions as may be reflected in the applicable
Stock Option Agreement:
(a) Option Price. The exercise price
(Option Price) per share of Stock for each Option
shall be set by the Committee at the time of grant; provided,
however, that no Option shall be granted with a per share
exercise price that is less than the Fair Market Value of a
share of Stock at the Date of Grant.
(b) Manner of Exercise and Form of
Payment. Options which have become exercisable
may be exercised by delivery of written notice of exercise to
the Committee accompanied by payment of the Option Price. The
Option Price shall be payable in cash
and/or
shares of Stock valued at the Fair Market Value on the date the
Option is exercised or, in the discretion of the Committee,
either (i) in other property having a fair market value on
the date of exercise equal to the Option Price, or (ii) by
delivering to the Committee a copy of irrevocable instructions
to a stockbroker to deliver promptly to the Company an amount of
sale or loan proceeds sufficient to pay the Option Price.
(c) Option Period and Expiration. Options
shall vest and become exercisable in such manner and on such
date or dates determined by the Committee and shall expire after
such period, not to exceed ten years from the Date of Grant, as
may be determined by the Committee (the Option
Period), provided, however, that notwithstanding any
vesting dates set by the Committee, the Committee may in its
sole discretion accelerate the exercisability of any Option,
which acceleration shall not affect the terms and conditions of
any such Option other than with respect to exercisability. If an
Option is exercisable in installments, such installments or
portions thereof which become exercisable shall remain
exercisable until the Option expires.
Unless otherwise stated in the applicable Option Agreement, the
Option shall expire earlier than the end of the Option Period in
the following circumstances:
(i) If prior to the end of the Option Period, the Holder shall
undergo a Normal Termination, the Option shall expire on the
earlier of the last day of the Option Period or the date that is
thirty days after the date of such Normal Termination. In such
event, the Option shall remain exercisable by the Holder until
its expiration, only to the extent the Option was exercisable at
the time of such Normal Termination.
(ii) If the Holder dies prior to the end of the Option Period
and while still in the employ or service of the Company or any
Related Entity or within thirty days of Normal Termination, the
Option shall expire on the earlier of the last day of the Option
Period or the date that is thirty days after the date of death
of the Holder. In such event, the Option shall remain
exercisable by the person or persons to whom the Holders
rights under the Option pass by will or the applicable laws of
descent and distribution until its expiration, only to the
extent the Option was exercisable by the Holder at the time of
death.
(iii) If the Holder ceases to be Eligible Person for reasons
other than Normal Termination or death, the Option shall expire
immediately upon such cessation of the Holders status as
an Eligible Person.
(d) Stock Option Agreement Other Terms and
Conditions. Each Option granted under the Plan
shall be evidenced by a Stock Option Agreement, which shall
contain such provisions as may be determined by the
A-5
Committee and, except as may be specifically stated otherwise in
such Stock Option Agreement, which shall be subject to the
following terms and conditions:
(i) Each Option issued pursuant to this Section 7 or
portion thereof that is exercisable shall be exercisable for the
full amount or for any part thereof.
(ii) Each share of Stock purchased through the exercise of
an Option issued pursuant to this Section 7 shall be paid
for in full at the time of the exercise. Each Option shall cease
to be exercisable, as to any share of Stock, when the Holder
purchases the share or exercises a related SAR or when the
Option expires.
(iii) Subject to Section 12(k), Options issued
pursuant to this Section 7 shall not be transferable by the
Holder except by will or the laws of descent and distribution
and shall be exercisable during the Holders lifetime only
by such Holder.
(iv) Each Option issued pursuant to this Section 7
shall vest and become exercisable by the Holder in accordance
with the vesting schedule established by the Committee and set
forth in the Stock Option Agreement.
(v) Each Stock Option Agreement may contain a provision
that, upon demand by the Committee for such a representation,
the Holder shall deliver to the Committee at the time of any
exercise of an Option issued pursuant to this Section 7 a
written representation that the shares to be acquired upon such
exercise are to be acquired for investment and not for resale or
with a view to the distribution thereof. Upon such demand,
delivery of such representation prior to the delivery of any
shares issued upon exercise of an Option issued pursuant to this
Section 7 shall be a condition precedent to the right of
the Holder or such other person to purchase any shares. In the
event certificates for Stock are delivered under the Plan with
respect to which such investment representation has been
obtained, the Committee may cause a legend or legends to be
placed on such certificates to make appropriate reference to
such representation and to restrict transfer in the absence of
compliance with applicable federal or state securities laws.
(vi) Each Incentive Stock Option Agreement shall contain a
provision requiring the Holder to notify the Company in writing
immediately after the Holder makes a disqualifying disposition
of any Stock acquired pursuant to the exercise of such Incentive
Stock Option. A disqualifying disposition is any disposition
(including any sale) of such Stock before the later of
(a) two years after the Date of Grant of the Incentive
Stock Option or (b) one year after the date the Holder
acquired the Stock by exercising the Incentive Stock Option.
(e) Incentive Stock Option Grants to 10%
Stockholders. Notwithstanding anything to the contrary in
this Section 7, if an Incentive Stock Option is granted to
a Holder who owns stock representing more than ten percent of
the voting power of all classes of stock of the Company or of a
Related Entity, the Option Period shall not exceed five years
from the Date of Grant of such Option and the Option Price shall
be at least 110 percent of the Fair Market Value (on the
Date of Grant) of the Stock subject to the Option.
(f) $100,000 Per Year Limitation for Incentive Stock
Options. To the extent the aggregate Fair Market Value
(determined as of the Date of Grant) of Stock for which
Incentive Stock Options are exercisable for the first time by
any Participant during any calendar year (under all plans of the
Company and its Subsidiaries) exceeds $100,000, such excess
Incentive Stock Options shall be treated as Nonqualified Stock
Options.
(g) Prohibition on Option Repricing. Subject to
Section 13, without the prior approval of the
Companys stockholders, the Company shall not, and the
Committee shall not authorize the Company to, (i) amend any
outstanding Option to reduce its Option Price or
(ii) cancel any Option and replace it with the grant of any
new Award with a higher intrinsic value. This prohibition on
Option repricing shall not be construed to prohibit the
adjustments for extraordinary changes in the Companys
capital structure that are otherwise permitted under
Section 13 of this Plan.
8. Stock Appreciation
Rights. Any Option granted under the Plan may
include SARs, either at the Date of Grant or, except in the case
of an Incentive Stock Option, by subsequent amendment. The
Committee also may award SARs independent of any Option. A SAR
shall confer on the Holder thereof the right to receive in
shares of
A-6
Stock, cash or a combination thereof the value equal to the
excess of the Fair Market Value of one share of Stock on the
date of exercise over the exercise price for the SAR, with
respect to every share of Stock for which the SAR is granted. An
SAR shall be subject to such terms and conditions not
inconsistent with the Plan as the Committee shall impose,
including, but not limited to, the following:
(a) Vesting. SARs granted in connection
with an Option shall become exercisable, be transferable and
shall expire according to the same vesting schedule,
transferability rules and expiration provisions as the
corresponding Option. A SAR granted independent of an Option
shall become exercisable, be transferable and shall expire in
accordance with a vesting schedule, transferability rules and
expiration provisions as established by the Committee and
reflected in an Award agreement.
(b) Automatic Exercise. If on the last
day of the Option Period (or in the case of a SAR independent of
an Option, the period established by the Committee after which
the SAR shall expire), the Fair Market Value of the Stock
exceeds the Option Price (or in the case of an SAR granted
independent of an Option, the Fair Market Value of the Stock on
the Date of Grant), the Holder has not exercised the SAR or the
corresponding Option, and neither the SAR nor the corresponding
Option has expired, such SAR shall be deemed to have been
exercised by the Holder on such last day and the Company shall
make the appropriate payment therefor.
(c) Payment. Upon the exercise of a SAR,
the Company shall pay to the Holder an amount equal to the
number of shares subject to the SAR multiplied by the excess, if
any, of the Fair Market Value of one share of Stock on the
exercise date over the Option Price, in the case of an SAR
granted in connection with an Option, or the Fair Market Value
of one share of Stock on the Date of Grant, in the case of a SAR
granted independent of an Option. The Company shall pay such
excess in cash, in shares of Stock valued at Fair Market Value,
or any combination thereof, as determined by the Committee.
Fractional shares shall be settled in cash.
(d) Method of Exercise. A Holder may
exercise a SAR after such time as the SAR vests by filing an
irrevocable written notice with the Committee or its designee,
specifying the number of SARs to be exercised, and the date on
which such SARs were awarded.
(e) Expiration. Each SAR shall cease to
be exercisable, as to any share of Stock, when the Holder
exercises the SAR or exercises a related Option, with respect to
such share of Stock. Except as otherwise provided, in the case
of SARs granted in connection with Options, a SAR shall expire
on a date designated by the Committee which is not later than
seven years after the Date of Grant of the SAR. In the case of
SARs granted independent of Options, a SAR shall expire on a
date designated by the Committee which is not later than ten
years after the Date of Grant of the SAR.
(f) Prohibition on SAR Repricing. Subject
to Section 13, without the prior approval of the
Companys stockholders, the Company shall not, and the
Committee shall not authorize the Company to, (i) amend any
outstanding SAR to reduce its exercise price or (ii) cancel
any SAR and replace it with the grant of any new Award with a
higher intrinsic value. This prohibition on SAR repricing shall
not be construed to prohibit the adjustments for extraordinary
changes in the Companys capital structure that are
otherwise permitted under Section 13 of this Plan.
(g) Fair Market Value. No SAR shall be
granted with an exercise price that is less than the Fair Market
Value of a share of Stock at the Date of Grant of the SAR.
9. Performance Share Units.
(a) Award Grants. The Committee is
authorized to establish Performance Share Unit programs to be
effective over designated Award Periods determined by the
Committee. The Committee may grant Performance Share Units to
Eligible Persons in accordance with such Performance Share Unit
programs. At the beginning of each Award Period, the Committee
will establish written Performance Goals based upon financial
objectives for the Company for such Award Period and a schedule
relating the accomplishment of the Performance Goals to the
Awards to be earned by Participants. Performance Goals may
include absolute or relative growth in earnings per share or
rate of return on stockholders equity or other measurement
of corporate performance and may be determined on an individual
basis or by categories of Participants. The Committee shall
determine the number of Performance Share Units to be awarded,
if any, to each Eligible Person who is selected to receive such
an Award.
A-7
The Committee may add new Participants to a Performance Share
program after its commencement by making pro rata grants.
(b) Determination of Award. At the
completion of an Award Period, or at other times as specified by
the Committee, the Committee shall calculate the number of
shares of Stock earned with respect to each Participants
Performance Share Units by multiplying the number of Performance
Share Units granted to the Participant by a performance factor
representing the degree of attainment of the Performance Goals.
(c) Partial Awards. A Participant for
less than a full Award Period, whether by reason of commencement
or termination of employment or otherwise, shall receive such
portion of an Award, if any, for that Award Period as the
Committee shall determine.
(d) Form of Payment. Performance Share
Units shall be payable in that number of shares of Stock
determined in accordance with Section 9(b); provided,
however, that, at its discretion, the Committee may make payment
to any Participant in the form of cash upon the specific request
of such Participant. The amount of any payment made in cash
shall be based upon the Fair Market Value of the Stock on the
day of payment. Payments of Performance Share Units shall be
made as soon as practicable after the completion of an Award
Period, but in no event later than two and one half months after
the end of the calendar year in which the Award Period ends.
(e) Adjustment of Performance Goals. The
Committee may, during the Award Period, make such adjustments to
Performance Goals as it may deem appropriate, to compensate for,
or reflect, (i) extraordinary or non-recurring events
experienced during an Award Period by the Company or by any
Related Entity whose performance is relevant to the
determination of whether Performance Goals have been attained;
(ii) any significant changes that may have occurred during
such Award Period in applicable accounting rules or principles
or changes in the Companys method of accounting or in that
of any Related Entity whose performance is relevant to the
determination of whether an Award has been earned or
(iii) any significant changes that may have occurred during
such Award Period in tax laws or other laws or regulations that
alter or affect the computation of the measures of Performance
Goals used for the calculation of Awards; provided, however,
that with respect to Performance Share Units intended to qualify
as performance-based compensation under
Section 162(m) of the Code, such adjustments shall be made
only to the extent that the Committee determines that such
adjustments may be made without a loss of deductibility of the
compensation includible with respect to such Award under
Section 162(m) of the Code.
10. Restricted Stock and Restricted Stock
Units.
(a) Award of Restricted Stock and Restricted Stock
Units.
(i) The Committee shall have the authority (A) to
grant Restricted Stock and Restricted Stock Units, (B) to
issue or transfer Restricted Stock to Eligible Persons, and
(C) to establish terms, conditions and restrictions
applicable to such Restricted Stock and Restricted Stock Units,
including the Restricted Period, which may differ with respect
to each grantee, the time or times at which Restricted Stock or
Restricted Stock Units shall be granted or become vested and the
number of shares or units to be covered by each grant.
(ii) The Holder of Restricted Stock shall execute and
deliver to the Company an Award agreement with respect to the
Restricted Stock setting forth the restrictions applicable to
such Restricted Stock. If the Committee determines that the
Restricted Stock shall be held in escrow rather than delivered
to the Holder pending the release of the applicable
restrictions, the Holder additionally shall execute and deliver
to the Company (A) an escrow agreement satisfactory to the
Committee, and (B) the appropriate blank stock powers with
respect to the Restricted Stock covered by such agreements. If a
Holder shall fail to execute a Restricted Stock agreement and,
if applicable, an escrow agreement and stock powers, the Award
shall be null and void. Subject to the restrictions set forth in
Section 10(b), the Holder shall generally have the rights
and privileges of a stockholder as to such Restricted Stock,
including the right to vote such Restricted Stock. Cash
dividends and stock dividends with respect to the Restricted
Stock shall be currently paid to the Holder.
(iii) Upon the Award of Restricted Stock, the Committee
shall either (i) cause a stock certificate registered in
the name of the Holder to be issued and, if it so determines,
deposited together with the stock powers with an escrow agent
designated by the Committee, or (ii) issue such Stock to be
held in a restricted book entry account in the name of the
Holder. If an escrow arrangement is used, the Committee shall
cause the
A-8
escrow agent to issue to the Holder a receipt evidencing any
stock certificate held by it registered in the name of the
Holder.
(iv) The terms and conditions of a grant of Restricted
Stock Units shall be reflected in a written Award agreement. No
shares of Stock shall be issued at the time a Restricted Stock
Unit Award is made, and the Company will not be required to set
aside a fund for the payment of any such Award.
(b) Restrictions.
(i) Restricted Stock awarded to a Participant shall be
subject to the following restrictions until the expiration of
the Restricted Period, and to such other terms and conditions as
may be set forth in the applicable Award agreement: (A) if
a stock certificate registered in the name of the Holder is
issued and an escrow arrangement is used, the Holder shall not
be entitled to delivery of the stock certificate; (B) the
shares shall be subject to the restrictions on transferability
set forth in the Award agreement; (C) the shares shall be
subject to forfeiture to the extent provided in subparagraph
(d) and the Award Agreement and, to the extent such shares
are forfeited, the stock certificates, if any, shall be returned
to the Company, and all rights of the Holder to such shares and
as a stockholder shall terminate without further obligation on
the part of the Company.
(ii) Restricted Stock Units awarded to any Participant
shall be subject to (A) forfeiture until the expiration of
the Restricted Period, to the extent provided in subparagraph
(d) and the Award agreement, and to the extent such Awards
are forfeited, all rights of the Holder to such Awards shall
terminate without further obligation on the part of the Company
and (B) such other terms and conditions as may be set forth
in the applicable Award agreement.
(c) Restricted Period. The Restricted
Period of Restricted Stock and Restricted Stock Units shall
commence on the Date of Grant and shall expire from time to time
as to that part of the Restricted Stock and Restricted Stock
Units indicated in a schedule established by the Committee and
set forth in a written Award agreement. Notwithstanding the
foregoing, the Committee shall have the authority to accelerate
the end of the Restricted Period on the Restricted Stock and
Restricted Stock Units whenever it may determine that, by reason
of changes in applicable laws or other changes in circumstances
arising after the Date of Grant such action is appropriate.
(d) Forfeiture Provisions. Except to the
extent determined by the Committee and reflected in the
underlying Award agreement, in the event a Holder terminates
their status as an Eligible Person during a Restricted Period
for any reason, that portion of the Award with respect to which
restrictions have not expired shall be completely forfeited to
the Company.
(e) Delivery of Restricted Stock and Settlement of
Restricted Stock Units. Upon the expiration of
the Restricted Period with respect to any shares of Stock
covered by a Restricted Stock Award, the restrictions set forth
in Section 10(b) and the Award agreement shall be of no
further force or effect with respect to shares of Restricted
Stock which have not then been forfeited. If an escrow
arrangement is used, upon such expiration, the Company shall
deliver to the Holder, or the Holders beneficiary, without
charge, the stock certificate evidencing the shares of
Restricted Stock which have not then been forfeited and with
respect to which the Restricted Period has expired (to the
nearest full share) and any cash dividends or stock dividends
credited to the Holders account with respect to such
Restricted Stock and the interest thereon, if any. If the shares
of Stock are held in a restricted book entry account in the name
of the Holder, upon such expiration, the Company shall remove
the restrictions of such restricted book entry account for such
shares of Restricted Stock which have not been forfeited and
with respect to which the Restricted Period has expired (to the
nearest full share) and any cash dividend or stock dividends
credited to the Holders account with respect to such
Restricted Stock and the interest thereon, if any.
As soon as administratively feasible, but in no event later than
two and one half months after the end of the calendar year in
which such occurs, upon the expiration of the Restricted Period
with respect to any Restricted Stock Units the Company shall
deliver to the Holder, or the Holders beneficiary, without
charge, one share of Stock for each Restricted Stock Unit which
has not then been forfeited and with respect to which the
Restricted Period has expired (Vested Unit);
provided, however, that, if so noted in the applicable Award
agreement, the Committee may, in its sole discretion, elect to
pay cash or part cash and part Stock in lieu of delivering
only Stock for Vested Units. If cash payment is made in lieu of
delivering Stock, the amount of such payment shall be equal to
the Fair Market Value of the Stock as of the date on which the
Restricted Period lapsed with respect to such Vested Unit.
A-9
(f) Stock Restrictions. Each certificate
representing Restricted Stock awarded under the Plan shall bear
the following legend until the end of the Restricted Period with
respect to such Stock:
Transfer of this certificate and the shares represented
hereby is restricted pursuant to the terms of a Restricted Stock
Agreement, dated as of
between Wright Medical Group, Inc. and
.
A copy of such Agreement is on file at the offices of the
Company at 5677 Airline Road, Arlington, Tennessee 38002.
Stop transfer orders shall be entered with the Companys
transfer agent and registrar against the transfer of legended
securities.
11. Stock Bonus. The
Committee may issue unrestricted Stock to Eligible Persons,
alone or in tandem with other Awards, in such amounts and
subject to such terms and conditions as the Committee shall from
time to time in its sole discretion determine. A Stock Bonus
shall be granted as or in payment of a bonus, to provide
incentives, or to recognize special achievements or
contributions.
12. General.
(a) Additional Provisions of an
Award. Awards may be subject to such other
provisions (whether or not applicable to the benefit awarded to
any other Participant) as the Committee determines appropriate
including, without limitation, provisions to assist the
Participant in financing the purchase of Stock upon the exercise
of Options, provisions for the forfeiture of or restrictions on
resale or other disposition of shares of Stock acquired under
any Award, provisions giving the Company the right to repurchase
shares of Stock acquired under any Award in the event the
Participant elects to dispose of such shares, and provisions to
comply with Federal and state securities laws and Federal and
state tax withholding requirements. Any such provisions shall be
reflected in the applicable Award agreement.
(b) Privileges of Stock Ownership. Except
as otherwise specifically provided in the Plan, no person shall
be entitled to the privileges of stock ownership in respect of
shares of Stock which are subject to Awards hereunder until such
shares have been issued to that person.
(c) Government and Other Regulations. The
obligation of the Company to make payment of Awards in Stock or
otherwise shall be subject to all applicable laws, rules, and
regulations, and to such approvals by governmental agencies as
may be required. Notwithstanding any terms or conditions of any
Award to the contrary, the Company shall be under no obligation
to offer to sell or to sell and shall be prohibited from
offering to sell or selling any shares of Stock pursuant to an
Award unless such shares have been properly registered for sale
pursuant to the Securities Act with the Securities and Exchange
Commission or unless the Company has received an opinion of
counsel, satisfactory to the Company, that such shares may be
offered or sold without such registration pursuant to an
available exemption therefrom and the terms and conditions of
such exemption have been fully complied with. The Company shall
be under no obligation to register for sale under the Securities
Act any of the shares of Stock to be offered or sold under the
Plan. If the shares of Stock offered for sale or sold under the
Plan are offered or sold pursuant to an exemption from
registration under the Securities Act, the Company may restrict
the transfer of such shares and may legend the Stock
certificates representing such shares in such manner as it deems
advisable to ensure the availability of any such exemption.
(d) Tax Withholding. Notwithstanding any
other provision of the Plan, the Company or any Related Entity,
as appropriate, shall have the right to deduct from all Awards
cash and/or
Stock, valued at Fair Market Value on the date of payment, in an
amount necessary to satisfy all Federal, state or local taxes as
required by law to be withheld with respect to such Awards and,
in the case of Awards paid in Stock, the Holder or other person
receiving such Stock may be required to pay prior to delivery of
such Stock, the amount of any such taxes which are required to
be withheld, if any, with respect to such Stock. Subject in
particular cases to the disapproval of the Committee, shares of
Stock of equivalent Fair Market Value in payment of such
withholding tax obligations may be accepted if the Holder of the
Award elects to make payment in such manner.
(e) Claim to Awards and Employment
Rights. No employee or other person shall have
any claim or right to be granted an Award under the Plan or,
having been selected for the grant of an Award, to be selected
for a grant of
A-10
any other Award. Neither the Plan nor any action taken hereunder
shall be construed as giving any Participant any right to be
retained in the employ or service of the Company or any Related
Entity.
(f) Designation and Change of
Beneficiary. Each Participant may file with the
Committee a written designation of one or more persons as the
beneficiary who shall be entitled to receive the rights or
amounts payable with respect to an Award due under the Plan upon
the Participants death. A Participant may, from time to
time, revoke or change the Participants beneficiary
designation without the consent of any prior beneficiary by
filing a new designation with the Committee. The last such
designation received by the Committee shall be controlling;
provided, however, that no designation, or change or revocation
thereof, shall be effective unless received by the Committee
prior to the Participants death, and in no event shall it
be effective as of a date prior to such receipt. If no
beneficiary designation is filed by the Participant, the
beneficiary shall be deemed to be the Participants spouse,
if the Participant is unmarried at the time of death, the
Participants estate.
(g) Payments to Persons other Than
Participants. If the Committee shall find that
any person to whom any amount is payable under the Plan is
unable to care for such persons affairs because of illness
or accident, or is a minor, or has died, then any payment due to
such person or such persons estate (unless a prior claim
therefor has been made by a duly appointed legal representative)
may, if the Committee so directs, be paid to such persons
spouse, child, relative, an institution maintaining or having
custody of such person, or any other person deemed by the
Committee to be a proper recipient on behalf of such person
otherwise entitled to payment. Any such payment shall be a
complete discharge of the liability of the Committee and the
Company therefor.
(h) No Liability of Committee Members. No
member of the Committee shall be personally liable by reason of
any contract or other instrument executed by such member or on
such members behalf in such members capacity as a
member of the Committee nor for any mistake of judgment made in
good faith, and the Company shall indemnify and hold harmless
each member of the Committee and each other employee, officer or
director of the Company to whom any duty or power relating to
the administration or interpretation of the Plan may be
allocated or delegated, against any cost or expense (including
counsel fees) or liability (including any sum paid in settlement
of a claim) arising out of any act or omission to act in
connection with the Plan unless arising out of such
persons own fraud or willful bad faith; provided, however,
that approval of the Board shall be required for the payment of
any amount in settlement of a claim against any such person. The
foregoing right of indemnification shall not be exclusive of any
other rights of indemnification to which such persons may be
entitled under the Companys certificate of incorporation
or bylaws, as a matter of law, or otherwise, or any power that
the Company may have to indemnify them or hold them harmless.
(i) Governing Law. The Plan shall be
governed by and construed in accordance with the internal laws
of the State of Delaware without regard to the principles of
conflicts of law thereof.
(j) Funding. No provision of the Plan
shall require the Company, for the purpose of satisfying any
obligations under the Plan, to purchase assets or place any
assets in a trust or other entity to which contributions are
made or otherwise to segregate any assets, nor shall the Company
maintain separate bank accounts, books, records or other
evidence of the existence of a segregated or separately
maintained or administered fund for such purposes. Holders shall
have no rights under the Plan other than as unsecured general
creditors of the Company, except that insofar as they may have
become entitled to payment of additional compensation by
performance of services, they shall have the same rights as
other employees under general law.
(k) Non-transferability. A persons
rights and interest under the Plan, including amounts payable,
may not be sold, assigned, donated, or transferred or otherwise
disposed of, mortgaged, pledged or encumbered except, in the
event of a Holders death, to a designated beneficiary to
the extent permitted by the Plan, or in the absence of such
designation, by will or the laws of descent and distribution;
provided, however, the Committee may, in its sole discretion,
allow for transfer of Awards other than Incentive Stock Options
to other persons or entities. Notwithstanding the foregoing
provision, in no event may an Award be transferred by a grantee
for value.
(l) Reliance on Reports. Each member of
the Committee and each member of the Board shall be fully
justified in relying, acting or failing to act, and shall not be
liable for having so relied, acted or failed to act in good
faith, upon any report made by the independent public accountant
of the Company and any Related Entity and upon any other
information furnished in connection with the Plan by any person
or persons other than himself.
A-11
(m) Relationship to Other Benefits. No
payment under the Plan shall be taken into account in
determining any benefits under any pension, retirement, profit
sharing, group insurance or other benefit plan of the Company
except as otherwise specifically provided in such other plan.
(n) Expenses. The expenses of
administering the Plan shall be borne by the Company.
(o) Pronouns. Masculine pronouns and
other words of masculine gender shall refer to both men and
women.
(p) Titles and Headings. The titles and
headings of the sections in the Plan are for convenience of
reference only, and in the event of any conflict, the text of
the Plan, rather than such titles or headings shall control.
13. Changes in Capital
Structure. Awards granted under the Plan and
any agreements evidencing such Awards, the maximum number of
shares of Stock subject to all Awards, and the maximum number of
shares of Stock with respect to which any one person may be
granted Options or SARs during any year, if applicable, shall be
subject to equitable adjustment or substitution, as determined
by the Committee in its sole discretion, as to the number, price
or kind of a share of Stock or other consideration subject to
such Awards (a) in the event of changes in the outstanding
Stock or in the capital structure of the Company by reason of
stock dividends, stock splits, reverse stock splits,
recapitalizations, reorganizations, mergers, consolidations,
combinations, exchanges, or other relevant changes in
capitalization occurring after the Date of Grant of any such
Award or (b) in the event of any change in applicable laws
or any change in circumstances which results in or would result
in any substantial dilution or enlargement of the rights granted
to, or available for, Participants in the Plan, or which
otherwise warrants equitable adjustment because it interferes
with the intended operation of the Plan. In addition, in the
event of any such adjustment or substitution, the aggregate
number of shares of Stock available under the Plan shall be
appropriately adjusted by the Committee, whose determination
shall be conclusive. With respect to Awards intended to qualify
as performance-based compensation under
Section 162(m) of the Code, such adjustments or
substitutions shall be made only to the extent that the
Committee determines that such adjustments or substitutions may
be made without a loss of deductibility for such Awards under
Section 162(m) of the Code. With respect to Awards of Stock
rights intended to be excluded from the definition of
deferred compensation under Code Section 409A,
such adjustments or substitutions shall be made only to the
extent that the adjustments or substitutions are made pursuant
to Treas. Reg. § 1.409A-1(b)(5)(v)(D). The Company
shall give each Participant notice of an adjustment hereunder
and, upon notice, such adjustment shall be conclusive and
binding for all purposes.
Notwithstanding the above, in the event of any of the following:
(a) the Company is merged or consolidated with another
corporation or entity and, in connection therewith,
consideration is received by shareholders of the Company in a
form other than stock or other equity interests of the surviving
entity; (b) all or substantially all of the assets of the
Company are acquired by another person; or (c) the
reorganization or liquidation of the Company; then the Committee
may, in its discretion and upon at least 10 days advance
notice to the affected persons, cancel any outstanding Awards
and pay to the Holders thereof, in cash, the value of such
Awards based upon the price per share of Stock received or to be
received by other shareholders of the Company in the event. The
terms of this Section 13 may be varied by the Committee in
any particular Award agreement.
14. Non-exclusivity of the
Plan. Neither the adoption of this Plan by
the Board nor the submission of this Plan to the stockholders of
the Company for approval shall be construed as creating any
limitations on the power of the Board to adopt such other
incentive arrangements as it may deem desirable, including,
without limitation, the granting of stock options otherwise than
under this Plan, and such arrangements may be either applicable
generally or only in specific cases.
15. Amendments and
Termination. The Board may at any time
terminate the Plan. Subject to Sections 7(g), 8(f) and 13,
with the express written consent of an individual Participant,
the Board or the Committee may cancel or reduce or otherwise
alter outstanding Awards if, in its judgment, the tax,
accounting, or other effects of the Plan or potential payouts
thereunder would not be in the best interest of the Company. The
Board or the Committee may, at any time, or from time to time,
amend or suspend and, if suspended, reinstate, the Plan in whole
or in part; provided, however, that any amendment of the Plan
shall require the approval of the Companys stockholders to
the extent that such approval is then required by the Plan,
applicable law, the rules and regulations of the Securities and
Exchange Commission, or the rules and regulations of any
national securities exchange on which the Stock is then listed
or any automated quotation system on which the Stock is then
quoted.
A-12
16. Effect of Section 162(m) of the
Code. The Plan, and all Awards issued
thereunder, are intended to be exempt from the application of
Section 162(m) of the Code, which restricts under certain
circumstances the Federal income tax deduction for compensation
paid by a public company to named executives in excess of
$1 million per year. The Committee may, without shareholder
approval, amend the Plan retroactively
and/or
prospectively to the extent it determines necessary in order to
comply with any subsequent clarification of Section 162(m)
of the Code required to preserve the Companys Federal
income tax deduction for compensation paid pursuant to the Plan.
To the extent that the Committee determines as of the Date of
Grant of an Award that the Award is intended to comply with
Section 162(m) of the Code, such Award shall not be
effective until any stockholder approval required under
Section 162(m) of the Code to provide a full Federal income
tax deduction has been obtained.
17. Compliance with Section 409A.
(a) This Plan shall at all times be administered and the
provisions of this Plan shall be interpreted consistent with the
requirements of Section 409A of the Code and any and all
regulations thereunder, including such regulations as may be
promulgated after the effective date of this Plan. Without
limiting the foregoing, for purposes of Section 409A of the
Code,
(i) each payment (as defined by
Section 409A of the Code) made under this Plan or an Award
shall be considered a separate payment;
(ii) payments shall be deemed exempt from the definition of
deferred compensation under Section 409A of the Code to the
fullest extent possible under (i) the short-term
deferral exemption of Treasury Regulation
§ 1.409A-1(b)(4), and (ii) with respect to
amounts paid as separation pay no later than the second calendar
year following the calendar year containing the
participants separation from service (as
defined for purposes of Section 409A of the Code) the
two years/two-times separation pay exemption of
Treasury Regulation § 1.409A-1(b)(9)(iii), which are
hereby incorporated by reference, and
(iii) if the Participant is a specified
employee as defined in Section 409A of the Code (and
as applied according to procedures of the Company and its
affiliates) as of the Participants separation from
service, to the extent any payment under the Plan or an Award
constitutes deferred compensation (after taking into account any
applicable exemptions from Section 409A of the Code) and to
the extent required by Section 409A of the Code, no
payments due under the Plan or an Award may be made until the
earlier of: (i) the first day of the seventh month
following the Participants separation from service, or
(ii) the Participants date of death; provided,
however, that any payments delayed during this six-month period
shall be paid in the aggregate in a lump sum, without interest,
on the first day of the seventh month following the
Participants separation from service. To the extent that
the payment terms for an Award are otherwise set forth in a
written employment agreement or change in control agreement with
a specified employee (or other Company plan applicable to the
specified employee) and such payment terms otherwise meet the
requirements of Section 409A of the Code and the
application of such terms does not result in a violation of
Section 409A of the Code, the foregoing payment terms shall
be disregarded and the payment terms set forth in the applicable
agreement or plan shall apply.
(b) If this Plan or any Award fails to meet the
requirements of Section 409A of the Code, neither the
Company nor any of its affiliates shall have any liability for
any tax, penalty or interest imposed on the Participant by
Section 409A of the Code, and the Participant shall have no
recourse against the Company or any of its affiliates for
payment of any such tax, penalty or interest imposed by
Section 409A of the Code.
IN WITNESS WHEREOF, the undersigned has caused the Plan to be
executed on behalf of the Company as of May 13, 2010.
WRIGHT MEDICAL GROUP, INC.
Gary D. Henley
President and Chief
Executive Officer
A-13
APPENDIX B
WRIGHT MEDICAL GROUP, INC.
2010 EXECUTIVE PERFORMANCE INCENTIVE PLAN
ARTICLE I.
GENERAL PROVISIONS
1.1. Objectives of the
Plan. The primary objectives of the Plan are
to attract, retain, recognize, engage, motivate and reward
Executives by providing them with the opportunity to earn
competitive compensation directly linked to the Companys
performance.
1.2. Definitions. The
following capitalized terms used in the Plan have the respective
meanings set forth in this Section:
(a) Award shall mean a payment made
under the Plan.
(b) Basis for Award Calculation shall
mean the base salary in effect at the end of the quarter or
Performance Year, prorated to cover the period under
consideration, plus any lump sum merit increases that may have
been granted during the Performance Year, prorated to cover the
period under consideration. All other compensatory incentives,
premiums, bonuses or payments of any kind shall be excluded from
the Basis for Award Calculation.
(c) Board shall mean the Board of
Directors of the Company.
(d) Code shall mean the Internal Revenue
Code of 1986, as amended, or any successor thereto.
(e) Committee shall mean the
Compensation Committee of the Board or any other committee
appointed by the Board which is composed solely of outside
directors as defined under the Code and the regulations
promulgated thereunder.
(f) Company shall mean Wright Medical
Group, Inc.
(g) Disability shall mean the complete
and permanent inability by reason of illness or accident to
perform the duties of the occupation at which a Participant was
employed or served when such disability commenced, as determined
by the Committee based upon medical evidence acceptable
to it.
(h) Effective Date shall mean the date
March 20, 2010.
(i) Executive means any person who is
legally employed by the Company or its Related Entities and who
has been designated an officer of the Company or its Related
Entities by the board of directors of such entity.
(j) Participant means a regular
full-time or part-time Executive who is eligible to participate
in the Plan as set forth in Article II.
(k) Performance Year means a calendar
year, beginning on January 1 of each year.
(l) Plan means this 2010 Executive
Performance Incentive Plan, as set forth herein and as may be
amended from time to time.
(m) Related Entity shall mean, when
referring to a subsidiary, any business entity (other than the
Company) which is in an unbroken chain of entities ending with
the Company, if stock or voting interests possessing 50% or more
of the total combined voting power of all classes of stock or
other ownership interests of each of the entities other than the
Company is owned by one of the other entities in such chain and,
when referring to a parent entity, the term Related
Entity shall mean any entity in an unbroken chain of
entities ending with the Company if each of the entities other
than the Company owns stock or other ownership interests
possessing 50% or more of the total combined voting power of all
classes of stock (or other ownership interests) in one of the
other entities in such chain.
B-1
ARTICLE II.
ADMINISTRATION, ELIGIBILITY AND PARTICIPATION
2.1. General
Administration. The Plan shall be
administered and interpreted by the Committee. Any determination
made by the Committee under the Plan shall be final and
conclusive. The Committee may employ such legal counsel,
consultants and agents (including counsel or agents who are
employees of the Company or a Related Entity) as it may deem
desirable for the administration of the Plan and may rely upon
any opinion received from any such counsel or consultant or
agent and any computation received from such consultant or
agent. All expenses incurred in the administration of the Plan,
including, without limitation, for the engagement of any
counsel, consultant or agent, shall be paid by the Company.
2.2. Performance
Objectives. The Committee shall establish the
performance objectives for each Performance Year in accordance
with Article III for such financial performance measures as
the Committee determines and shall determine the time periods
(e.g., quarterly or full-year) for which performance goals shall
be measured. The Committee, or its designee, shall communicate
performance goals, financial performance measures, the relative
weighting of each measure, and the performance minimum
threshold, target bonus and maximum bonus to each Participant.
Notwithstanding the foregoing, the weighting of measures of cash
flow shall not be greater than the weighting of measures of net
income.
2.3. Eligibility. The
Committee shall have the sole and absolute authority to
designate actual Participants. At a minimum, a Participant shall
be a regular full-time or part-time Executive who meets all of
the following criteria:
(a) Participant must be employed by the Company or a
Related Entity for at least three (3) months during the
Performance Year with a hire date on or prior to September 30
and must be an employee on December 31 of the Performance Year;
(b) Participant must have met minimum job expectations and
have performed satisfactorily, as determined by the
Participants manager/supervisor in conjunction with the
Companys Human Resource Department;
(c) Subject to Section 5.2, the Participant must not
have participated in another formal non-equity incentive plan
during the same period in the Performance Year; and
(d) Participant must be employed in the United States,
Canada or in a European country in the business unit designated
by the Company as EMEA.
2.4. Participation. Participation
in one Performance Year does not constitute a right to continue
or participate in succeeding Performance Years.
ARTICLE III.
SETTING, DETERMINATION AND CALCULATION OF AWARDS
3.1. Setting of Performance
Goals. Within ninety (90) days of the
start of each Performance Year, but no case, later than the date
which is 25% of the period being measured, the Committee shall
establish performance goals for all applicable periods during
the Performance Year. The performance goals shall be based upon
performance measures such as sales revenue, operating income
before or after taxes, net income before or after taxes, net
income before securities transactions, net or operating income
excluding non-recurring charges, return on assets, return on
equity, return on capital, market share, earnings per share,
cash flow, revenue, revenue growth, expenses, stock price,
dividends, total stockholder return, price/earnings ratio,
market capitalization, book value, product quality, customer
retention, unit sales, strategic business objectives or any
other performance measure deemed appropriate by the Committee in
its discretion.
3.2. Determination of the
Awards. The Committee may grant, terminate,
decrease, reduce or eliminate Awards as it may determine during
the Performance Year; provided, however, that the Committee
shall not take action to terminate, decrease, reduce or
eliminate Awards after the conclusion of the Performance Year to
which the determination relates.
B-2
3.3. Target Performance
Bonus. The Committee shall determine a target
performance bonus, stated as a percentage of base pay, for each
Participant. The target performance bonus shall represent the
Award that the Participant will receive if all performance goals
for each performance measure are met or exceeded.
3.4. Minimum Performance
Thresholds. The Committee shall determine
minimum performance thresholds for each of the performance
measures. Partial payments of the target performance bonus shall
only be paid if the minimum performance thresholds are achieved.
A Participant shall not be paid for performance below the
minimum performance threshold of any component of an Award.
Further, if a Participant does not maintain an acceptable level
of overall performance, the Participant may, at the sole
discretion of the Committee, be suspended from the Plan.
3.5. Maximum Performance
Bonus. If the performance goals for a
Performance Year are exceeded, the Committee may pay additional
bonus in excess of the target performance bonus; provided
however, that no Participant shall be paid an amount that
exceeds twice the target performance bonus unless otherwise
determined by the Committee and in no event shall any payment to
any individual under this Plan exceed $1,500,000 for any
Performance Year.
3.6. Basis for Award
Calculation. Based on the terms of the Plan,
the Committee shall determine in its sole discretion the Awards
to be made. Awards shall be calculated based on the
Participants Basis for Award Calculation and shall be
expressed as a percentage of the Participants Basis for
Award Calculation.
3.7. Payout Matrices. Awards
will be prorated for each component of the Plan between the
minimum performance threshold and the target performance goal
and between the target performance goal and the maximum
performance bonus.
ARTICLE IV.
TIMING, CERTIFICATION, CALCULATION AND PAYMENT OF AWARDS
4.1. Timing of Awards. Award
payments under the Plan based on quarterly financial results of
the first, second or third quarter shall be paid in the
following calendar quarter. Awards under the Plan based on the
financial results of the fourth quarter and for the entire
Performance Year shall be made after the end of the Performance
Year and will include
make-up
awards and overachievement awards based on the full year
financial results. Payments based on quarterly financial results
of the first, second or third quarter each shall not exceed
twenty percent (20%) of a Participants target bonus for
the entire Performance Year.
4.2. Certification of
Results. Financial results will be determined
as soon as practicable after the end of each quarter and the end
of the Performance Year. The Committee shall review, approve and
certify payments for each quarter and for the fourth
quarter/full Performance Year Awards.
4.3. Grant of Awards. No
Award shall be inconsistent with the terms of the Plan or fail
to satisfy the requirements of applicable law. Each Award shall
relate to a specific designated Performance Year.
4.4. Payment. Except as
otherwise provided for hereunder, payment of any Award
determined under Article III shall be made to each
Participant as soon as practicable after the Committee certifies
that one or more of the applicable performance objectives have
been attained and the Award. Delivery of the approved Awards
must occur on or prior to March 15 of the calendar year
following the Performance Year for which Awards are to be made.
All Awards hereunder shall be paid in cash.
ARTICLE V.
EMPLOYMENT STATUS CHANGES
5.1. New Hires. All eligible
Executives newly hired on or prior to September 30th of a
Performance Year will have their Awards prorated for the period
of participation in the Plan. Awards granted to such newly hired
Executives shall not be based upon performance measures achieved
under the Plan prior to the date of hire.
5.2. Transfer. Executives
who transfer within the Company or its Related Entities to or
from another
non-equity
incentive plan or business unit performance measures during the
Performance Year will be eligible for
B-3
an Award under the Plan on a prorated basis, provided that all
eligibility requirements are met. Awards granted to such
transferred Executives shall not be based upon performance
measures achieved under the Plan prior to the date of transfer.
5.3. Prorated Award. An
Award will be prorated, and paid, if a Participant meets all
other eligibility requirements during the Performance Year but
is not a regular, active Executive on December 31 of the
Performance Year due to one of the following reasons:
(a) Participant leaves his or her position due to a
Disability; or
(b) Participant dies during a Performance Year (the
prorated Award, if any, will be paid to the Participants
estate); or
(c) Participant takes a military leave during the
Performance Year.
5.4. Termination of
Employment. Unless otherwise determined by
the Committee, a Participant shall not be entitled to any
payment hereunder with respect to a Performance Year in the
event of the termination of the Participants employment
with the Company and its Related Entities for any reason prior
to the last day of the applicable quarter or Performance Year.
ARTICLE VI.
MISCELLANEOUS MATTERS
6.1. Term of the Plan. The
Plan became effective on March 20, 2010, the date on which
it was adopted by the Compensation Committee (the
Effective Date). The Plan shall expire on
May 13, 2015.
6.2. Amendment. The Board or
the Committee may at any time amend, suspend, discontinue or
terminate the Plan; provided, however, that no such amendment,
suspension, discontinuance or termination shall adversely affect
any then existing rights of any Participant in any respect of
any Performance Year that has already begun.
6.3. Claim to Awards and Employment
Rights. Neither the Plan nor any action taken
hereunder shall be construed as giving any Participant any right
to be retained in the employ or service of the Company or any
Related Entity. There is no obligation for uniformity of
treatment of Participants. The terms and conditions of Awards
and the Committees determinations and interpretations with
respect thereto need not be the same with respect to each
Participant (whether or not the Participants are similarly
situated).
6.4. No Liability of Committee
Members. No member of the Committee shall be
personally liable by reason of any contract or other instrument
executed by such member or on his behalf in his capacity as a
member of the Committee nor for any mistake of judgment made in
good faith, and the Company shall indemnify and hold harmless
each member of the Committee and each other employee, officer or
director of the Company to whom any duty or power relating to
the administration or interpretation of the Plan may be
allocated or delegated, against any cost or expense (including
counsel fees) or liability (including any sum paid in settlement
of a claim) arising out of any act or omission to act in
connection with the Plan unless arising out of such
persons own fraud or willful bad faith; provided, however,
that approval of the Board shall be required for the payment of
any amount in settlement of a claim against any such person. The
foregoing right of indemnification shall not be exclusive of any
other rights of indemnification to which such persons may be
entitled under the Companys certificate of incorporation
or bylaws, as a matter of law, or otherwise, or any power that
the Company may have to indemnify them or hold them harmless.
6.5. No Limitation on Corporate
Actions. Nothing in this Plan shall be
construed to prevent the Company or any of its Related Entities
from taking any corporate action which is deemed by it to be
appropriate or in its best interest, whether or not such action
would have any adverse effect on any Awards made under the Plan.
No employee or other person shall have any claim against the
Company or any Related Entity as a result of any such action.
6.6. Non-transferability. A
Participants rights and interest under the Plan, including
amounts payable, may not be sold, assigned, donated, or
transferred or otherwise disposed of, mortgaged, pledged or
encumbered except, in the event of a Participants death,
to a designated beneficiary to the extent permitted by the Plan,
or in the absence of such designation, by will or the laws of
descent and distribution.
B-4
6.7. Tax
Withholding. Notwithstanding any other
provision of the Plan, the Company or any Related Entity, as
appropriate, shall have the right to deduct from all Awards an
amount necessary to satisfy all Federal, state or local taxes as
required by law to be withheld with respect to such Awards.
6.8. Severability. If any
provision of this Plan is held unenforceable, the remainder of
the Plan shall continue in full force and effect without regard
to such unenforceable provision and shall be applied as though
the unenforceable provision were not contained in the Plan.
6.9. Governing Law. The Plan
shall be governed by and construed in accordance with the
internal laws of the State of Delaware without regard to the
principles of conflicts of law thereof.
6.10. Other Compensation
Plans. The Plan shall not affect any other
compensation plan in effect for the Company, nor shall the Plan
preclude the Company from establishing any other forms of
compensation for Executives of the Company.
6.11. Effect of Section 162(m) of the
Code. Upon approval of the Plan by the
Stockholders of the Company, the Plan and all Awards issued
hereunder, are intended to be performance-based compensation
exempt from the application of Section 162(m) of the Code,
which restricts under certain circumstances the Federal income
tax deduction for compensation paid by a public company to named
executives in excess of $1 million per year. The Committee
may, without stockholder approval, amend the Plan retroactively
and/or
prospectively to the extent it determines necessary in order to
comply with any subsequent clarification of Section 162(m)
of the Code required to preserve the Companys Federal
income tax deduction for compensation paid pursuant to the Plan.
To the extent that the Committee determines as of the payout
date of an Award that the Award is intended to comply with
Section 162(m) of the Code, such Award shall not be
effective until any stockholder approval required under
Section 162(m) of the Code to provide a full Federal income
tax deduction has been obtained.
6.12. Compliance with
Section 409A. This Plan shall at all
times be administered and the provisions of this Plan shall be
interpreted consistent with the requirements of
Section 409A of the Code and any and all regulations
thereunder, including such regulations as may be promulgated
after the effective date of this Plan.
IN WITNESS WHEREOF, the undersigned has caused the Plan to be
executed on behalf of the Company as of March 20, 2010.
WRIGHT MEDICAL GROUP, INC.
Gary D. Henley
President and Chief
Executive Officer
B-5
|
|
|
|
|
|
|
Wright Medical Group, Inc.
|
|
5677 Airline Road, Arlington, Tennessee 38002
|
|
901-867-9971
|
|
www.wmt.com |
April 15, 2010
Dear Stockholder:
It is a great pleasure to have this opportunity to provide you with our 2009 Annual Report and the
Proxy Statement for our 2010 Annual Meeting of Stockholders. The Annual Report discusses our
performance in 2009 as well as our business strategy for the future. The Proxy Statement provides
you with information relating to the business to be conducted at our annual meeting on May 13,
2010.
YOUR VOTE IS IMPORTANT!
You can submit your proxy in one of two ways:
1. |
|
Call toll-free 1-800-PROXIES (1-800-776-9437) in the United States or 1-718-921-8500 from foreign countries on a touch-tone telephone at any time and follow the instructions on the reverse side; or
|
|
2. |
|
Complete, sign, date, and return your proxy card in the accompanying envelope. |
Thank you for your continued interest in, and ownership of, Wright Medical Group, Inc.
|
|
|
|
|
|
|
Sincerely,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gary D. Henley |
|
|
|
|
President and Chief Executive Officer |
|
|
WRIGHT MEDICAL GROUP, INC.
2010 ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON MAY 13, 2010
THIS PROXY IS SOLICITED ON BEHALF OF OUR BOARD OF DIRECTORS
The 2010 Annual Meeting of Stockholders of Wright Medical Group, Inc. (the Company)
will be
held at the River Inn of Harbor Town, located at 50 Harbor Town Square, Memphis, Tennessee, on May 13, 2010, beginning at 8:00 a.m.
(Central Time). The undersigned hereby acknowledges receipt
of the combined Notice of 2010 Annual Meeting of Stockholders and Proxy Statement dated April 15,
2010, accompanying this proxy, to which reference is hereby made for further information regarding
the meeting and the matters to be considered and voted on by the stockholders at the meeting.
The undersigned hereby appoints Gary D. Henley, Lance A. Berry, and Thomas L. McAllister, and each
of them,
attorneys and agents, with full power of substitution, to vote, as the undersigneds
proxy, all the shares of common stock of the Company owned of record by the undersigned as of the
record date and otherwise to act on behalf of the undersigned at the meeting and any postponement
or adjournment thereof, in accordance with the instructions set forth herein and with discretionary
authority with respect to any other business, not known or determined at the time of the
solicitation of this proxy, that properly comes before such meeting or any postponement or
adjournment thereof.
The undersigned hereby revokes any proxy heretofore given and directs said attorneys and
agents to vote or act as indicated on the reverse side hereof.
(Continued and to be signed on the reverse side)
CONFIDENTIAL
2010 ANNUAL MEETING OF STOCKHOLDERS
OF
WRIGHT MEDICAL GROUP, INC.
May 13, 2010
PROXY VOTING INSTRUCTIONS
TELEPHONE
Call toll-free 1-800-PROXIES (1-800-776-9437) in the United States or
1-718-921-8500 from foreign countries
from any touch-tone telephone and follow the instructions. Have your proxy card available when you
call and use the Company Number and Account Number shown on your
proxy card.
Vote by
telephone until 11:59 PM EST the day before the meeting.
MAIL Sign, date, and mail your proxy card in the envelope provided as soon as possible.
IN
PERSON You may vote your shares in person by attending
the Annual Meeting.
COMPANY NUMBER
ACCOUNT NUMBER
NOTICE
OF INTERNET AVAILABILITY OF PROXY MATERIAL: The Notice of
Meeting, proxy statement and proxy card are available at
www.wmt.com/proxy.
6 Please detach along perforated line and mail in the envelope provided IF you are not voting via telephone. 6
OUR BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE FOR THE PROPOSALS.
PLEASE SIGN, DATE, AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE.
PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE. ý
1. |
|
To elect directors to serve on our Board of Directors for a term of one year. |
|
|
|
o
|
|
FOR ALL NOMINEES |
|
|
|
o
|
|
WITHHOLD AUTHORITY FOR ALL NOMINEES |
|
|
|
o
|
|
FOR ALL NOMINEES EXCEPT (See instruction below.) |
|
|
|
|
|
|
|
|
|
NOMINEES:
|
|
¡
|
|
Gary D. Blackford |
|
|
|
|
¡
|
|
Carmen L. Diersen |
|
|
|
|
¡
|
|
Martin J. Emerson |
|
|
|
|
¡
|
|
Lawrence W. Hamilton |
|
|
|
|
¡
|
|
Gary D. Henley |
|
|
|
|
¡
|
|
John L. Miclot |
|
|
|
|
¡
|
|
Amy S. Paul |
|
|
|
|
¡
|
|
Robert J. Quillinan |
|
|
|
|
¡
|
|
David D. Stevens |
INSTRUCTION: To withhold authority to vote for any individual nominee(s), mark FOR ALL
NOMINEES EXCEPT and fill in the circle next to each nominee from whom you wish to withhold your
vote as shown here: l
CONFIDENTIAL
2. |
|
To approve an amendment to our 2009 Equity Incentive Plan to increase by 700,000 the number of shares of our common stock available for awards thereunder. |
o FOR o AGAINST o
ABSTAIN
3. |
|
To approve the material terms of our 2010 Executive Performance Incentive Plan for the purpose of enabling us to fully deduct for tax purposes compensation paid thereunder. |
o FOR o AGAINST o
ABSTAIN
4. |
|
To ratify the selection of KPMG LLP as our independent auditor for 2010. |
o FOR o AGAINST o
ABSTAIN
With respect to any other item of business that properly comes before the meeting, the proxy
holders are authorized to vote the undersigneds shares in accordance with their best judgment.
THIS PROXY IS SOLICITED ON BEHALF OF OUR BOARD OF DIRECTORS AND WILL BE VOTED IN ACCORDANCE WITH
THE UNDERSIGNEDS INSTRUCTIONS SET FORTH HEREIN. IF NO INSTRUCTIONS ARE PROVIDED, THIS PROXY WILL
BE VOTED FOR EACH OF THE PROPOSALS DESCRIBED ABOVE.
To change the address on your account, please check the box at right and indicate your new address
in the address space provided above. Please note that changes to the registered name(s) on the
account may not be submitted via this method. o
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Signature of Stockholder
|
|
|
|
|
|
Date: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Signature of Stockholder
|
|
|
|
|
|
Date: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note:
Please sign exactly as your name or names appear on this proxy. When shares are held
jointly, each holder should sign. When signing as executor, administrator, attorney, trustee, or
guardian, please give full title as such. If the signer is a corporation,
please sign full corporate name by duly authorized officer, giving
full title as such. If signer is a partnership, please sign in
partnership name by authorized person.